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Abstract 
Breast Cancer Associated gene 2 (BCA2), is a little-studied E3 ligase 
that is overexpressed in 56% of all primary breast cancers and has 
been linked with increased cell proliferation and invasion in vitro.  
BCA2 has been implicated in EGFR degradation however there is 
conflicting evidence surrounding its function and effect on receptor 
biology.  This project aimed to elucidate the role of BCA2 in EGFR 
endocytosis and downregulation and to determine its link with breast 
cancer survival.  
Data generated with online mRNA analysis tools indicated that high 
BCA2 levels were often associated with improved breast cancer 
prognosis.  In silico studies also demonstrated that many genes 
coexpressed with BCA2 were regulators of membrane trafficking and 
suggested that BCA2 expression was repressed by HER2/EGFR/Ras 
signalling.  
Experimentally, it was shown that siRNA depletion of BCA2 led to 
increased EGFR protein levels while transient BCA2 overexpression 
reduced levels of the receptor.  It was found that BCA2 
overexpressing, EGF stimulated cells demonstrated reduced 
lysosomal degradation of both receptor and ligand.  Associated with 
this, downstream EGFR signalling in BCA2 overexpressing cells was 
reduced in magnitude but prolonged in duration and ultimately cell 
viability was impaired.      
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These findings support a role for BCA2 in the endolysosomal system.  
In agreement with this it was shown that BCA2 overexpression 
inhibited the vesicle membrane association of Rab7, a regulator of 
late endocytosis and reported BCA2 interactor.   
Transferrin receptor levels and transferrin uptake were unaffected by 
BCA2 overexpression suggesting trafficking effects may be restricted 
to EGFR, a distinct class of receptor and/or to later (degradation) 
stages of endocytosis. 
This thesis provides a detailed exploration of BCA2 biology and 
presents evidence of a functional role for the protein in the endocytic 
regulation of EGFR.  The mechanism/s underlying the complex 
relationship between BCA2 and breast cancer outcome have yet to be 
fully determined.  
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Chapter 1: Introduction 
1.1 Cancer 
Cancer is a hypernym that encompasses a number of diseases 
characterised by aberrant cell division, survival and motility (WHO 
2011).  Cancer develops from cells in which critical genomic mutations 
have given rise to altered gene expression and/or abnormal protein 
function.  This process of malignant transformation generally involves 
multiple, sequential mutations that may be inherited or spontaneously 
acquired (Bertram 2000).      
Cancer constitutes a substantial burden of disease and incidence 
continues to rise.  GLOBOCAN figures show that, worldwide, around 
14.1 million individuals were newly diagnosed with cancer in 2012.  
Cancer is also a major cause of global mortality: in 2012 over 8.2 million 
deaths were attributed to this group of diseases; a figure which is 
predicted to rise to 13 million by 2030 (WHO 2012; Ferlay et al. 2013). 
The taxonomy of cancer is dependent on both the morphological and 
molecular features of the disease.  Gross classification is typically based 
on the organ/tissue of origin and the type of cell from which the disease 
evolved.  Cancers are often further sub-classified according to particular 
traits such as chromosome abnormalities, expression of prognostic 
proteins, drug resistance etc. (Berman 2004).  The stage of a cancer is 
also an important disease descriptor and broadly speaking relates to the 
size of a tumour and the degree to which it has spread (Piccirillo and 
Feinstein 1996).    
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1.2 Breast Cancer 
1.2.1 Epidemiology  
Breast cancer is a significant cause of morbidity and mortality 
worldwide.  In 2012 GLOBOCAN reported an annual, global incidence 
of around 1.67 million and mortality of over 520 thousand.  Breast cancer 
is the second most common form of all cancers and is the most frequently 
diagnosed cancer in females (Ferlay et al. 2013).   
There is a great deal of variation in breast cancer incidence and survival 
between global regions of differing socio-economic development.  In the 
developed world, disease detection and treatment success rates are 
relatively high compared with those in less developed areas.  As a result, 
the 5-year relative survival rate (RSR) for breast cancer is above 80% in 
North America, Japan and much of Western Europe while Slovakia and 
Brazil have rates below 60% and in Algeria the 5-year RSR is only 40% 
(Coleman et al. 2008).  Despite significant advances in clinical 
intervention, breast cancer incidence is still rising, even in the Western 
world.  The UK incidence per 100,000 women increased by over 30% 
between 1989 and 2009 and breast cancer is now the most common form 
of cancer in Britain (CRUK 2011).  The reasons behind the rise in breast 
cancer rates are complex and multifactorial.  The increase is partly due to 
positive changes: better disease detection as a result of improved testing 
methods, greater public awareness and the introduction of a national 
screening programme.  Since age is a key risk factor for breast cancer, as 
life expectancy has increased so too has incidence (WHO 2014).   There 
are a number of lifestyle factors, primarily those influencing life-time 
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oestrogen exposure, that are also thought to have contributed to the 
increased frequency of breast cancer.  Such factors include: increased 
alcohol consumption, obesity and the use of hormone replacement 
therapy (HRT) by post-menopausal women (McPherson et al. 2000).  
1.2.2 Pathophysiology 
As with all malignancies, breast cancer arises when somatic or heritable 
aberrations in cellular DNA lead to the acquisition of oncogenic traits.  
The vast majority of breast cancers are adenocarcinomas, so called 
because they develop from the glandular epithelial cells that make up the 
lactiferous ducts and lobules of the breast (Fig. 1-1).  70-80% of breast 
cancers are ductal and 10-15% are lobular in origin (CRUK 2011).   
 
Figure 1-1: Gross anatomy of the breast (sagittal section). Most breast cancers 
originate from the lactiferous (milk) ducts or lobules.  As the disease progresses 
tumours will spread through the breast tissue either outwards to the skin or inwards 
towards and/or through the chest wall.  Highly invasive breast cancers will spread into 
the lymph nodes and/or blood vessels before metastasising to other organs.   
Following transformation, breast cancer cells proliferate in situ, the 
malignant cells initially drawing nutrients from the surrounding tissues 
by passive diffusion.  As a tumour expands angiogenic factors are 
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secreted by malignant cells to promote the formation of a new capillary 
network from the normal breast vasculature.  The development of a 
nutritive blood supply supports the continued growth of expanding 
tumour masses.  Invasive breast cancers will then spread from the duct or 
lobe of origin, through the basement membrane and into the surrounding 
breast tissues (local invasion).  If tumour cells reach and enter the 
bloodstream, or if there is regional lymph node involvement, then there is 
a high risk that the cancer will metastasise to distant sites such as the 
bones, brain and liver (Fig. 1-2) (Fidler 2003; Steeg 2003).  In 
non-invasive disease the basement membrane remains intact and 
malignant cells are limited to their original position.  Non-invasive breast 
cancers, the most common of which are ductal and lobular carcinoma in 
situ, can eventually progress to invasive disease and have high risks of 
recurrence (Wiechmann and Kuerer 2008).      
The growth and development of the majority of breast cancers is driven 
by the hormone oestrogen but more aggressive tumours rely on growth 
factors for oncogenic progression.  The importance of the oestrogen 
receptor (ER) and growth factor receptors in breast carcinogenesis will 
be covered in later sections (1.2.6 and 1.2.7). 
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Figure 1-2: The development and progression of breast cancer.  Primary breast 
tumours develop from aberrantly proliferative cells that have failed to undergo 
apoptosis following irreparable DNA damage.  A) By taking up nutrients from 
surrounding tissue, tumours can grow to around 1-2mm diameter but in order to expand 
further a dedicated blood supply is needed.  B) Malignant cells secrete angiogenic 
signalling proteins, such as Vascular Endothelial Growth Factor (VEGF), which 
stimulate the development of a tumour capillary network.  C) Undetected and untreated, 
breast cancers spread through the breast and may reach the skin or grow through the 
chest wall.  D) Ultimately invasive breast cancers reach and enter the bloodstream either 
directly or via the lymphatic system.  E) Circulating breast cancer cells can then spread 
to other organs and tissues where micrometastases form and eventually develop into 
secondary/metastatic tumours. 
A B 
C 
D 
E 
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1.2.3 Breast cancer classification 
Breast cancers are classified according to the Tumour Nodes Metastases 
(TNM) staging system which categorizes disease based on measures of 
tumour size and spread.   
In addition to staging, breast cancers are also “graded” from 1-3 or low-
high (depending on the system used).  Histological grade describes the 
potential aggressiveness of a tumour based on the degree of cellular 
differentiation.  Differentiation is the process by which cells develop 
from progenitor stem cells into specialised cell types.  In the context of 
staging: the degree of differentiation refers to how closely the tumour 
cells resemble the cell types from which the cancer developed.   
Breast cancer grade depends on measures of malignant cell morphology, 
organization and proliferation.  Grading is important for determining 
disease prognosis and usually influences the aggressiveness of the 
therapeutic approach (Elston and Ellis 1991; Rakha et al. 2010).   
The Nottingham prognostic index (NPI) is a system for predicting patient 
outcome based on key histopathalogical indicators.  In the NPI, breast 
cancers are classified according to the score produced by following 
calculation: (0.2 x S) x N x G.  S is the tumour size in centimetres, N is 
the number of lymph nodes involved and G is the tumour grade.  Tumour 
grade is determined by scoring from 1-3 in each of the following three 
categories: nuclear pleomorphism, mitotic rate and glandular formation.  
Nuclear pleomorphism/atypia relates to the degree of irregularity in the 
size, shape and staining intensity of malignant cell nuclei.  Mitotic rate is 
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a measure of the number of cells in the tumour periphery that are in 
metaphase, anaphase or telophase.   Glandular formation describes the 
degree of structural normality within the tumour i.e. the percentage of 
cells which are organized into the typical lobular/tubular structures of 
breast tissue.   Histopathologists will microscopically examine a tumour 
and, based on quantitative and qualitative assessment, will assign a score 
between 3 and 9.  A score of 3-5 indicates a low grade/grade I tumour 
which is well differentiated, 6-7 represents an intermediate/grade II 
tumour that is moderately differentiated.  A grade score of 8-9 reflects 
high/grade III disease i.e. an highly aggressive, poorly differentiated 
tumour (Elston and Ellis 1991; Galea et al. 1992).  
The molecular classification of breast cancer subdivides disease 
according to the expression of key genetic markers (Table 1-1).  
Stratification of breast cancer into the subtypes Luminal A, Luminal B, 
Basal-like and HER2 is important for patient prognosis and treatment. 
  
 33 
 
Table 1-1: The main molecular subtypes of breast cancer. Figure compiled from: 
(Schnitt 2010; Zhang et al. 2014) 
 Luminal A Luminal B Basal-like HER2 
Percentage of 
breast cancers 
≈ 40% ≈ 30%  ≈ 15%  ≈ 15%  
ER  Positive Positive Negative Negative 
HER2 expression Negative Positive OR 
high Ki-67 
(proliferation) 
Negative Positive 
Cytokeratins Luminal 
markers: 
CK8
+
 and 
CK18
+
 
Luminal 
markers: 
CK8
+
 and 
CK18
+
 
Basal markers: 
CK5/6
+
, 14
+
, 
17
+
 
 
Other 
overexpressed 
genes 
GATA‑3, 
XBP-1, 
FOXA1, 
and ADH1B 
 
FGFR1, 
EGFR, Ki-67, 
cyclin D1, 
CCNB1 and 
MYBL2 
EGFR, c-Kit, 
FOXC1, p63, 
P-cadherin, 
vimentin, 
laminin 
GRB7  
Targeted 
treatment 
response  
Respond to 
endocrine 
therapy 
(tamoxifen/ 
aromatase 
inhibitors) 
 
Endocrine 
therapy 
response more 
variable than 
in luminal A 
Trastuzumab 
for HER2+ 
tumours. 
Insensitive to 
endocrine 
therapy or 
trastuzumab. 
Some 
response to 
platinum-
based 
chemotherapy, 
PARP 
inhibitors and 
anti-
angiogenics 
Trastuzumab. 
De novo or 
acquired 
trastuzumab 
resistant 
tumours 
treated with 
combined 
PI3K/mTOR 
inhibitor 
5-year RSR  95% 50% 30% 30% 
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1.2.4 Treatment 
There is no single treatment for breast cancer.  Therapy involves a 
combination of different approaches designed to remove or reduce the 
tumour burden and to prevent its recurrence or further progression.  
Generally the more aggressive and advanced the disease, the more drastic 
the therapeutic approach will be.  However, a patient’s personal needs 
and wishes are also taken into consideration when planning their 
particular treatment regimen.  Thus breast cancer treatment usually 
reflects a balance between effectiveness and tolerability of side-effects. 
Surgery is the therapeutic mainstay of breast cancer treatment.  Surgical 
options range from wide local excision (lumpectomy) to radical 
mastectomy and lymph node resection which involves removal of the 
breast, the muscles of the chest wall and the lymph nodes (CRUK 2011).   
Typically surgical intervention will be followed by a course of 
radiotherapy.  Radiotherapy involves the use of ionising particles or high 
energy electromagnetic waves to destroy cancer cells.  Ionising radiation 
directly causes breaks and mutations in DNA as well as generating 
cytotoxic free-radicals and peroxides that damage both the DNA and 
cellular proteins.  Cells can ordinarily repair DNA breaks but it is thought 
that radiation treatment, of a high enough dose and long enough duration, 
saturates the DNA repair pathways such that exposed cells are 
irreparably and fatally damaged.   Radiotherapy is targeted to the tissues 
surrounding the excised tumour in order to remove any residual/locally 
spread disease.  Although radiotherapy is targeted to the tumour site, the 
treatment is not specific for cancer cells: there is a great deal of collateral 
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damage to the irradiated healthy tissues surrounding the cancer 
(Dormand et al. 2005).  
Chemotherapy is a common adjuvant to both surgery and radiotherapy.  
Chemotherapy regimens usually involve combinations of different drugs 
that are designed to exert the greatest possible damage to the tumour cells 
with minimal damage to healthy cells.  The major difference between 
malignant and healthy cells that is exploited by most chemotherapeutic 
agents is the rate of cell division.  Because cancer cells are much more 
proliferative than normal cells, drugs designed to inhibit cell division 
have a greater effect on cancerous tissue.  Unfortunately therapeutic 
specificity is limited because highly proliferative tissues such as the 
colonic epithelium are also damaged by these agents.  Chemotherapy is 
particularly important in the treatment of ER
-
 breast cancers and high-
risk ER
+
 disease.  Some of the common chemotherapeutic agents are 
described in Table 1-2; a typical treatment regimen will involve 
combinations of these drugs.  
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Table 1-2: Common chemotheraputic agents for the treatment of breast cancer 
and their mechanisms of action. Figure compiled from: (Cerqueira et al. 2007; CRUK 
2011; Brenner and Stevens 2013) 
Drug Type of drug Mechanism of action 
Fluorouracil (5FU) Anti-metabolite Inhibits thymidylate synthase, preventing 
synthesis of thymidine and therefore inhibiting 
DNA replication. 
Epirubicin Intercalating 
agent 
Causes intercalation of DNA strands, 
inhibiting DNA replication and RNA 
synthesis. 
Cyclophosphamide Alkylating 
agent 
Metabolised to phosphoramide mustard which 
causes cross-links within and between DNA 
strands.  Inhibits DNA and RNA synthesis.  
Methotrexate Anti-metabolite Inhibits Dihydrofolate reductase which is 
required for synthesis of thymidine and 
therefore DNA.  Methotrexate also inhibits 
RNA synthesis since folate is necessary for 
cells to make adenine and guanine.   
Doxorubicin Intercalating 
agent 
Causes intercalation of DNA strands, 
inhibiting DNA replication and RNA 
synthesis. 
Docetaxel Anti-mitotic Binds to and prevents depolymerisation of 
microtubules, thereby inhibiting cell division 
and the accumulation of tubulin promotes 
apoptosis. 
Mitoxanthone Intercalating 
agent 
Inhibits topoisomerase II causing intercalation 
of DNA strands, inhibiting DNA replication 
and RNA synthesis. 
Mitomycin C Alkylating 
agent 
Causes cross-links within and between DNA 
strands.  Inhibits DNA and RNA synthesis. 
Gemcitabine Anti-metabolite Incorporated into DNA and prevents further 
addition of bases. Inhibits ribonucleotide 
reductase preventing deocyribonucleotide 
synthesis. DNA synthesis inhibition. 
In addition to relatively non-specific chemotherapy, targeted treatments 
have been developed which will be discussed in more detail in the 
sections on the oestrogen receptor (1.2.6) and receptor tyrosine kinases 
(1.2.7).  
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1.2.5 Aetiology 
The root cause of breast cancer, as for all cancers, is genetic alteration in 
cells.  Of the many risk factors that have been identified for cancer, the 
vast majority relate to variables that increase the likelihood of DNA 
mutations occurring.   
In breast cancer, most risk factors for disease development are hormonal; 
more specifically they are oestrogen dependent.  It has been shown that 
the longer an individual is exposed to oestrogen (i.e. the larger their 
oestrogen window) the greater their risk of developing breast cancer.  
Reproductive history therefore has an important aetiological influence on 
the disease: being female, early menarche, not having children, high body 
fat, having hormone replacement therapy (HRT) are all factors known to 
increase breast cancer risk (Henderson 2006).  The role of oestrogen in 
breast cancer development will be covered more thoroughly in section 
1.2.6.    
Gender is the single biggest risk factor for breast cancer: females are over 
100 times more likely to develop the disease than males (IARC 2008).  
Prognosis is often thought to be poorer in men as a result of reduced 
disease awareness and longer delays before medical advice is sought 
(Fentiman et al. 2006).  When survival figures are standardised for age at 
diagnosis and cancer stage there appears to be no significant difference in 
prognosis between genders (Gómez-Raposo et al. 2010).  
After gender, age is the next most important risk factor for developing 
breast cancer.  The effect of age can in part be explained by cumulative 
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risk: the chance of DNA damage occurring, and therefore the likelihood 
of malignant transformation, accrues over time.  Figures show that the 
lifetime risk of a UK female developing breast cancer is 1 in 8 but the 
majority (81%) of cases are diagnosed in those over 50 years old (CRUK 
2011).  A number of key genetic events are associated with mammary 
carcinogenesis including mutation of the critical tumour suppressor gene 
TP53 and upregulation of the HER2 oncoprotein.  
Most breast cancers develop sporadically from acquired mutations but a 
small proportion of breast cancers are familial in origin.   Between 5 and 
10% of breast cancers are thought to arise from inherited breast cancer 
genes (Khadim et al. 2013).  Breast cancer type 1 and 2 susceptibility 
proteins (BRCA1 and BRCA2) are tumour suppressor enzymes that are 
involved in double-stranded DNA break repair.  Cells lacking functional 
BRCA1 or BRCA2 amass critical chromosomal aberrations such as 
breaks, centrosome amplification and aneuploidy (Welcsh and King 
2001).  Germline mutations in the BRCA1 and BRCA2 genes have been 
shown by meta-analysis to increase the carrier’s risk of developing breast 
cancer.  Before the age of 70, the risk of breast cancer is raised by 47-
66% in BRCA1 mutation carriers and 40-57% of those with BRCA2 
mutations (Chen and Parmigiani 2007).  
1.2.6 Oestrogen Receptors and Breast Cancer 
The oestrogen receptors (ERs), ER-α and ER-β, are nuclear hormone 
receptors and as such are ligand inducible transcription factors that 
regulate the expression of an array of genes.  Both receptors have been 
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implicated in breast cancer though the role of ER-α is better understood 
and considered to be of greater importance in the disease.  Where ER
+
 
breast cancer is discussed, ER-α is the receptor being referred to. 
The genes, signalling proteins and cellular processes affected by ER-α 
and -β vary widely between and within tissues, though the two receptors 
often act antagonistically.  Different interacting cofactors can also induce 
disparate downstream responses from the ERs so a single cell may 
respond differently to oestrogen stimulation depending on context 
(McDonnell and Norris 2002).   
The normal physiological roles of oestrogens and the ERs in controlling 
breast and reproductive growth, development and function are well 
characterised.  Interactions between oestrogens and the ERs are also 
known to affect other processes such as bone remodelling, blood pressure 
regulation and clotting factor synthesis (Oelkers 1996; Raisz 1999). 
ER-α and ER-β share considerable homology but differences in the 
activating function (AF-1) domains of ER-α and ER-β are thought to 
confer the two receptors with differing abilities to stimulate gene 
expression (Singh and Kumar 2005).  The AF-1 domain in ER-α renders 
strong transcriptional activity to the receptor that is not conferred by the 
equivalent domain in ER-β.  Moreover, the AF-1 ER-β has been shown 
to contain a repressive motif that when removed enhances the 
transcriptional activity of the receptor (Hall and McDonnell 1999). 
In the absence of steroid hormone ligand, ERs are bound to an inhibitory 
complex of heat shock proteins (HSPs; Fig. 1-3).  The binding of an 
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oestrogen ligand to an ER stimulates dissociation of the HSPs and 
promotes receptor dimerization, nuclear translocation and DNA binding.  
In the classical genomic pathway of ER activity: ER dimers then bind to 
recognition sequences called oestrogen response elements (EREs), which 
are found in the promoter regions of target genes.  Once ERs are bound 
to EREs, transcriptional cofactors and chromatin remodelling proteins are 
recruited by the AF-1 and AF-2 domains.  The cofactors that are 
recruited can vary and may be transcriptional coactivators or 
corepressors.  The complexes formed by the ERs, ligands and cofactors 
then alter the expression of downstream genes (Weinberg 2006).   
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Figure 1-3 E2 induced transcription of ER target genes. Oestradiol (E2) binds to the 
ligand binding domain (LBD) of the ER, and the HSP inhibitory complex dissociates. 
The ER undergoes conformational change and then forms a dimer-ligand complex 
before being translocated to the nucleus. The ER dimer forms a transcriptional complex 
with coregulator proteins and binds via the DNA binding domain (DBD) to EREs in the 
promoter regions of target genes  (Driggers and Segars 2002; Nilsson et al. 2011) 
Ligand activated ERs can also indirectly affect gene expression by 
interacting with other transcription factors and modulating their function.  
This transcriptional cross-talk is known as the non-classical genomic ER 
pathway, an example of which is the relationship between ER-α and 
nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB). 
Target genes of NFκB have been shown to be downregulated by ER-α, 
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and the two transcription factors appear to be mutually co-repressive 
(Gionet et al. 2009).   
ER-α can also regulate gene transcription in a ligand-independent 
manner. It has been shown that the ER-α can be phosphorylated at serine 
118 in the AF-1 domain by mitogen activated protein kinase (MAPK).  
Phosphorylation of ER-α by MAPK enhances the transcriptional activity 
of the hormone receptor (Kato et al. 1995). MAPK is a key protein in 
growth factor signalling by receptor tyrosine kinases (RTKs), a family of 
cell-surface receptors that are also important in breast cancer (see section 
1.2.7).  Through MAPK there is cross-talk between the RTK and ER-α 
signalling pathways and effector mechanisms. The phosphorylation and 
transcriptional activity of ER-α can be increased by pathways that 
enhance MAPK phosphorylation e.g. by cell stimulation with epidermal 
growth factor (EGF). Overexpression of wild-type or constitutively 
active MAPK, or of the upstream signalling protein Ras, also enhance 
ER-α transcriptional activity (Kato et al. 1995; Bunone et al. 1996). 
Ligand-independent activation of ER-α is also achieved via 
phosphorylation of other serines in the AF-1 domain e.g. ser167 which is 
phosphorylated by Akt (Martin et al. 2000). Akt is a serine/threonine 
kinase and an important pro-survival oncogene owing to its role in 
inhibiting apoptosis. Akt is activated by growth factor stimulation and as 
such represents another key overlap between hormone and growth factor 
receptor actions.  In addition to interaction with downstream signalling 
proteins, ER-α has been shown to directly interact with RTKs such as 
EGFR.  ER-α can associate with the endocytic scaffold protein caveolin-
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1 (see section 1.2.8.2) at the cell membrane where it can induce 
transactivation of RTKs and promote downstream receptor signalling 
(Razandi et al. 2002; Razandi et al. 2003).  Bi-directional cross-talk 
between ER-α and growth factor receptors and their downstream 
signalling kinases is increasingly thought to be important in breast cancer 
resistance to endocrine therapy (Shou et al. 2004; Gee et al. 2005; Wang 
et al. 2011b).   
ER-α has been shown to be overexpressed in at least 70% of breast 
cancers and the links between oestrogen exposure and mammary 
carcinogenesis are well-established (Anderson et al. 2002).  
Downregulation of ER-β has been reported in invasive breast cancers but 
its role in breast cancer is less well understood than ER-α (Roger et al. 
2001; Skliris et al. 2003)  
Oestrogens have been shown to have direct mitogenic effects on ER-α 
positive breast cancers.  Oestradiol (E2) increases the number of mitotic 
breast cancer cells in hormone treated cultures (Doisneau-Sixou et al. 
2003).  The proliferative effects are partly attributed to upregulation of 
the ER target proteins c-Myc and cyclin D whose expression rapidly 
increases in response to E2 (Butt et al. 2005).  Cyclin D directly drives 
cell cycle progression by promoting G1/S phase transition. c-Myc is a 
transcription factor, and proto-oncogene, that promotes transcription of 
pro-proliferative cyclins and downregulates the cell cycle inhibitor p21. 
ER-α has also been shown to promote cell survival. For example, 
expression of the anti-apoptotic protein Bcl-2 has been shown to be 
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induced by E2 stimulation of ER
+ 
breast cancer cells (Teixeira et al. 
1995). 
Endocrine therapies that target oestrogen synthesis and ER signalling 
have displayed profound efficacy in the treatment of ER-positive breast 
cancers.  Treatment with Tamoxifen reduces the rate of recurrence of 
these tumours by nearly 50% and mortality by 30%.  Nonetheless, the 
issues of de novo and acquired therapeutic resistance pervade and are 
believed to affect around 25-50% of all cases (Musgrove and Sutherland 
2009).  
Tamoxifen binds to the ER, inducing dimersation and nuclear transport 
but inhibiting cofactor recruitment to, and therefore transcriptional 
activity of, the AF-2 domain (Shiau et al. 1998).   Function of the AF-1 
domain remains intact, in fact Tamoxifen has been shown to promote 
transcription of AF-1 responsive genes (Tzukerman et al. 1994).  
Different tissues have different patterns of AF-1 and AF-2 responsive 
genes: AF-2 genes are more prevalent in the breast while AF-1 genes are 
predominantly found in the uterus.  Tamoxifen is consequently described 
as a selective oestrogen receptor modulator (SERM) as it can act as an 
agonist or an antagonist depending on the histological context (Ring and 
Dowsett 2004).  The inability of Tamoxifen to completely abolish the 
transcriptional activity of ER-α is thought to be a contributing factor in 
therapeutic resistance.    
Anastrazole (Arimidex®) is a third generation aromatase inhibitor that 
prevents oestrogen biosynthesis from androgen precursors. The strategy 
of aromatase inhibition was developed in order to overcome the problems 
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of Tamoxifen’s ER agonist activity.   In a large scale phase 3 clinical trial 
anastrozole demonstrated greater efficacy (increased disease free 
survival) and fewer side-effects than Tamoxifen for over 9000 post-
menopausal women who had early stage breast cancer. Therapeutic 
resistance was however still reported for anastrazole and osteoporosis 
was a notable side-effect (Howell et al. 2005).  Following surgery, 
anastrazole is now the recommended first-line hormone treatment for 
ER
+
 breast cancer according to National Institute for Health and Clinical 
Excellence (NICE) guidelines (CRUK 2011). 
The need for better ER-targeted therapies led to the development of 
selective oestrogen receptor downregulators (SERDs) such as fulvestrant 
(Faslodex®).  Fulvestrant has a high affinity for the ER and competes 
with E2 for the LBD.  Binding of fulvestrant to the ER inhibits receptor 
dimerization, nuclear transport and cofactor interaction (Fawell et al. 
1990; Dauvois et al. 1993). Degradation of the ER is also accelerated 
when bound to fulvestrant leading to a significant reduction in receptor 
numbers, attenuation of signalling and ablation of all ER transcriptional 
function (Morris and Wakeling 2002).  
Fulvestrant shows greater potency than Tamoxifen against ER
+
 breast 
tumours in the laboratory and is associated with reduced development of 
resistant disease.  Fulvestrant also shows activity against Tamoxifen-
resistant disease models (Osborne et al. 1995).  Fulvestrant has 
demonstrated efficacy slightly superior to anastrazole and equal 
tolerability in a double-blind randomized clinical trial in Tamoxifen 
resistant disease (Osborne et al. 2002).  Fulvestrant is not currently 
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approved over anastrazole in the UK for use in locally advanced or 
metastatic breast cancer (NICE 2011). 
Increased expression, activity and downstream signalling of growth 
factor receptors is also thought to contribute to resistance to endocrine 
therapies via enhanced ER agonist activity (Gee et al. 2005; Nicholson et 
al. 2007) as well as acting independently of ER in ER
-
 disease.  Proteins 
with connections to both ER and RTK function may therefore represent 
important targets for predicting, preventing or reversing hormone 
refractory breast cancer.  Such proteins may also be useful targets for the 
treatment of ER
- 
cancers that are critically dependent on growth factor 
receptor expression and downstream signalling.  
1.2.7 Receptor Tyrosine Kinases and Breast Cancer 
Receptor Tyrosine Kinases (RTKs) such as EGFR, HER2 and c-Met are 
transmembrane proteins that are essential for normal cell function but are 
often overexpressed/ineffectively downregulated in breast cancer.   
Estimates vary, but in one of the largest studies to date, EGFR 
overexpression was demonstrated in 18% of breast cancers and HER2 
positivity in 18% of cases.  High levels of EGFR and HER2 were 
associated with a more aggressive cancer phenotype and poorer 
prognosis in patients who had received adjuvant systemic therapy and/or 
had suffered relapse (Rimawi et al. 2010). 
 c-Met is another RTK that is expressed in normal epithelial cells but is 
upregulated in breast cancer.  Around 20–30% of all breast tumours have 
 47 
 
been shown to overexpress c-Met and high levels of the receptor are 
associated with poor clinical outcome (Lengyel et al. 2005).    
EGFR and HER2 belong to the ErbB family of RTKs of which there are 
four, structurally homologous, members: EGFR (ErbB1, HER1), HER2 
(ErbB2), HER3 (ErbB3) and HER4 (ErbB4).   
All ErbB receptors have an ectodomain which can, in all family members 
but HER2, bind to compatible extracellular ligands.  A summary of all 
documented ErbB ligands is shown in Figure 1-4. 
 
 
 
 
 
Figure 1-4: Unique and shared ligands of the ErbB receptors. Circles/ovals 
represent named receptors.  Ligands are listed within limits of their activating receptor.  
Overlapping regions reflect & contain shared ligands. HER2 is an orphan receptor with 
no known ligands. EGF = epidermal growth factor, TGFα = transforming growth factor 
alpha, AREG = amphiregulin, EPG = epigen, DEC = decorin, ERG = epiregulin, HB-
EGF = heparin binding EGF,  BTC = betacellulin, NRG = neuregulin.  Figure compiled 
from: (Harris et al. 2003; Lin and Winer 2004; Bouyain et al. 2005; Iozzo et al. 1999; 
Schneider and Yarden, 2014) 
 
 When activated by ligand binding, RTKs initiate signalling cascades that 
transduce mitogenic, angiogenic, pro-migratory and survival signals to 
the nucleus.  The sequence of activation events in the ErbB family can be 
summarized as: homo- or heterodimerization of ligand-bound receptors 
followed by receptor activation through trans-autophosphorylation of 
intracellular tyrosine residues.  All but one of the ErbB receptors has a 
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cytosolic domain with tyrosine kinase functionality (Fig. 1-5).  The 
exception is HER3 which lacks crucial catalytic residues and as such is 
generally considered to be “kinase dead”.   There is however evidence 
that in certain conditions HER3 may possess some kinase activity, e.g. 
when in a heterodimer with HER2 (Shi et al. 2010).   
 
Figure 1-5: Domain structure of the ErbB family of RTKs. ErbB2 (HER2) is an 
orphan receptor with no known ligands.  ErbB3 has no/minimally active tyrosine kinase 
domain. 
Activation of RTKs initiates pro-oncogenic intracellular phosphorylation 
cascades.  EGFR and HER2 predominantly signal via the MAPK and 
Phosphatidylinositol 3-Kinase (PI3K) pathways.  Overexpression of 
EGFR/HER2 leads to increased MAPK and PIK3/Akt signalling and to 
aberrant transcription of genes associated with malignant transformation.  
Some examples of upregulated genes include: cell division cycle-
associated protein 7 (CDCA7) (Trang et al. 2009), FOS-like antigen 1 
(FOSL1) and osteopontin (OPN) (Janka et al. 2010). CDCA7 and FOSL1 
stimulate proliferation and osteopontin is an anti-apoptotic protein, and 
all are associated with malignant overexpression. Due to changes in gene 
expression profile, RTK overexpressing cells are immortalised, highly 
proliferative and have an enhanced capacity to adhere, invade, 
metastasise and promote angiogenesis (Nicholson et al. 2007).   
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The activation and signalling of c-Met shares many similarities with the 
ErbB receptors: activation is primarily induced by ligand binding and 
downstream signalling is mainly via the pro-oncogenic MAPK and 
PI3K/Akt pathways. The role of dimerisation in c-Met activation and 
signalling is less well understood but dimerization is known to occur by 
ligand-dependant and independent mechanisms. Ligand-independent 
dimerisation of c-Met and mutations in the dimerisation domain of the 
receptor are thought to be important in cancer (Wickramasinghe and 
Kong-Beltran 2005). 
Overexpression of RTKs in breast cancer enables therapeutic targeting.  
For example, the humanised monoclonal antibody trastuzumab 
(Herceptin®) and the small molecule inhibitor gefitinib (IRESSA®) have 
exhibited activity against HER2
+
 and EGFR
+
 breast cancers respectively 
(Normanno et al. 2009).  Despite some successes with these therapies, 
present strategies are still far from perfect.  For example, 15% of patients 
with early stage breast cancers relapse in spite of trastuzumab treatment 
and those with metastatic disease often develop resistance to the inhibitor 
(Nanda 2007).   
Despite relatively wide usage in the treatment of HER2
+
 breast cancer, 
trastuzumab’s mechanism of action is not yet fully understood but is 
known to be complex.  Trastuzumab binds HER2 with high affinity and 
this has been shown to inhibit cellular proliferation and promote 
apoptosis via a number of mechanisms, including: decreased cyclin 
dependent kinase 2 (CDK2) activity (Lane et al. 2001), reduced 
PI3K/Akt signalling (Nagata et al. 2004) and inhibited DNA repair and 
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synthesis following chemo- and radiotherapy (Pietras et al. 1994; Pietras 
et al. 1999). The induction of immune based cytotoxic responses 
(antibody and complement mediated) has also been described for 
trastuzumab (Stockmeyer et al. 2003), and the mAb has also 
demonstrated anti-angiogenic activity via reduced VEGF production 
(Izumi et al. 2002).  Trastuzumab induced HER2 downregulation via 
increased receptor endocytosis (see section 1.2.8) has been reported and 
may contribute to the mAb’s anti-cancer effects (Cuello et al. 2001). In 
2009 (Ben-Kasus et al.) suggested that trastuzumab and HER2 may form 
lattices at the cell membrane which collapse into the cytoplasm and are 
subject to lysosomal degradation, a phenomenon the group had 
previously reported for anti-EGFR mAbs (Friedman et al. 2005). HER2 
itself has been shown to be resistant to internalisation, a property 
attributed to a number of factors including, the receptor’s association 
with membrane protrusions (Hommelgaard et al. 2004), inhibited clathrin 
pit formation (Cortese et al. 2013) and to a cystosolic region of HER2 
termed the “blocking ErbB2 degradation” (BED) domain (Shen et al. 
2008). Internalisation-resistance reduces receptor downregulation 
allowing prolonged activation and downstream signalling, potentially 
important factors in trastuzumab resistance.  Other mechanisms believed 
to contribute to trastuzumab resistance include: constitutive activation of 
downstream HER2 signalling pathways, masking of the trastuzumab 
epitope by mucin-4 overexpression, increased compensatory signalling 
through other ErbB receptors and cross-talk between IGF-R1 and HER2 
signalling pathways (Nahta and Esteva 2006). 
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Therapeutic resistance to EGFR inhibitors has been linked to alterations 
in receptor endocytosis (Hopper-Borge et al. 2009).  Gefitinib’s activity 
against EGFR overexpressing cancers is a result of the drug 
competitively inhibiting ATP-binding in the tyrosine kinase domain of 
EGFR.  Gefitinib binding to this intracellular site ablates receptor 
phosphorylation and tyrosine-kinase activity which in turn suppresses 
pro-growth and survival signalling (Tiseo et al. 2010).  In gefitinib 
sensitive non-small cell lung cancer (NSCLC) cells EGFR is rapidly 
internalised and degraded following ligand stimulation.  However, 
gefitinib resistant  NSCLC cell lines have shown impaired EGFR 
downregulation compared with sensitive cell counterparts (Ono et al. 
2004).  Aberrant accumulation of EGFR in early endosomes of resistant 
cells has also been described in both the presence and absence of 
gefitinib (Nishimura et al. 2007). Squamous cell carcinoma of the head 
and neck (SCCHN) cells that are resistant to the EGFR inhibitor mAb 
cetuximab show aberrant persistence of EGFR on the cell membrane 
following ligand stimulation (Wheeler et al. 2008).  Together these 
findings suggest that impaired endocytic trafficking may be involved in 
conferring therapeutic resistance. There is a need to better understand the 
mechanisms governing RTK endocytosis and to identify potential 
mechanisms and targets for promoting receptor downregulation.     
1.2.8 Downregulation of Receptor Tyrosine Kinases 
Endocytosis is the process by which cells internalise ligand-bound 
receptors.  There are a number of internalisation routes through which 
RTKs are trafficked and generally-speaking these routes may be divided 
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into two categories: clathrin-mediated endocytosis (CME) and clathrin 
independent endocytosis. 
1.2.8.1 Clathrin-Mediated Endocytosis 
Clathrin and various accessory proteins are recruited to the site of 
activated receptors where they assemble into a layered structure on the 
local membrane. (See Figure 1-6 for a schematic diagram of RTK 
endocytosis).   The membrane surrounding the receptor then invaginates 
and pinches off, forming a clathrin-coated vesicle containing the receptor 
and ligand. The C-terminus of the receptor remains exposed to the 
cytosol and continues to activate signalling pathways during vesicle 
translocation
  
(Wieffer et al. 2009). Vesicles are shuttled into the cell 
before being uncoated and associating with Rab5. Rab5 is a member of 
the Rab family of small GTPase proteins that are responsible for 
coordinating membrane trafficking. Rab5 mediates vesicle transport to, 
and fusion with, the early endosome and has also been implicated in 
clathrin pit formation (McLauchlan et al. 1998). The early endosome is a 
peripheral, membrane-bound organelle where many endocytic pathways 
intersect. Receptors are sorted in early endosome and subsequently 
trafficked along different routes (Jovic et al. 2010).  
From the early endosome, a receptor may follow one of three pathways: 
fast or slow recycling (exocytosis) or degradation. Fast recycling is 
coordinated by Rab4 and is the process by which receptors are rapidly 
shuttled back to the cell membrane. Slow recycling is organized by Rabs 
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4 and 11. Degradation is coordinated by Rab7, a protein responsible for 
receptor sorting in late endosomes and transport to lysosomes. 
The late endosome or multivesicular body (MVB) is a large sorting 
compartment that is densely packed with lumenal vesicles.  MVB 
maturation and receptor internalisation into the MVB is controlled by the 
endosomal sorting complex for transport (ESCRT) machinery comprised 
of ESCRT-I, -II and -III.  The ESCRT-I complex recognises receptors 
that have been targeted for degradation by ubiquitin tags on the 
receptor’s cytoplasmic tail (for more detailed discussion about 
ubiquitination see Section 1.2.9).  The binding of ubiquitinated receptor 
to the ESCRT-1 complex effectively tethers the receptor to the maturing 
endosome and prevents it from being recycled.  ESCRT-II and –III are 
then recruited and mediate further receptor sorting and invagination of 
the endosomal membrane around the receptor.   Eventually the vesicle-
bound receptor buds off into the MVB lumen and the ESCRT machinery 
can be recycled (Katzmann et al. 2002; Raiborg and Stenmark 2009).  
Receptors in the late endosome no longer actively signal as they are fully 
enclosed within its multivesicular structure.  Receptors (and ligands) are 
broken down in lysosomes by acid hydrolases, marking the end of the 
degradation pathway.   
Rab7 controls receptor trafficking to the lysosome by mediating fusion of 
the MVB and the lysosome.  The GTPase is also critically involved in 
lysosome biogenesis, acidification and localisation (Bucci et al. 2000; 
Vanlandingham and Ceresa 2009).  Interestingly, Rab7 appears to have a 
dual, potentially antagonistic role in endocytosis through an interaction 
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with the E3 ligase, and subject of this thesis, BCA2.  The consequence of 
the interaction has been shown separately to inhibit and promote RTK 
degradation (Mizuno et al. 2003; Sakane et al. 2007; Smith et al. 2013). 
For more detailed discussion of the interaction between BCA2 and Rab7 
see section 1.5.2. 
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Figure 1-6: Receptor Tyrosine Kinase Endocytosis. Following internalisation and transport to early endosomal sorting compartments, activated 
receptor tyrosine kinases (RTKs) such as EGFR may be trafficked along one of three main endocytic pathways: A) Fast or slow recycling of RTKs 
maintains receptor numbers on the cell surface and facilitates repeated stimulation and prolonged oncogenic signalling. B) The degradation pathway 
leads to cessation of signalling as the RTKs become bound within the multivesicular structure of the late endosome. The receptors and their ligands 
are ultimately destroyed by acid hydrolase enzymes in the lysosomes. 
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The importance of endosomal signalling has been demonstrated by a 
number of in vitro studies.  Recruitment and activation of downstream 
signalling proteins at early endosomes has been demonstrated in EGF 
stimulated cells following receptor internalisation  (Wang et al. 2002).  
One study showed reduced activation of downstream EGFR signalling 
when receptor endocytosis was inhibited (Vieira et al. 1996) and another 
showed that the subcellular localisation of EGFR during endocytosis is 
important for modulating cellular effects such as viability (Hyatt and 
Ceresa 2008).  In vivo research examining the role and significance of 
endosomal signalling is more limited.  A study by Schenck et al. in 2008 
showed that endosomal regulation of Akt signalling was important for 
vertebrate development. Depletion of the endosomal protein Appl1 
(which interacts with Akt) was shown to specifically decrease 
downstream activation of glycogen synthase kinase 3 (GSK3)-β while 
phosphorylation of tuberous sclerosis protein-2 (TSC2) was not reduced.  
Studies in Drosophila mutants engineered to block cargo entry into 
specific endosomal compartments have demonstrated that Notch must 
enter early endosomes to undergo cleavage and instigate signalling 
(Vaccari et al. 2008).  It was suggested that diseases such as cancer and 
developmental disorders involving aberrant Notch signalling, may arise 
from, or involve, endocytic defects that impair endosomal entry of Notch.  
Various molecules involved in regulating RTK endocytosis have also 
been implicated in cancer. Rab5 has a role in the regulating downstream 
integrin signalling with functional consequences for cell survival and 
migration (Torres et al. 2010).   Rab7 has been shown to affect cell 
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survival and adhesion via coordination of the later stages of EGFR and 
HER2 endocytosis (Wang et al. 2011a).    
1.2.8.2 Clathrin Independent Endocytosis 
Clathrin independent pathways are most often classified according to the 
key proteins governing the internalisation process: caveolae-mediated 
endocytosis (CvME), Arf6-dependent, flotillin-1-dependent, Cdc42-
dependent and RhoA-dependent endocytosis.  Macropinocytosis is also 
considered to be a NCME and is the process by which cells engulf more 
substantial volumes of extracellular fluid through membrane ruffling and 
the formation of large macropinosome vesicles (Doherty and McMahon 
2009). Of these pathways, the most relevant to RTK internalisation are 
CvME and macropinocytosis. 
CvME is a form of raft-dependent endocytosis: oligomerised caveolin 
proteins assemble in microdomains (rafts) in the plasma membrane.  
Cholesterol accumulation in the microdomains allows membrane 
invagination and the formation of caveolin associated vesicles 
(caveosomes).  Caveosome budding from the cell surface is mediated by 
dynamin II  (Nabi and Le 2003).  Caveosomes can fuse with early 
endosomes, linking CvME and CME pathways (Parton and Simons 
2007).  
Sigismund et al. in 2005, 2008 and 2013 published data showing that low 
concentrations of EGF (< 3ng/mL) lead to EGFR internalisation solely 
by CME but high EGF concentrations ( >20 ng/mL) stimulated EGFR 
internalisation by CvME. These works also demonstrated that CME was 
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required for prolonged EGFR signalling but was not essential for 
receptor degradation. Contrary to these findings, however, are data from 
Rappaport et al. (2009) which showed that EGFR does not localize to 
caveolae either prior to or following activation.   
Macropinocytosis can be induced by EGF stimulation.  In response to 
stimulation with this growth factor, cells have been shown to produce 
large waves / circular dorsal ruffles which proceed inwards from the cell 
surface, engulfing extracellular material. This membrane ruffling is 
associated with dramatic reorganization of filamentous actin. In the study 
by Orth et al. (2006) ligand-induced ruffles were responsible for the 
sequestration and internalization of approximately half of the EGF-bound 
EGFR from the cell surface. 
1.2.9 E3 Ligases and Breast Cancer 
E3 ligases are a family of enzymes that are involved in the post-
translational modification of proteins through the addition of smaller 
regulatory protein tags: either ubiquitin or small ubiquitin like modifiers 
(SUMO).  The addition of an Ub or SUMO tag can alter the stability, 
localisation and activity of cellular proteins. Ubiquitination and 
sumoylation are homologous modification processes that begin with the 
activation of the protein tags by E1 enzymes. E1-activases adenylate 
Ub/SUMO at the expense of one adenosine-5'-triphosphate (ATP) 
molecule. This is followed by the attachment of activated Ub/SUMO to 
E2-conjugase proteins. Finally the tags are transferred to target proteins 
by E3 ligases. E3 ligases mediate formation of isopeptide bonds between 
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the C-terminus of Ub/SUMO tags and the internal lysines of specific 
substrate proteins (Mani and Gelmann 2005).  The process is summarised 
in Figure 1-7. 
 
Figure 1-7: The process of ubiquitination. Ubiquitination begins with ACTIVATION 
of Ub by E1-activase enzymes. This is followed by CONJUGATION of Ub to E2 
conjugase enzymes. E3-ligase enzymes then mediate the TRANSFER of Ub to substrate 
proteins. The addition of a single Ub tag (mono-ubiquitination) can influence the 
substrate’s activity and trafficking. The addition of a chain of Ub moieties to a target 
protein is a signal for degradation by the 26S proteasome.  
Two main classes of E3 ligase exist: the adaptor ligases and the homologous 
to the E6AP carboxyl terminus (HECT) type. Adaptor E3 ligases can be 
subdivided into those that contain: a really interesting new gene (RING) 
finger, a U-box, or a plant homeo domain (PHD). HECT-type E3 ligases, 
directly bind to E2-conjugated ubiquitin via a thioester bond before 
delivering the ubiquitin to a target protein. In contrast, adaptor-type E3 
ligases mediate transfer of ubiquitin to the substrate protein from the E2 
conjugase without actively binding to the tag (Mani and Gelmann 2005).  
Dysregulation of E3 ligase expression and/or function has potentially critical 
consequences within the cell. Depending on the particular substrates of an 
E3 ligase, altered expression or functional activity could potentially result in 
accumulation of proto-oncoproteins and/or a reduction in tumour 
suppressors. A number of E3 ligases have been implicated in breast cancer 
including: BRCA1, RNF11, c-Cbl, Efp and breast cancer associated protein 
 60 
 
2 (BCA2) (Burger et al. 2006).  The importance of the latter protein in 
breast cancer will be discussed in more detail in section 1.3.  
c-Cbl is an E3 ligase that is activated and recruited to EGFR upon ligand 
binding.  C-Cbl has been shown to ubiquitinate activated EGFR at the 
plasma membrane and to remain associated with the receptor during 
endocytosis  (de Melker et al. 2001).  Others have shown that c-Cbl 
continues to ubiquitinate EGFR after internalisation (Umebayashi et al. 
2008).  Through its role in RTK ubiquitination and downregulation, loss or 
mutation of c-Cbl has been linked with oncogenesis (Peschard et al. 2001; 
Bao et al. 2003). 
1.3 BCA2 
Breast Cancer Associated gene 2 (BCA2) is named for the disease in 
which its overexpression was first identified.  Differential display and 
subtractive hybridization screening in normal and malignant mammary 
cell lines revealed that BCA2 was significantly upregulated in breast 
cancer (Burger et al. 2005).  Functional links between BCA2 expression 
and breast cancer pathology have since been suggested by in vitro 
experiments and clinical expression analyses (Brahemi et al. 2010; 
Burger et al. 2010).  
1.3.1 The BCA2 gene 
BCA2 is found on chromosome 1q21.1 (Fig. 1-8).  The long arm of 
chromosome 1 is a region often associated with cytogenetic 
abnormalities in breast cancer (Bièche et al. 1995).  An increase in 1q 
copy number has been reported in 55% of primary breast cancers and the 
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aberration is significantly correlated with positive ER status (Rennstam et 
al. 2003).  It has been proposed that there may be an overlap between the 
breast cancers that are affected by chromosome 1 partial polysomy and 
those in which BCA2 is overexpressed (Burger et al. 2005).  However, 
possible links between chromosome amplification and BCA2 have not 
been explored experimentally and so may not exist or be biologically 
significant.  It has been reported that although gain of 1q is common in 
breast cancer, corresponding genetic overexpression is relatively rare.  
Indeed, BCA2 was not among those genes identified in a screen for 
overexpression correlating with 1q copy increase (Orsetti et al. 2006).  
This same study also showed that the long arm of chromosome 1 
contained a number of candidate oncogenes thus if BCA2 overexpression 
were to be correlated with 1q gain in breast cancer, non-
specific/bystander upregulation would need to be ruled out. Gene 
coexpression studies form part of the in silico research carried out as part 
of this project, see Chapter 3. 
 
Figure 1-8: Ideogram showing the location of the BCA2 gene on chromosome 
1q21.1. Also labelled are RAB25, PLU1 and Rab4, candidate oncogenes from 
chromosome 1 shown to be overexpressed in cancers associated with increased 1q copy 
number (Orsetti et al. 2006). 
 
1.3.2 The BCA2 protein 
The BCA2 gene codes for a 304 amino acid protein, the sequence of 
which is highly conserved in chordates.  Key structural domains are also 
maintained in species from other phyla.  Conserved BCA2 regions that 
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have been identified and explored in the literature include: a RING-H2 
domain, a zinc finger, a site that is purported to be phosphorylated by Akt 
and residues that are autoubiquitinated (Fig. 1-9).  These key domains are 
thought to allow BCA2 to interact with a range of other proteins and to 
be important for the protein’s roles in cellular function and disease 
(Amemiya et al. 2008).  BCA2 has a number of aliases and the majority 
of these relate to the protein’s functional domains and interaction 
partners e.g. zinc finger protein 364 (ZNF364), RING finger protein 115 
(RNF115) and Rab7-interacting RING finger protein (Rabring7).  
 No structural data has yet been obtained for BCA2 by experiment but a 
homology model of the RING-H2 domain has been created using the 
nuclear magnetic resonance (NMR) structure of an homologous protein 
as a template (Brahemi et al. 2010).   The homology model was produced 
to enable screening for potential BCA2 inhibitors that would target the 
zinc co-ordinates in the RING-H2 domain. The schematic of BCA2 
structural domains in Fig. 1-9 is based on this model.    For further 
information on BCA2 as a therapeutic target see section 1.7.  
 
Figure 1-9: Key functional domains of the BCA2 protein. Figure complied from 
(Brahemi et al. 2010; Bacopulos et al. 2012). 
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The RING-H2 domain of BCA2 is structurally characteristic of an E3 
ligase and has been shown to confer autoubiquitination functionality to 
the protein upon interaction with the E2-conjugase UbcH5b (Amemiya et 
al. 2008). Autoubiquitination is a typical attribute of E3 ligases and is 
believed to be an essential mechanism for regulating their stability in 
cells (Zhang and Xiong 2001; Wu et al. 2004) .  Mutation of the critical 
zinc-coordinate cysteine residues in the RING-H2 domain (Fig. 1-9) 
abolishes BCA2’s facility for autoubiquitination. As a result of reduced 
proteasomal targeting, RING-H2 mutant BCA2 accumulates in cells 
(Amemiya et al. 2008).   
The interaction between BCA2 and Akt is potentially significant for the 
protein’s role in apoptotic inhibition and cancer. Evidence for the 
existence of BCA2’s Akt phosphorylation site is fairly limited. In silico 
analyses show that the internal region of BCA2 contains a consensus Akt 
phosphorylation site (RXRXXS) but only one experiment has shown that 
the phosphorylation actually occurs. The in vitro phosphorylation assay 
involved incubating recombinant BCA2 with recombinant Akt and 
radioisotope 32P-γATP at 37 or 4oC. When the samples were separated 
by SDS-PAGE, radiolabelled bands signifying phospho-BCA2 (pBCA2) 
were only detected in the 37ºC reaction. The authors concluded that 
BCA2 was phosphorylated by Akt (Connor et al. 2005) but no further 
data have been published to conclusively show that the phosphorylation 
occurs in cells or in vivo. Akt activity has however been indirectly linked 
to BCA2 stability: cells co-transfected with GST-BCA2 and 
constitutively active Akt show higher levels of BCA2 protein (Bacopulos 
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et al. 2012). It has also been claimed that the Akt phosphorylation site 
(and by inference that phosphorylation of BCA2) is required for BCA2 to 
interact with the endocytic co-ordinator Rab7 (Burger et al. 2006). 
However, no data have been published to support this assertion.  
1.4  Subcellular localisation of BCA2 
Using antibodies recognising endogenous or overexpressed BCA2 
reveals a high degree of variability with respect to subcellular 
localisation. 
BCA2 localisation has variously been shown or described in the literature 
as: 
-  Nuclear (in MCF-7 cells) by Amemiya et al. (2008). 
- Cytoplasmic and or late endosome/lysosome associated  (in BHK 
cells) by Mizuno et al. (2003) 
- Punctate cytoplasmic staining  (MCF-7 cells) by Bacopulos et al. 
(2012) 
- Faint cytoplasmic and intense nucleolar staining (in MCF-7 cells) 
by Kona et al. (2012) 
 
The Human Protein Atlas (HPA) is an antibody-based proteomics project 
where antibodies are tested for determining expression and localisation of 
target proteins. An anti-BCA2 antibody has been screened by HPA 
researchers and different subcellular distributions were reported: the 
tested cell lines showed nucleolar and/or reticular-like staining. 
From the available IF data it is very difficult to get a clear picture of the 
true subcellular localisation of endogenous BCA2.  There appears to be a 
great deal of variability between and even within cell lines. The 
difference may reflect true biological heterogeneity or may be the result 
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of using different antibodies and different methods of fixing and 
processing the cells for IF. Since no antibodies have been suitably 
validated for IF, it is difficult to assess the reliability of the published 
localisation data. The true subcellular distribution of BCA2 therefore 
remains to be discovered. 
1.5 BCA2 and Breast Cancer 
The role of BCA2 in breast cancer was first explored in detail in a 2005 
publication by Burger et al.  A large scale tissue microarray analysis of 
archived samples showed that BCA2 was overexpressed in 56% of 
primary invasive breast cancers.   Accompanying in vitro data indicated 
an oncogenic role of the protein: siRNA depletion of BCA2 significantly 
reduced cell growth and invasion of T47D (ER
+
) breast cancer cells 
while overexpression of BCA2 in NIH3T3 (mouse) cells increased 
proliferation by 50%.  Further analysis of the archived patient samples 
revealed that high levels of nuclear BCA2 were present in 74% of ER 
positive tumours and this was associated with improved disease-free 
survival for regional recurrence and reduced lymph node metastasis.  The 
correlations with positive prognostic factors were thought to relate to the 
relationship between BCA2 and the ER rather than to reflect a tumour 
suppressive role of the E3 ligase.  The archive studies additionally 
indicated that BCA2 did not affect overall survival.  Survival was not 
examined by breast cancer subtype and this gap in our understanding still 
remains.  More work is required to explore the relationship between 
BCA2 function and outcome in breast cancer.   
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1.5.1 BCA2 and the oestrogen receptors 
BCA2 appears to have an important role in ER positive breast cancer. 
74% of ER
+
 breast cancers also overexpress BCA2 (Burger et al. 2005) 
but in addition to this correlative relationship, there is mounting evidence 
that the two proteins may be mutually regulatory.  The BCA2 promoter 
contains multiple, ERE half-sites and the ERα has been shown by 
chromosome immunoprecipitation (ChIP) to bind to these elements 
(Kona et al. 2012).  ChIP is a method of determining whether a protein 
(such as a transcription factor) binds to a particular region of the DNA.  
This is achieved by first cross-linking the genomic DNA and interacting 
proteins.  The DNA is then sheared and antibody coated beads are used 
to extract the protein of interest.  Crosslinked DNA is then eluted, 
purified and sequenced.   
Dual luciferase reporter assays have also been used to show that protein 
expression downstream of the BCA2 promoter is ER-α responsive (Kona 
et al. 2012).  These findings are supported by data which show that 
endogenous BCA2 expression is oestradiol (E2) inducible at the mRNA 
level by Northern blotting (NB) and at the protein level by Western 
blotting (WB) and immunofluorescence (IF) (Burger et al. 2010; Burger 
and Westwell 2011; Kona et al. 2012).   Other potential transcriptional 
regulators of BCA2 have been found by in silico approaches but have not 
been explored experimentally.  Binding sites for the following 
transcription factors have been predicted by bioinformatic analysis of the 
BCA2 promoter  (Burger et al. 2010): 
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- Progesterone receptor (PR) 
- NFκB 
- Octamer transcription factor (OCT1)  
- Activator protein 1 (AP1) 
- YY1 
- T3R 
- Specificity protein 1 (SP1)   
Further to the evidence for transcriptional regulation of BCA2 by ER-α 
there is also some, more speculative, data which suggest that BCA2 may 
have a role in the regulation of ER-α.  ER-α and BCA2 have been 
described as co-localised in the nucleus (Burger et al. 2010) but 
interaction of the two proteins has not been demonstrated, e.g. by Förster 
resonance energy transfer (FRET) or co-immunoprecipitation (Co-IP).   
The transcriptional activity of ERα is modulated by ubiquitination and by 
sumoylation. It has been postulated that BCA2 may sumoylate ERα as 
the two proteins share an interaction partner in the E2 SUMO 
conjugating protein Ubc9 (Burger et al. 2010).  Ubc9 has been shown to 
promote activation of ER-α through sumoylation of the receptor’s hinge 
region (Sentis S et al. 2005).  GST pull-down experiments and dual IF 
have demonstrated that BCA2 and Ubc9 interact in vitro.  The authors of 
the paper in which this was shown suggested that BCA2 may therefore 
be involved in a reciprocal regulatory loop with ER-α but this remains 
unproven (Burger et al. 2010). 
1.5.2 BCA2 and Receptor Tyrosine Kinase Endocytosis 
BCA2 has been shown in three publications to affect the endocytic 
degradation of EGFR.  The first paper to explore the role of BCA2 in 
EGFR trafficking was published in 2003 by Mizuno et al.  BCA2 was 
identified as a Rab7 binding partner by Cytotrap screening and 
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subsequent investigations demonstrated that Rab7 interacted with the N-
terminus of BCA2.  The data from the in vitro studies suggested that the 
BCA2 was recruited to the late endosomes and lysosomes by the GTP-
bound (active) form of Rab7.  The recruitment caused perinuclear 
aggregation of late endolysosomes and resulted in impaired EGF 
degradation.  The effects were shown by co-transfection of His-BCA2 
and EGFP-Rab7 (and Rab7 mutants) into baby hamster kidney (BHK) 
cells.  IF-microscopy analysis was performed to visualise the co-
localisation and re-localisation effects.  EGF degradation was measured 
using a trichloroacetic acid (TCA) assay with 
125
I-labelled EGF.  
Although the experiments were all performed in BCA2 and Rab7 
overexpressing systems, the data suggested that BCA2 may be an 
important regulator of EGFR trafficking.  A hypothesis to explain the 
effects may be that BCA2 competitively inhibits Rab7-mediated delivery 
of vacuolar ATPase to the lysosomes.  This might then lead to the altered 
lysosomal pH and localization shown in the study (Mizuno et al. 2003).   
Interestingly in 2007 the same research group published a second, 
seemingly contradictory, article in which BCA2 was suggested to have 
the opposite effect on EGFR degradation.  In experiments with human 
embryonic kidney (HEK293) cells, Sakane et al. (2007) showed that 
BCA2 promoted ligand-induced EGFR degradation. Again a BCA2 
overexpression system was used but this time EGFR was also 
exogenously introduced by transfection.  Degradation was measured by 
immunoprecipitation (IP) and WB.  The data showed that after one and 
three hours of EGF treatment, the levels of EGFR were reduced in BCA2 
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over-expressing HEK293 cells compared with mock-transfected controls, 
though the difference was slight.  In cells cotransfected with BCA2, 
EGFR, c-Cbl and ubiquitin however BCA2 inhibited EGFR degradation.   
A study published in 2013 by (Smith et al.) examined the relationship 
between BCA2 and EGFR trafficking by shRNA depletion of BCA2 in 
HeLa cervical cancer cells .  Data were presented that showed BCA2 
promoted EGFR and c-Met degradation.  IP and WB data showed that 
level of EGFR and phosphorylated (pEGFR) in EGF-stimulated HeLa 
remained higher in BCA2 depleted cells at 30 min compared with 
controls.  By 60 min however EGFR levels were comparable between the 
two groups. The study also incorporated Co-IP which demonstrated that 
BCA2 could directly interact with EGFR in vitro and that this interaction 
was dependent on c-Cbl.  BCA2 was also shown to ubiquitinate EGFR, 
notable because this is the first documented substrate of BCA2’s E3 
ligase activity.  Other key data from the paper include microscopy which 
shows that a) the number of multivesicular bodies (MVBs) was reduced 
in BCA2
 
depleted cells and b) that BCA2 depletion caused EGFR to 
accumulate in late endolysosomal compartments.   
The relationship between BCA2 and EGFR endocytosis and 
downregulation is clearly complex.  More work is needed to fully 
elucidate the effects of BCA2 on EGFR biology and the mechanism/s 
behind them. 
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1.6 Other interaction partners of BCA2 
BCA2 has been shown to interact with a number of other proteins 
including: 14-3-3σ, hHR23a, MM-1 and tetherin (Miyakawa et al. 2009; 
Bacopulos et al. 2012; Narita et al. 2012) 
14-3-3σ is a tumour suppressor and positive regulator of p53 that acts by 
antagonising ubiquitination of p53 by Mdm2.  It has been shown to 
interact with BCA2 via a conserved binding site between amino acids 
133 and 140 (SRPDRSPS). Transfection of increasing quantities of 
plasmid encoding BCA2 into cells with fixed amounts of a plasmid for 
14-3-3σ indicated that BCA2 may negatively regulate the tumour 
suppressor.  Levels of 14-3-3σ were progressively depleted in response to 
increasingly overexpressed BCA2 and authors suggested that 14-3-3σ 
may therefore be a substrate of BCA2’s E3 ligase activity (Bacopulos et 
al. 2012) 
hHR23a (the human homolog of rad23) is a DNA repair protein that can 
also abrogate proteasomal degradation of proteins by inhibiting the 
formation of polyubiquitin chains (Ortolan et al. 2000). hHR23a has been 
shown to prevent BCA2 autoubiquitination and to promote its cellular 
stability (Bacopulos et al. 2012) 
Tetherin, also known as BST-2 is a lipid raft associated, transmembrane 
protein that is involved in the interferon dependent antiviral response 
pathway (Van Damme et al. 2008).  Tetherin restricts the budding of 
virions from human immunodeficiency virus (HIV) infected cells.  
Overexpression of BCA2 in tetherin positive HeLa cells has been shown 
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to promote tetherin-mediated inhibition of HIV particle release. This was 
also supported by co-transfection of BCA2 and tetherin in negative HOS 
cells where the BCA2-tetherin interaction promoted HIV restriction. 
BCA2 was also shown to promote trafficking of the unreleased, 
intracellular HIV particles to the lysosomes for degradation (Miyakawa 
et al. 2009).  More recently BCA2 has also demonstrated tetherin-
independent anti-viral activity which it exerts by promoting 
ubiquitination and lysosomal degradation of HIV-1 gag, inhibiting virus 
particle assembly and release (Nityanandam, and Serra-Moreno 2014).   
BCA2 has been shown to form a complex with, and to mono-
ubiquitinate, a c-myc binding protein MM-1. Monoubiquitination of 
MM-1 by BCA2 appears to downregulate c-myc and reduce cellular 
proliferation. The proposed model states that when levels of c-myc are 
raised, BCA2 binds to MM-1 which is then monoubiquitinated. The Ub 
tag causes the complex to translocate to the nucleus where it binds to c-
myc. c-myc is then poly-ubiquitinated by BCA2’s E3 ligase activity and 
is degraded by the proteasome. The reduced cellular proliferation 
reported in BCA2 transfected cells was thought to relate to reduced 
expression of c-myc regulated genes that promote cell cycle progression 
such as cyclin D1 (Narita et al. 2012). 
1.7 BCA2 as a zinc binding protein and therapeutic target  
Disulfiram (DSF) is a zinc-ejecting agent that has been suggested to have 
selective activity against BCA2 overexpressing breast cancer cells 
(Brahemi et al. 2010).  It has been proposed that DSF can inhibit BCA2 
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by modifying cysteine residues and expelling zinc from the RING-H2 
domain (Fig. 1-9).   
The therapeutic potential of targeting BCA2 has been demonstrated in 
siRNA depletion experiments which show decreased proliferation in cells 
with diminished BCA2 levels (Burger et al. 2005).  DSF has shown 
micromolar activity against high BCA2 expressing MCF-7 breast cancer 
cells.   Putative BCA2
 
negative/low MDA-MB-231 cells become 
sensitised to DSF when transfected with ER-α to induce BCA2 
expression (Brahemi et al. 2010).  Experiments conducted as part of this 
project and a co-running Cancer Research Wales project suggest the 
cytotoxic effect may pertain to altered intracellular zinc levels and 
endolysosomal function rather than BCA2 expression (Wiggins et al. 
2014, 2015).  
Overall there is fairly limited evidence to support the use of DSF as a 
specific inhibitor of BCA2 (Brahemi et al. 2010).  Overexpression of ER-
α in the “triple negative” cell line MDA-MB-231 may have conferred 
DSF sensitivity to the cells but this is not necessarily an effect mediated 
by BCA2.  Expression of ER-α in MDA-MB-231 cells has been shown 
by others to induce upregulation of many genes associated with cell 
proliferation and survival e.g. hepatoma-derived growth factor, insulin-
like growth factor binding proteins 1 and 3 and the cytokine interleukin 
7R-α (Levenson et al. 2002).  In the study by Brahemi et al. (2010) DSF 
sensitivity may have been conferred to the MDA-MB-231/ER-α cells by 
upregulation of one or a combination of many other ER regulated genes.  
The effect of ER-α induced DSF sensitivity cannot therefore conclusively 
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be attributed to BCA2.  There may be greater therapeutic potential in 
targeting BCA2 with DSF analogues structurally tailored to specifically 
inhibit BCA2, indeed such drugs showed greater anti-breast cancer 
efficacy than DSF in the Brahemi et al. studies. Despite this, DSF is a 
more appealing potential cancer treatment since it is already available as 
an aldehyde dehydrogenase 1 (ALDH1) inhibitor for the treatment of 
alcohol dependence.  DSF toxicity/side effects are extremely rare so 
should efficacy be supported by research, patients could begin receiving 
DSF much sooner than would be possible with a new drug.  A caveat to 
this however is that the specificity of DSF is poor: DSF has been shown 
to affect a number of cellular proteins including vATPase and β-tubulin 
though the effects were seen at higher concentrations than used in our 
experiments (Potchoo et al. 1986; Johnson et al. 2010).    
The well documented effect of DSF on ALDH1 may actually be a 
mechanism that could be exploited in breast cancer treatment.   
Mammary cancer stem cells have been shown to express significantly 
elevated levels of ALDH1 and therefore may be more sensitive to its 
inhibition (Charafe-Jauffret et al. 2010).  ALDH1 inhibition has been 
shown to reduce the chemo- and radiotherapeutic resistance of a stem-
like population of breast cancer cells (Croker and Allan 2012).  DSF may 
present an effective, inexpensive and minimally toxic adjuvant to 
standard breast cancer therapies. 
  
 74 
 
1.8 Hypothesis 
There is a need for further research to explore BCA2’s role in EGFR 
endocytosis, downregulation and signalling, particularly with 
consideration of cellular context in data analysis and interpretation.  
There is also a need to examine the effects of BCA2 on breast cancer 
survival in different disease subtypes, again to explore possible context-
dependent effects that may help to explain some of the current conflict in 
the literature with regard to BCA2 function and pathology.   
The hypothesis for this study is:  
BCA2 plays an important role in breast cancer development and 
progression involving its effects on EGFR trafficking. 
1.9 AIMS 
The overall purpose of this project is to extend the body of existing 
BCA2 knowledge and to resolve some of the apparent conflict in the 
current literature.  This will be achieved by meeting the following key 
aims: 
-     Investigate the role of BCA2 in breast cancer development,     
      progression, resistance and prognosis.  This will include  
      exploration of links with breast cancer subtypes, ErbB expression  
      and signalling and additional analyses of co-expressed genes. 
-      Determine the subcellular localisation of BCA2  
-     Describe the role of BCA2 in EGFR endocytosis and signalling 
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Chapter 2: Materials and Methods 
2.1   Materials 
Details of specific experimental materials and their suppliers are listed in 
Appendix A.  Otherwise:  tissue culture plasticware was manufactured by 
Corning® and supplied by Fisher Scientific (Loughborough, UK). 
Laboratory disposables and organic solvents were also obtained from 
Fisher Scientific.  General usage chemicals and reagents were supplied 
by Sigma-Aldrich (Poole, UK) unless otherwise indicated in Appendix 
A.  Cell lines and plasmids that were gifts to the laboratory are indicated 
in the text, along with the source.  Antibodies are listed in Tables 2-3 and 
2-6.    
2.2 In silico procedures 
To gain a better understanding of the role of BCA2 in breast cancer, 
publically-available, Affymetrix microarray datasets were interrogated.  
The datasets ranged from large patient cohorts, where the effects of gene 
expression on survival could be examined, to data from in vitro studies 
where the experimental conditions were pertinent to examining BCA2 
expression levels.  
Expression of BCA2 (mRNA) was primarily determined by the signal 
intensity of the “JetSet” probe Affymetrix ID 212742_at.  JetSet probes 
provide the most reliable gene expression estimates based on assessment 
of gene specificity, splice variant coverage and resistance to degradation 
(Li et al. 2011).  JetSet scores are between 0 and 1, and the closer the 
score to 1, the better the predicted probe performance.  The JetSet scores 
 93 
 
for the 212742_at probe set are given in Table 2-1.    The 212742_at 
probe set scored highly for specificity and coverage and moderately for 
robustness.  The overall score was sub-optimal but adequate for use. 
Table 2-1: JetSet scores (out of a maximum of 1) for the 212742_at probe set for 
BCA2 
Probe set Specificity Coverage Robustness Overall 
212742_at 0.818181818 1 0.327884 0.268269 
Where expression data from another probe set (226468_at) were also 
available they were examined alongside the JetSet probe data.  Using 
information from multiple probes meant increased confidence in the 
reliability of findings i.e. trends in expression change that were detected 
with both probe sets were considered more likely to reflect true changes 
in BCA2 expression. 
Patient numbers for the KM Plotter and GOBO data subsets examined 
are presented in Appendix J. 
2.2.1.1 KM Plotter 
The KM Plotter online biomarker analysis tool (http://www.kmplot.com/) 
was used to produce Kaplan-Meier plots for relapse free survival (RFS) 
based on BCA2 expression in 3458 patients.  The median expression of 
BCA2 mRNA was used to split the dataset into high and low expressing 
groups and survival curves were generated across all breast cancers and 
for analyses restricted according to ER status and molecular subtype. The 
hazard ratio for RFS with 95% confidence intervals and logrank P value 
were calculated by the software for low vs. high BCA2 expression.  
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2.2.1.2 GOBO: gene expression-based outcome 
The online biomarker assessment tool GOBO (http://co.bmc.lu.se/gobo) 
was also used to generate Kaplan-Meier survival plots based on 
Affymetrix ID 212742_at (BCA2) signal intensity.  Association with 
breast cancer outcome was investigated in the 1881-sample dataset which 
was stratified into high, medium and low BCA2 expressing disease.  
Kaplan-Meir plots were created across all samples and for subgroups 
defined by: ER-status, molecular subtype (basal-like, HER2-enriched, 
luminal A, luminal B, normal-like), histological grade, and lymph-node 
status.  Logrank P values were calculated by the software across the three 
expression quartiles.  
The expression levels of BCA2 across different subgroups were also 
analysed using the GOBO patient samples and panel of 51 breast cancer 
cell lines. Mean log2 expression levels were displayed by the software in 
box-plots for each of the groups and analysis of variance (ANOVA) 
statistics was used to assess differences between them. 
2.2.2 Gene co-expression analysis 
2.2.2.1 MEM: Multi experiment matrix 
Forty-eight genes, whose expression correlated most highly with BCA2 
across 1794 human transcriptome datasets, were identified using the 
MEM online tool (http://biit.cs.ut.ee/mem/).  The MEM tool ranks genes 
according to expression similarity using a novel algorithm that allows 
expression levels to be compared between different datasets (Adler et al. 
2009).  Similarity ranking is mainly informed by Pearson’s correlation 
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and takes into account inverse-expression.  The output of the MEM 
algorithm is a set of genes with P values that represent the degree of 
expression similarity with the gene of interest.  For the BCA2 analysis a 
standard deviation cut-off filter of 0.29 was applied; 0.29 being the MEM 
creator’s recommended level for eliminating the noise generated by 
experimental variability, as established by computational simulation.  As 
in other in silico experiments, the BCA2 probeset used in the analysis 
was the Affymetrix ID 212742_at. 
2.2.2.2 DAVID: database for annotation, visualization, and 
integrated discovery 
DAVID (http://david.abcc.ncifcrf.gov/) is an online tool that enables a 
gene list input to be interrogated and clustered by functional keyword 
associations (Alvord et al. 2007).  The co-expressed gene list generated 
by MEM (2.2.2.1) was subjected to functional annotation clustering 
analysis with DAVID using the default (medium) stringency setting.   
2.2.3 Gene expression changes: BioGPS 
BioGPS (http://www.biogps.org/) is an online gene annotation portal that 
provides access to gene expression information from a vast number of 
published datasets.  The deposited expression data have been normalised, 
background corrected and summarised using the GeneChip Robust 
Multiarray Averaging (GC-RMA) procedure.  
BCA2 mRNA expression (as measured by the Affymetrix ID 212742_at 
probeset) were obtained from the following Gene Expression Omnibus 
(GEO) datasets: GSE15192, GSE5116, GSE4668, GSE20361, 
GSE14986, GSE10696, GSE14987, GSE13274, and GSE3151.   More 
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information on the individual datasets is provided in Chapter 3.  
Microsoft Excel was used for analysis and graphical presentation of the 
BioGPS data.  In the absence of expression call information, log2 BCA2 
expression was first calculated and tabulated.  Positive log2 expression 
values were considered to indicate sufficient levels of gene expression 
for further analysis.  Where BCA2 expression was suppressed by 
experimental conditions, log2 was calculated for the lowest expression 
data point to ensure the mRNA levels did not fall below detectable levels. 
Mean log2 fold changes in BCA2 expression were determined by first 
converting the fluorescence intensity values to fold-change relative to 
control.  These values were then log2 transformed and means were 
calculated and plotted graphically. Where possible/ applicable 95% 
confidence intervals were generated and T-Tests or ANOVA plus Tukey 
post-hoc tests were performed as appropriate.    
2.3 In vitro procedures 
2.3.1 General cell culture 
2.3.2 Cell lines 
Low-passage (P9) MCF-7, MDA-MB-231, BT474 and T47D human 
breast cancer cells were a gift from the Breast Cancer Molecular 
Pharmacology Group (BCMPG), Cardiff University.  The authenticated 
cells were donated to the group by Astrazeneca or purchased from the 
American Type Culture Collection (ATCC).  The passage number relates 
to the number of times the cells have been split by researchers in the 
BCMPG.  Cell stocks were produced by freezing down 70% confluent 
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cells in media containing 20% serum, 5% DMSO, ~2.5 x 10
6
 cells were 
aliquotted into each cryovial.  The vials of cells were first stored at -20
o
C 
for 5 hr, then at -80
o
C overnight before being transferred to liquid 
nitrogen for long-term storage.    
New, authenticated “near-normal” MCF-10A breast cells were purchased 
from the ATTC’s approved UK supplier LGC Standards.  Stocks of the 
MCF-10A cells were produced by freezing down 70% confluent cells in 
complete media (recipe in section Media 2.3.3) containing 7.5% DMSO.  
The cryovials of cells were frozen in a Mr. Frosty™ freezing container 
filled with ispropanol to allow cooling at the rate of 1
o
C per minute.  The 
freezing protocol was as follows: -20
o
C for 1 hr, then at -80
o
C overnight 
then transfer to liquid nitrogen for long-term storage. 
HeLa cells were obtained from the European Molecular Biology 
Laboratory  (Simpson et al. 2004).  Low passage cell stocks (P14) were 
made by freezing down 70% confluent cells in media containing 20% 
serum, 5% DMSO.  The cryovials in the Mr. Frosty container were first 
frozen at -20
o
C for 5 hr, then at -80
o
C overnight before being transferred 
to liquid nitrogen for long-term storage. 
All cell lines were used up to a maximum passage number of 28 and 
were subject to regular mycoplasma testing (section 2.3.5). 
2.3.3 Media 
MCF-7, MDA-MB-231, BT474 and T47D breast cancer cells were 
cultured in Roswell Park Memorial Institute media (RPMI) containing 
phenol red and supplemented with 10% Foetal Bovine Serum (FBS).  
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MCF-10A cells were grown in Dulbecco's Modified Eagle Medium: 
Nutrient mixture F12 (DMEM/F12) supplemented with 5% horse serum, 
20 ng/mL EGF, 0.5 µg/mL  hydrocortisone, 100 ng/mL cholera toxin and 
10 µg/mL insulin.  HeLa were grown in DMEM supplemented with 10% 
FBS.  No antibiotics were used in routine cell culture.  
2.3.4 Routine maintenance 
 All cells were cultured at 37
o
C with 5% CO2 in a humidified 
atmosphere.   The cells were passaged every 3-5 days by washing with 
phosphate buffered saline (PBS) then incubating with 0.05% trypsin 
ethylenediaminetetraacetic acid (EDTA) for 3 min to detach the cells.  
After trypsinisation the cells were collected in 10 mL of culture media 
then centrifuged at 900 x g for 3 min.  The supernatant was then removed 
and the pellet was resuspended in the appropriate volume of media for 
the cell line’s required split ratio (see Table 2-2).  1 mL of cells was then 
transferred to a new T-75 flask.     
Table 2-2 Split ratios for the routine maintenance of different cell lines used 
throughout the project. Ratios are for the passage of cells every 3-5 days. 
Cell line Split ratio 
MCF-7 1:5 
MDA-MB-231 1:7 
MCF-10A 1:5 
HeLa 1:6 
T47D 1:5 
BT474 2:7 
2.3.5 Mycoplasma testing 
All cell lines were subjected to quarterly mycoplasma testing by PCR. 
1 mL of media was extracted from confluent cells and transferred to a 
sterile Eppendorf.  The media was then centrifuged at 250 x g for 30 s to 
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sediment cells and debris.  The supernatant was then transferred to a new 
sterile Eppendorf and centrifuged at 20,000 x g for 10 min to sediment 
mycoplasma (if present).  The supernatant was then discarded and the 
pellet was resuspended in 50 µL of resuspension buffer (supplied with 
EZ-PCR kit). The resuspended pellet was heated for 3 min at 95
o
C then 
5 µL of this sample was added to a pre-prepared PCR tube.  The PCR 
tube contained 35 µL of sterile dH2O to and 10 µL of EZ-PCR reaction 
mix (containing primers, nucleotides and thermostable polymerase). The 
positive control was prepared by adding 39 µL of dH2O to 10 µL of 
reaction mix and adding 1 µL of positive template (supplied with the kit). 
The tubes were gentle tapped to remove bubbles then transferred to a 
thermocycler where they were subjected to the following programme: 
 -  Initial denaturation:  94
oC … 30s 
 -    Cycles (x36):     
- 94
oC … 30s     denaturation 
- 60
oC … 120s   annealing 
- 72
oC … 60s     elongation 
-   Final elongation step:    72
oC … 4 min 
Results were analysed by agarose gel electrophoresis of the post-PCR 
solution.  
2.3.5.1 Agarose Gel electrophoresis 
2.3.5.1.1 Agarose gel preparation 
 A 2% agarose gel was prepared by dissolving 1g of agarose in sterile 
TAE buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA) to give a 
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final volume of 100 mL.  To dissolve the agarose and destroy any 
nucleases the agarose-TAE mixture was microwaved for 6x 30 s on full 
power.  The mixture was gently swirled between each heating interval to 
ensure even heating and mixing.  After microwaving the agarose solution 
was allowed to cool for 3 min before 50 µL of 5 µg/mL ethidium 
bromide was mixed in and the solution was poured into the clean gel box.  
A well comb was placed into the liquid agarose and the gel was left for 
40 min to solidify.  Once the gel had set, the electrophoresis tank was 
filled with sterile 1x TAE buffer and the comb was removed. 
2.3.5.1.2 Gel loading and running  
2 µL of the DNA was mixed with 3 µL of dH2O and 1 µl of 6x sample 
loading buffer (30% glycerol, 0.2% bromophenol blue in dH20).  
Samples were loaded onto the agarose gel alongside 1 µL of DNA 
ladder.  The gel was run at 80 V for 4 hr to achieve the required band 
separation before the gel was transferred to cling film and imaged on the 
Biorad Chemidoc imaging system.     
2.4 Immunofluorescence microscopy (IF) 
2.4.1 Cell culture 
Cells were seeded onto glass coverslips in 12-well plates and grown in 
antibiotic-free, serum supplemented media (complete media).  Cells were 
incubated at 37
o
C in a 5% CO2 humidified atmosphere until reaching 70-
80% confluence on the day of fixation.  Seeding densities (12 well plate; 
per well) were as follows: 
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- MCF-7:  150,000 
- MDA-MB-231: 75,000 
- MCF-10A: 150,000 
- HeLa: 67,000 (for transfection) 
2.4.2 Fixation and permeabilisation 
2.4.2.1 Standard fixation & permeabilisation protocol: 
paraformaldehyde & Triton X-100  
The media was aspirated and the cells were washed three times in PBS 
before being fixed in 3% paraformaldehyde for 15 min.  The cells were 
washed again x3 in PBS and free aldehyde groups were blocked with 
50 mM ammonium chloride for 10 min.  The cells were washed x3 in 
PBS then permeabilised for 5 min with 0.2% Triton X-100: 2% bovine 
serum albumin (BSA). The cells were then washed a further x3 in PBS. 
2.4.2.2 PFA fixation: saponin permeabilisation 
The media was aspirated and the cells were washed 3 times in PBS 
before being fixed in 3% paraformaldehyde for 15 min.  The cells were 
washed again x3 in PBS then incubated with 50 mM ammonium chloride 
for 10 min.  The cells were washed x3 in PBS then permeabilised with 
0.4% saponin in PBS for 5 min before being washed a further x3 in PBS.   
2.4.2.3 Acetone fixation/permeabilisation 
The media was aspirated and the cells were washed x1 in ice-cold PBS.  
The cells were then fixed and permeabilised in 80% acetone at -20
o
C for 
10 min.  After fixation the cells were washed x3 in room temperature 
PBS. 
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2.4.2.4 Methanol fixation/permeabilisation 
The media was aspirated and the cells were washed x1 in ice-cold PBS.  
The cells were then fixed and permeabilised in 100% methanol at -20
o
C 
for 10 min.  After fixation the cells were washed x3 in room temperature 
PBS. 
2.4.2.5 Ethanol fixation/permeabilisation 
The media was aspirated and the cells were washed once in ice-cold PBS.  
The cells were then fixed and permeabilised in 95% ethanol: 5% acetic 
acid at -20
o
C for 10 min.  After fixation the cells were washed x3 in 
room temperature PBS. 
2.4.3 Immunolabelling  
2.4.3.1 Antibodies 
Table 2-3 contains a list of the different proteins analysed by 
immunofluorescence microscopy and antibodies used in their detection.  
Where available, journal article references for immunofluorescence are 
given, though the datasheets for the antibodies were the primary source 
of information used for method development. 
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Table 2-3: Primary antibodies, dilutions and associated fixation method used for IF. 
Including references for antibody use in IF. 
 
Target Primary Antibodies Dilution Fixation 
Haemagglutinin tag 
(HA) 
Transiently/stably 
expressed HA-tagged 
proteins 
-   Mouse anti-HA HA.11 clone 16B12 
(#MMS-101P, Covance) 
Scotter et al. 2014 
-  Mouse anti-HA (#H9658, Sigma 
Aldrich) 
Bijsmans et al. 2012 
-  Mouse anti-HA (#2362. Cell 
Signalling)   
Faux et al. 2008 
1:1,000 PFA 
BCA2 -  Goat anti-BCA2 (#SAB2500854, 
Sigma Aldrich) 
-  Rabbit anti-BCA2 (#HPA019130, 
Sigma Aldrich) 
1:200 
(endogenous) 
1:5,000 
(over-
expressed) 
PFA 
acetone 
methanol 
ethanol* 
Early Endosome Antigen 
1 (EEA1) 
Early endosomes 
-  Goat anti-EEA1 (#SC-6415, Santa-
Cruz) 
Clementz et al. 2013 
-  Mouse anti-EEA1 (#610457, BD 
Bioscience) 
Sato et al. 2014 
1:200 PFA 
Trans-Golgi Network 46 
Golgi apparatus 
Sheep anti-TGN46 (#AHP500, AbD 
Serotec) 
Cornfine et al. 2011 
1:750 PFA 
Transferrin Receptor 
Recycling endocytic 
pathway 
Mouse anti-Transferrin receptor (#13-
6800, Life Technologies) 
Simpson et al. 2004 
1:300 PFA 
EGFR -  Mouse anti-EGFR (#Ab-10,  
   Neo-Markers)  
Xu et al. 2006 
-  Rabbit anti-EGFR  
    (#HPA018530, Sigma) 
Luke et al. 2014 
1:100 PFA 
Lysosomal-Associated 
Membrane Protein 2 
(LAMP2) 
Late endosomes & 
lysosomes 
Mouse anti-LAMP2 (#H4B4, 
Developmental studies hybridoma bank 
[DSHB]) 
Orenstein et al. 2013 
1:200 Methanol 
Tubulin 
Microtubule cytoskeleton 
Mouse anti-tubulin (#T9026, Sigma 
Aldrich) 
Jin et al. 2008 
1:2,000 Methanol 
LAMP1** 
Late endosomes & 
lysosomes 
Rabbit anti-LAMP1 (#L1418, Sigma 
Aldrich) 
Yogalingam and Pendergast 2008 
1:100 PFA 
Rab7 ** 
Late endosomes & 
lysosomes 
Rabbit anti-Rab7 (#9367, Cell 
Signalling) 
Pacheco-Quinto and Eckman 2013 
1:100 PFA 
LC3B** 
Autophagosomes 
Rabbit anti-LC3B (#2775, Cell 
Signalling) 
Bejarano et al. 2014 
1:100 PFA 
* Multiple methods are given to demonstrate the various techniques trialled in 
optimising the antibodies for immunofluorescence.  The method in bold indicates the 
optimal method.   
**Indicates that a non-standard immunofluorescence procedure was used for these 
antibodies.  See sections 2.4.3.4 and 2.4.3.5. 
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2.4.3.2 Standard, single antibody immunolabelling 
After fixation and permeabilisation the cell-coated coverslips were 
blocked in 150 µL of 2% FBS, 2% BSA blocking solution for 1 hr.  The 
cells were then incubated for 1 hr with 100 µL of primary antibody 
diluted in blocking solution (see Table 5 for dilutions).    The coverslips 
were washed 2x 5 min in 0.05% Triton X-100 in PBS and 1x in PBS 
before being incubated with species-specific Alexa labelled secondary 
antibodies (diluted 1:400) and Hoechst (1 μg/mL) for 1 hr.  The cells 
were washed a final 2x 5 min in 0.05% Triton X-100 in PBS and 1x in 
PBS.   After washing, the coverslips were dipped once into PBS, once 
into dH2O then mounted onto glass slides with 12 µL of Dako oil and 
after half an hour were sealed with clear nail varnish. 
Secondary antibody only controls were performed alongside IF 
experiments and unless stated otherwise in the text were all confirmed to 
be negative. 
2.4.3.3 Double antibody immunolabelling 
The protocol for double immunolabelling followed the protocol for single 
labelling until after the three PBS washes following the secondary 
antibody incubation.  At this point the cells were blocked for a second 
time in 150 µL blocking buffer for 30 min before being incubated with 
100 µL of the second diluted primary antibody (raised in a different 
species from either of the previously applied antibodies).  After 
incubation for one hour at room temperature the coverslips were washed 
twice for 5 min in 0.05% Triton X-100 in PBS and once in PBS.  The 
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cells were then incubated with the appropriate species of Alexa labelled 
secondary antibody (1:400) for 1 hr.  The coverslips were washed a final 
2x 5 min in 0.05% Triton X-100 in PBS and once more with PBS.   
Following the washing steps, the coverslips were treated as described for 
single antibody labelling. 
2.4.3.4 Immunolabelling with anti-LAMP1 antibody 
LAMP1 immunolabelling was performed in a 12-well plate.  Following 
PFA fixation and saponin permeabilisation (2.4.2.2) the cells were 
blocked in 350 μL 2% FBS, 2% BSA, 0.4% saponin blocking solution 
for 1 hr. The cells were then incubated overnight with primary antibodies 
diluted 1:100 in 350 μL of blocking solution.  Antibody incubation was 
performed at 4ºC with gentle agitation and in a humidified chamber. On 
the second day cells were washed 3x 5 min in PBS before being 
incubated with Alexa labelled secondary antibodies (1:400) and Hoechst 
(1 μg/mL) for 30 min. The cells were washed a final 3x 5 min in PBS. 
After washing the coverslips were washed and mounted as for single 
antibody labelling. 
2.4.3.5 Immunolabelling with anti-LC3B and anti-Rab7 antibodies 
The cells were fixed in PFA and the autofluorescence was quenched with 
ammonium chloride as in 2.4.2.1 but the separate cell permeabilisation 
step was omitted.  After the three PBS washes post-quenching the cells 
were blocked in 150 µL of 5% BSA, 0.3% (v/v) Triton X-100 blocking 
solution for 1 hr.  The cells were then incubated overnight with primary 
antibodies at 4
o
C with gentle agitation and in a humidified chamber. The 
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antibody diluent was 1% BSA, 0.3% (v/v) Triton X-100, 350 µL of 
solution was used per well and the concentrations of antibody are listed 
in table 2-3.  On the second day cells were washed 3x 5 min in PBS 
before being incubated with Alexa labelled secondary antibodies (1:400) 
and Hoechst (1 μg/mL) for 1 hr.  The cells were washed a final 3x 5 min 
in PBS.   Following the washing steps, the coverslips were washed and 
mounted as described for single antibody labelling. 
2.4.3.5.1 Chloroquine  positive control for LC3B antibody labelling 
As a positive control for autophagy/LC3B immunolabelling: cells were 
incubated with 100 µM chloroquine for 6 hr prior to IF for LC3B.  
Chloroquine treatment induces the accumulation of LC3B in autophagic 
vacuoles (Lichtenstein et al. 2011). 
2.5 Direct fluorescence methods 
2.5.1 EGF-Alexa 488 and EGF-Tetramethylrhodamine 
Cells were pre-incubated in 1 mL serum-free media (SFM) for 1 hr at 
37°C, 5% CO2.  The SFM was then replaced with 500µL of SFM 
containing Alexa-labelled EGF (0.5 µg/mL) or EGF-Rhd (1 µg/mL) 
diluted in SFM.  The cells were incubated in uptake media for time 
periods between 0 and 120 min at 37°C, 5% CO2.  The culture plates 
were placed on ice and rinsed twice with ice-cold PBS.  The cells were 
then ready for fixation and IF. 
2.5.2 Transferrin-Alexa 488 / 647 
Cells were pre-incubated in 1 mL SFM for 60 min at 37°C, 5% CO2.  
After 60 min the media was replaced with 500µL of uptake media 
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comprising 100 nM Alexa-488/647 transferrin diluted in SFM.  The cells 
were incubated in uptake media for time points between 0 and 120 min at 
37°C, 5% CO2.  The culture plates were then placed on ice and rinsed 
2x1 min with ice-cold SFM and 2x with ice-cold PBS.  The cells were 
then ready for fixation and IF. 
2.5.3 Mitotracker Red 
The growth medium of cells grown on coverslips in 12-well plates was 
replaced with 500 µL of complete media containing 100 nM of 
Mitotracker red.  The cells were incubated with the Mitotracker media 
for 30 min at 37°C, 5% CO2.  The cells were washed x1 in room 
temperature PBS and were then ready for IF. 
2.5.4 Rhodamine phalloidin 
Actin filaments in PFA fixed, Triton X-100 permeabilised cells were 
labelled by incubation with 2µg/ml rhodamine phalloidin. Where used, 
rhodamine phalloidin incubation was incorporated into the secondary 
antibody step of IF experiments.  Drug treatment and growth factor 
stimulation 
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2.6 Drug treatments and growth factor stimulation 
2.6.1 Cell treatment with disulfiram 
70% confluent MDA-MB-231 and MCF-7 cells were treated for 3 hr 
with 1µM DSF (Brahemi et al. 2010).  DSF stocks were 1 mM 
reconstituted in DMSO and were diluted to working concentrations in 
cell media. 
2.6.2 EGF stimulation  
Cells were incubated for 1 hr in SFM before being stimulated with EGF 
(20 ng/mL SFM) for time periods up to 120 min.  In the experiment using 
low-dose EGF, 1 ng/mL of the ligand was used (Sigismund et al. 2005; 
2008 and 2013). 
2.7 Microscopy 
2.7.1 Confocal microscopy 
Confocal fluorescence microscopy analysis was conducted on a Leica 
SP5 inverted confocal laser scanning microscope.  The microscope was 
equipped with a 65x oil-immersion objective and different combinations 
of the 405, 488, 453 and 633 nm lasers.  Gain and offset settings were 
optimised for each fluorescent channel within an experiment.  Images 
were recorded using the sequential scanning mode to prevent 
fluorescence channel crosstalk/bleedthrough.  Images were scanned at 
100 Hz with a line average of three to reduce noise.  
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2.7.2 Epifluorescence microscopy 
Epifluorescence microscopy analysis was performed using a Leica 
DMIRB inverted microscope equipped with a 40x oil immersion 
objective. 
2.7.3 Differential interference contrast microscopy 
Differential interference contrast (DIC) microscopy was performed using 
a Leica DMIRB inverted microscope equipped with 10x objective and 
using the brightfield mode with a “Ph1” setting on the phase selector 
ring.   
2.8 Western blotting 
2.8.1 Cell culture 
Cells were seeded in 6-well plates and grown in complete media at 37
o
C 
in a 5% CO2 humidified atmosphere.  Cells were subjected to various 
experimental procedures, such as transfection and EGF stimulation 
before lystates were collected.  Cells were 70-80% confluent on the day 
of lysate collection. Seeding densities (per well) were as follows: 
MCF-7: 220,000 
MDA-MB-231: 160,000 
BT474: 300,000 
T47D: 300,000 
MCF-10A: 250,000 
HeLa: 160,000  
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2.8.2 Lysate collection and preparation 
2.8.2.1 Lysate collection 
The cell culture plates were placed on ice, the media was removed from 
the wells and the cells were washed twice with ice-cold PBS.  100 μL of 
lysis buffer (150 mM NaCl, 50 mM Tris base pH 8, 1% Nonidet p-40 
[NP-40] including protease and phosphatase inhibitors) was added to 
each well.  The well plates (on ice) were placed on a lateral, circular 
shaker for 5 min before lyates were scraped and transferred to pre-cooled 
eppendorfs.  Samples were then centrifuged at 4
o
C, 13,800  x g for 
10 min.  The supernatants were finally transferred to fresh, pre-cooled 
eppendorfs.    
2.8.2.2 Bicinchoninic acid assay 
The protein concentration of each sample was determined by 
bicinchoninic acid (BCA) assay.  BSA protein standards were prepared in 
lysis buffer at concentrations from 0 to 1 mg/mL.  In order for the sample 
absorbance measurements to fit in the linear range of the assay, cell 
lysate samples were diluted 1:6 in lysis buffer. The BCA working 
solution was then prepared by mixing 49 parts biochoninic acid with 1 
part copper sulphate pentahydrate. 200 µL of working BCA solution was 
pipetted into a flat-bottomed 96 well plate.  Enough wells were prepared 
to take duplicate measurements for BSA standards and triplicate for 
samples. 1 µL of the standards/samples was added to the appropriate 
number of measurement wells.  The plate was incubated 37ºC for 30 min 
before the absorbance was measured at 562 nm on a plate reader.  
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A calibration curve was created by plotting the absorbance measurements 
against the known BSA standard concentrations.  The equation of the line 
of best fit for the calibration graph was then used to determine unknown 
sample concentrations (taking into account the dilution factor). 
2.8.2.3 Standard lysate sample preparation 
Sample concentrations were equalised by addition of appropriate 
volumes of lysis buffer.  Appropriate volumes of 4x loading buffer (2% 
sodium dodecyl sulphate [SDS], 10% glycerol, 0.02% bromophenol blue, 
62.5 mM Tris-HCL) were added to each of the samples which were then 
denatured by heating at 98
o
C for 5 min.  Samples were returned to ice to 
cool then centrifuged at room temperature at 13,800 x g for 30 s.  
Samples were stored at -20
o
C. 
2.8.3 Standard SDS-PAGE gel preparation 
The gels were cast and run using a BioRad Mini-Protean II SDS-PAGE 
kit.  The front and back plates were assembled in the clamp frame and 
secured into the casting stand.  The resolving gel was prepared using the 
following recipe table (the TEMED was added last): 
Table 2-4: Resolving gel recipes for 10% and 12% acrylamide gels 
 10% gel 12% gel 
Total volume of gel / 
mL 
10 20 10 20 
40% acrylamide/Bis 
/mL 
2.5 5 3 6 
3M Tris pH 8.8 / mL 1.25 2.5 1.25 2.5 
10% SDS / µL 100 200 100 200 
dH20  /  mL 6.10 12.2 5.6 11.2 
10% APS (freshly 
made) /µL 
75 150 75 150 
TEMED /µL 7.5 15 7.5 15 
Once the TEMED had been added the liquid gel was quickly mixed by 
inverting the capped universal tube.  The mixture was then poured into 
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the casting mould, leaving a 2.5 cm gap at the top which was then filled 
with 100% isopropanol.  The resolving gel was then left to set for 
45 min.  Once the gel had solidified the isopropanol was poured away 
and the gap at the top of the resolving gel was gently washed eight times 
with dH2O.  The stacking gel was then made according to the following 
recipe table: 
Table 2-5: Stacking gel recipes for 2 or 4 gels. 
 4% stacking gel 
Total volume of gel / mL 10 15 
40% acrylamide/Bis    / mL 1 1.5 
1M Tris pH 6.8    / mL 1.3 1.95 
10% SD  / µL     100 150 
dH20    / mL 7.22 10.82 
0.1% Bromophenol blue / µL     300 450 
10% APS  (freshly made)  / µL                 75 112.5 
TEMED 10 15 
Again the TEMED was added last and the liquid gel was mixed by 
inverting.  The stacking gel mixture was poured on top of the set 
resolving gel and the well comb was inserted.  The stacking gel was left 
to set for 30 min before the comb was removed and the gels (in their 
casting plates and clamps) were transferred to the running tank and 
immersed in running buffer (385 mM glycine, 250 mM Tris base, 0.5% 
SDS) ready for sample loading. 
2.8.4 Native PAGE and non-reducing conditions 
The majority of the Western blotting experiments were performed in 
denaturing, reducing conditions, as described in Section 2.8.2.3 and 
2.8.3).  However, for one experiment investigating the effect of Western 
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blotting conditions on immunoblotting results, native and non-reducing 
PAGE were carried out.  The experimental procedures for these were 
very similar to the standard Western blotting protocol but with some 
minor adjustments.  For non-reducing PAGE/SDS-PAGE, DTT was 
omitted from the sample buffer.  For native PAGE, SDS was excluded 
from the sample buffer, the resolving and stacking gels and the running 
buffer.  The heat denaturing step following addition of the sample buffer 
was also omitted.  With the exception of these changes samples were 
otherwise treated as per the standard Western blotting procedure. 
2.8.5 Sample loading and SDS-PAGE 
18 μg of protein from each sample was loaded onto a 4% acrylamide 
stacking gel alongside 10 µL of protein standard molecular weight 
marker.  The proteins were separated by SDS-PAGE at 100 V on a 10% 
acrylamide resolving gel for 80-100 min, typically for 85 min.  The 
separation time depended on the molecular weight of the target protein, 
the desired resolution, and the percentage of acrylamide in the gel.  
2.8.6 Protein transfer and ponceau staining 
Proteins were transferred to a Polyvinylidene fluoride (PVDF) membrane 
at 100 V for 1 hr at 4
o
C.   The membrane was then washed briefly in 
dH2O before being placed in ponceau S solution for 1 min.  The 
membrane was returned to dH2O and the staining was checked to ensure 
even transfer and sample loading.  The membrane was cut into three 
strips of lighter (<100 kDa) and heavy weight (>100 kDa) proteins.  The 
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ponceau solution was recycled and the membrane strips were washed 4 x 
5 min in PBS to remove all traces of the red stain.   
2.8.7 Protein detection by immunoblotting  
The standard protocol for immunoblotting with most antibodies was as 
follows: the membrane strips were blocked for 1 hour at room 
temperature in 5% milk in PBS containing 0.025% Tween20 (PBST).  
Each strip was incubated for 1 hour with the primary antibodies, listed in 
Table 2-6, diluted in 2% milk in PBST.     
The membranes were then washed 3x 15 min in PBST before being 
incubated for 1 hour at room temperature with the appropriate secondary 
antibody diluted in 2% milk in PBST (complimentary secondary 
antibodies listed in Table 2-6). 
The membrane was washed a further 3 x 5 min in PBST before 
development.  Equal volumes of enhanced chemiluminescence (ECL) 
reagents were mixed, applied to the PVDF membrane and left for 5 min.  
Clarity™ Western ECL was used for most standard Western blotting 
procedures but for low level expression (where indicated) SuperSignal 
West Femto was used.  Following incubation with the ECL mixture, 
excess solution was shaken from the membrane which was subsequently 
wrapped in cling film.  The membranes were then either imaged using a 
BioRad ChemiDoc system or were placed inside a developer cassette and 
transferred to the dark room for imaging with ECL hyperfilm that was 
then processed in an x-ray developer.  
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Antibody protocols that deviated from the methods outlined above were 
for: antibodies against phosphoproteins (where BSA was substituted for 
milk and used at the same concentrations), goat anti-BCA2 which was 
diluted in 3% or 5% milk (for endogenous or overexpressed protein 
respectively) and mouse anti-β-tubulin HRP which was diluted in 5% 
milk and for which no secondary antibody was required. 
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Table 2-6: Primary and secondary antibodies and dilutions for Western blotting. 
Including references for antibody use in immunoblotting. 
 
Primary Antibodies Dilution Secondary antibodies 
(all Pierce) 
Dilution 
Goat anti-BCA2 (#SAB2500854, 
Sigma Aldrich) 
1:500 Rabbit anti-goat HRP 1:8,000 
Mouse anti-HA HA.11 clone 
16B12 (#MMS-101P, Covance) 
Wolken et al. 2014 
1:4,000 Goat anti-mouse HRP 1:2,000 
Mouse anti-Transferrin Receptor 
(#13-6800, Life Technologies) 
Malik et al. 2011 
1:500 Goat anti-mouse HRP 1:2,000 
Mouse anti-c-Met (#3127, Cell 
Signalling) 
Cen et al. 2014 
1:500 Goat anti-mouse 1:2,000 
Rabbit anti-EGFR 
(#HPA018530, Sigma) 
Arabi et al. 2012 
1:1,000 Goat anti-rabbit HRP 1:2,000 
Rabbit anti-pEGFR Tyr1068 
(#3777, Cell Signalling) 
Katayama et al. 2012 
1:1,000 Goat anti-rabbit HRP 1:2,000 
Rabbit anti-AKT 
(#9272, Cell Signalling) 
Masiello et al. 2014 
1:1,000 Goat anti-rabbit HRP 1:2,000 
Rabbit anti-pAKT  Ser473 
(#9271, Cell Signalling) 
Masiello et al. 2014 
1:500 Goat anti-rabbit HRP 1:2,000 
Rabbit anti-ERK 1/2 
(#9102, Cell Signalling) 
Baek et al. 2014 
1:500 Goat anti-rabbit HRP 1:2,000 
Rabbit anti-pERK 1/2  
Thr202/Tyr204 
(#9101, Cell Signalling) 
Baek et al. 2014 
1:500 Goat anti-rabbit HRP 1:2,000 
Mouse anti-Flotillin 1 
(#610820, BD Biosciences) 
Al Soraj et al. 2012 
1:500 Goat anti-mouse HRP 1:2000 
Mouse anti-β-actin 
(#A5441, Sigma) 
Ciucci et al. 2014 
1:1,000 Goat anti-mouse HRP 1,2000 
Mouse anti-β-tubulin HRP 
conjugated (#AB21058, Abcam) 
Castro-Diaz et al. 2014 
1:50,000 - - 
2.8.8 Antibody stripping procedure for membrane reprobing 
Where proteins of similar molecular weights needed to be detected e.g. 
for phospho- and total protein, a stripping and reprobing protocol was 
employed.  After the first immunoblotting procedure had been completed 
and imaged, the membrane was washed 2x 5 min in PBS then 2 x 5 min 
in dH2O.  The membrane was then stripped in 0.2M NaOH for 10 min 
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before being washed twice more for 5 min in dH20 and 2 x 5min in PBS.  
The membrane was then ready for the blocking step of the second 
immunoblotting procedure.  
2.8.9 Band intensity quantification using ImageJ  
Band intensities were quantified from digital images using ImageJ 
software.  The analysis began by using the Rectangular selection tool to 
draw a tall, narrow box around the first band representing the expression 
level of a protein of interest.  The Analyze>Gels>Select First Lane 
command was then used to highlight the box and identify it as lane “1”.  
Subsequent lanes were outlined with equally sized rectangles which were 
highlighted and assigned lane numbers using the following command: 
Analyze>Gels>Select Next Lane (Fig. 2-1 A).  Profile plots were then 
drawn by using the Analyze>Gels>Plot Lanes command.  The resulting 
plots showed the relative density within each of the highlighted lanes.  
The width of the peaks represented the size/area of the bands and the 
peak height represented the shade/darkness of the bands.  The Straight 
Line tool was used to draw a line across the base of each peak so that the 
area under each one could be measured with little/no background noise 
(Fig. 2-1 B).  Once each peak was enclosed the Wand tool was used to 
select and highlight the peaks.   Measurements for the area under each 
peak then appeared in a pop up Results window (Fig. 2-1 C).  These 
measurements for the band densities of the protein of interest were then 
exported to Excel.  The process was repeated for bands representing 
housekeeping/loading control proteins.  Figure 2-1 D demonstrates the 
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calculations involved for determining the relative density of a protein of 
interest, normalised to the loading control.   
 
Figure 2-1:  ImageJ quantification of immunoblotting data 
2.9 Statistical methods 
In the results chapters, either all the data from three independent 
experiments are shown or representative images/immunoblots are 
presented.  Where replicates were performed (and data was quantitative) 
separate means were calculated for each independent experiment.  These 
independent means were then averaged to give an estimate of the true 
mean (µ) and 95% confidence intervals.  Quantitative data are presented 
as means ± 95% confidence intervals as outlined and recommended by 
(Cumming et al. 2007).  
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Prior to conducting statistical analyses to compare means, F-tests for 
heteroscedasticity were performed.  P values ≥ 0.05 returned by an F-test 
indicate populations with equal variance (homoscedastic) which is a 
basic assumption of the one-way analysis of variance (ANOVA) test.  
F-test scores were also used to determine whether a T-test for equal or 
unequal variance should be used.    
Student’s independent T-tests were performed when determining the 
significance of differences between two groups/means.  For comparisons 
between ≥ 3 groups: one-way ANOVA for independent samples was 
carried out.  If the overall difference between groups was determined to 
significant by ANOVA, Tukey’s post-hoc testing was then conducted to 
identify specifically which groups were different from each other.   
2.10 HA-BCA2 plasmid extraction from filter paper, amplification 
and purification 
2.10.1 Plasmid extraction from filter paper 
The pCMV-HA plasmid containing the BCA2 insert was a kind gift from 
Naoki Yamamoto at the AIDS Research Centre, National Institute of 
Infectious Diseases, Tokyo.  The plasmid had been previously used in the 
2009 publication by (Miyakawa et al.).  The vector map is included in 
Appendix D. 
A sterile scalpel was used to cut out the marked circle area containing 
dried plasmid DNA.  Using clean forceps, the filter paper was then 
inserted into a 1.5 mL eppendorf.  400 μL of sterile dH2O was added to 
the filter paper and the eppendorf was vortexed for 10 s. The sample was 
then incubated at room temperature for 5 min to allow plasmid DNA to 
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leach into the water.  The sample was then vortexed for another 10 s.  
The sample was centrifuged at 800 x g for 2 min to sediment loose filter 
paper etc.  The supernatant, containing the plasmid DNA solution was 
then transferred to a new eppendorf.   
2.10.2 Plasmid amplification and purification 
2.10.2.1  Transformation of competent E.coli 
400 µL of competent DH5α cells were defrosted on ice.  90 µL of cells 
were added to four separate, sterile eppendorfs containing 0.1, 1 and 
10 µL of the extracted HA-BCA2 DNA.   The cells and DNA were 
incubated for 20 min on ice then heat-shocked for 90 s at 42
o
C before 
being returned to ice for 2 min.  600 µL of SOC medium* was added to 
each eppendorf and the cells and DNA were incubated at 37
o
C for 1 hr 
with constant agitation (150 RPM shaking).   
The transformed cells were then cultured for 24 hr on 100μg/mL 
ampicillin LB-agar plates.  
*SOC medium: liquid medium containing 2% tryptone, 0.5% yeast 
extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 
20 mM glucose. 
2.10.3 Stocks of transformed bacteria cultures 
Single, transformed bacteria colonies were picked from the selection 
plates with a sterile pipette tip.  The inoculated tip was then stirred into a 
vial of Cryobank™ ceramic beads.  After thorough mixing, the fluid was 
drained from the vial which was then stored at -80
o
C.  When more stocks 
of the plasmid needed to be made: single beads were removed from the 
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frozen vials and rubbed across the surface of a fresh antibiotic selection 
plate.  After overnight incubation the plasmids could then be extracted 
and purified as described below.  
2.10.4 Plasmid amplification, extraction and purification 
Colonies grown on selection plates were picked with sterile pipette tips 
and cultured at 37
o
C/150 RPM in LB broth (containing 100 μg/mL 
ampicillin).  The volume of broth, duration of the incubation and 
subsequent purification protocol used depended on the amount of 
plasmid DNA required.  For the initial testing, that a plasmid of the 
correct molecular weight had been amplified, only a small amount of 
plasmid was required.  In the first instance therefore only 5 mL of broth 
was needed for a small culture; grown in a sterile universal with the cap 
loosely screwed on.  After an overnight incubation the Qiagen Mini-prep 
procedure was then performed, following the manufacturer’s instructions 
(Section 2.10.4.1).  A restriction digest followed by agarose gel 
electrophoresis was carried out to check that a plasmid of the correct size 
had been produced before scaling up the amplification and purification 
protocol.  Agarose electrophoresis was performed as described in 2.3.5.1 
but using a 1% gel. For large-scale/batch cultures to make plasmid 
stocks:  5 mL of inoculated broth was cultured as for the mini-prep but, 
initially, for a shorter time of 7 hr.  After 7 hr incubation, 500 µL of this 
starter culture was then transferred to large conical flask containing 
100 mL of the LB/ampicillin broth for overnight culture at 37
o
C with 
constant agitation of 150 RPM.  The plasmids were extracted and 
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purified from the batch cultures using the Qiagen Maxi-prep kit, 
according to manufacturer’s instructions (Section 2.10.4.2). 
2.10.4.1 Plasmid mini-prep 
Bacteria were harvested by centrifuging 1.5 mL of culture in a large 
Eppendorf tube at 6,800 x g for 3 min.  The supernatant was discarded 
and a further 1.5 mL of culture was added on top of the pellet.  These 
steps were repeated once more until a bacterial pellet from a total of 
4.5 mL of culture was produced.  The supernatant from the final 
harvesting step was discarded and the pellet was then thoroughly 
resuspended in 250 µL of buffer P1.  250 µL of lysis buffer P2 was then 
added to the bacterial suspension and the tube was gently inverted 5 
times to fully mix the solutions without damaging the plasmid DNA.  
The tube was incubated at room temperature for 4 min 45 s before 
350 µL of neutralisation buffer N3 was added and mixed by inverting 4-6 
times until the blue colour of the lyse blue indicator had completely 
disappeared.  The sample was centrifuged at 17,900 x g for 10 min to 
sediment the precipitated cell debris.  The supernatant was then carefully 
decanted into a QIAprep spin column and centrifuged for 60 s at 17,900 
x g; all centrifugation steps after this point were performed at this speed.  
The flow-through from the column was discarded and 750 µL of wash 
buffer PE was added to the top reservoir.  The column was centrifuged 
for 60 s, the flow through discarded and then the column was centrifuged 
“dry” for a further 60 s to remove residual wash buffer.  The column was 
then transferred to a sterile Eppendorf tube and 25 µL of elution buffer 
EB was gently pipetted onto the top of the column and incubated for 60 s.  
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The column was centrifuged for 60 s before another 25 µL of buffer EB 
was added to the top, incubated for 60 s and centrifuged for 120 s.  The 
eluted plasmid DNA was then stored at -80 
o
C for long-term storage or at 
4 
o
C for quantification and use in experiments.  
2.10.4.2 Plasmid maxi-prep 
After overnight incubation, half of the 100 mL batch culture was 
transferred into a 50 mL falcon tube and centrifuged at 6000 x g, 4
o
C for 
15 min.  The supernatant was discarded and the remaining half of the 
batch culture was poured into the falcon tube.  The sample was again 
centrifuged at 6000 x g, 4
o
C for 15 min.  The supernatant was discarded 
and the bacterial pellet was thoroughly resuspended in 10 mL of buffer 
P1.  10 mL of lysis buffer P2 was then added the tube was gently 
inverted 5 times to mix the buffer into the bacterial suspension without 
causing shearing of the DNA.  The lysing bacteria were incubated at 
room temperature for 4 min 45 s before 10 mL of neutralisation buffer P3 
was added and thoroughly mixed by inverting 6 times.  The sample was 
then incubated on ice for 20 min to allow the cell debris to precipitate.  
The solution and precipitate were transferred to high-speed centrifuge 
tubes and centrifuged at 20,000 x g for 15 min at 4
o
C.  While the sample 
was being centrifuged, a Qiagen-tip 500 column was equilibrated by 
applying 10 mL of buffer QBT.  The column emptied by gravity flow 
and the flow through was discarded.  After centrifugation the sample 
supernatant containing the plasmid DNA was quickly transferred to the 
top of the equilibrated column.  The sample passed through the resin of 
the column by gravity flow and once the column had emptied the flow 
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through was discarded.  The column was washed twice, each time with 
30 mL of wash buffer QC which was discarded after passing through the 
resin.  After washing, the column was transferred to a new 50 mL 
centrifuge and taped in place at the top of the tube.  The plasmid DNA 
was eluted by applying 15 mL of elution buffer QF to the column; the 
flow through was retained and the column discarded.  10.7 mL of 
isopropanol was mixed with the eluate to precipitate the DNA.  The 
sample was the centrifuged at 5000 x g, 4
o
C for 60 min to pellet the DNA 
precipitate.  The supernatant was carefully discarded and the plasmid 
pellet was washed with 70% ethanol.  The sample was centrifuged for a 
final time at 5000 x g, 4
o
C for 60 min.  After carefully decanting the 
supernatant the DNA pellet was left to air dry for 10 min before it was 
resuspended in 750 µL of sterile Tris-EDTA (TE) buffer.   
2.10.4.3 Determining DNA concentration 
The concentration of DNA in the purified plasmid solution was 
determined using the nanodrop spectrophotometer.  A sample of 
approximately 1 µL was taken from the plasmid solution using a thin-
walled quartz capillary tube.  The end of the capillary tube was sealed 
with cork and the sample concentration was measured relative to a TE 
buffer only reference using the spectrophotometer’s DNA concentration 
setting.  Once the DNA concentration had been determined the sample 
was diluted in additional sterile TE buffer to produce plasmid stocks with 
a concentration of 0.5 mg/mL.  
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2.10.4.4 Agarose electrophoresis 
2 µl of each of the plasmid eluate produced by mini-prep and their 
corresponding maxi-prep plasmid solutions were analysed by agarose 
electrophoresis using a 2% gel (Fig. 2-2).   
 
Figure 2-2: Agarose gel electrophoresis of amplified and purified pCMV-HA-
BCA2.  2 µL of plasmid product amplified and purified from 4 colonies/cultures of 
transformed E.coli first by mini-prep (1a-4a) then by maxi-prep (1b-4b). 
The HA-BCA2 construct consisted of a pCMV-HA-N vector of ~3.8 kb 
(Appendix D) into which a ~1 kb BCA2 sequence had been cloned.  The 
size of the complete HA-BCA2 vector was therefore ~4.8 kb. 
Separation by agarose gel electrophoresis (Fig. 2-2) indicated that a 
plasmid of the correct size had been produced by the transformation, 
extraction and amplification process. 
2.11 Subcloning of BCA2 from pCMV-HA into EGFP –N1  and -
C1 plasmids 
2.11.1 EGFP-N1 and EGFP-C1 destination vector preparation 
2 µg of each destination vector were digested with EcoR1 and PspOMI 
restriction enzymes.  For each restriction reaction 5 µL NEBuffer 4 was 
mixed with 37 µL of sterile dH2O and 4 µL of DNA.  2 µL of EcoR1 and 
2 µL of PspOMI were added to give a total volume of 50 µL and each 
reaction mixture was incubated at 37
o
C for 1 hr.  The linearized plasmids 
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were then dephosphorylated by adding 5.7 µL of 10X reaction buffer and 
1 µL of Antarctic Phosphatase to each completed digest and incubating at 
37
o
C for 30 min.  The phosphatase and restriction enzymes were then 
inactivated by heating the reaction mixture at 65
o
C for 20 min.     
2.11.2 BCA2 insert preparation  
2 µg of the HA-BCA2 pCMV parental vector was digested with EcoR1 
and Not1 restriction enzymes.   Four times the amount of Not1 enzyme 
was used compared with EcoR1 as a greater excess of this restriction 
enzyme is needed to cut supercoiled plasmids.  5 µL NEBuffer 3 was 
mixed with 30.5 µL of sterile dH2O, 0.5 µL of 10X (100µg/mL) BSA 
and 4 µL of DNA.  2 µL of EcoR1 and 8 µL of Not1 were added to give 
a total volume of 50 µL and each reaction mixture was incubated at 37
o
C 
for 1 hr.   The restriction enzymes were then inactivated by heating the 
reaction mixture at 65
o
C for 20 min. 
2.11.3 Gel preparation 
A 1% agarose gel was formed as described in 2.3.5.1 but the ethidium 
bromide was omitted from the agarose solution before being poured into 
the clean gel box to set.  A larger-well comb was prepared by taping 
together two adjacent teeth of a standard comb and this was placed into 
the unset gel.  After 40 min the gel had solidified, the electrophoresis 
tank was then filled with sterile 1x TAE buffer and the comb was 
removed. 
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2.11.4 Gel loading and running  
50µL of the digested parental and destination vectors were each mixed 
with 10 µL of 6x sample loading buffer.  The samples were loaded onto 
the agarose gel alongside 1 µL of 1 kB DNA ladder.  The gel was run at 
80 V for 4 hr to achieve the required band separation.  The gel was then 
stained in 100 mL of 5 µg/mL ethidium bromide in TAE buffer for 
10 min. The gel was then transferred to cling film and placed on a UV 
transluminator.  The required bands were visible at approximately 4.7 kb 
(EGFP-C1 and –N1) and 1 kb (BCA2 insert).  The bands were excised 
from the gel using sharp, sterile scalpels and were transferred to sterile 
eppendorfs.   The gel excision was performed in <40 s to minimise DNA 
damage from the UV light and ethidium bromide.   
2.11.5 Gel extraction – DNA purification  
The DNA was extracted from the agarose gel using the QIAquick gel 
extraction kit according to the manufacturer’s instructions.  The gel slices 
were weighed and 3 uL of Buffer QG per 1 mg of gel was added to each 
eppendorf.  The samples were then incubated at 50
o
C for 10 min and 
were vortexed every 2 min to aid dissolution.  The resulting solutions 
were yellow which indicated that the pH was in the desired range and did 
not need to be adjusted.   To each sample: 1 µL isopropanol was added 
per 1 mg gel and mixed.  The samples were then added to QIAquick spin 
columns in 2 mL collection tubes.  The loaded columns were centrifuged 
at 17,900 x g for 1 min to bind the DNA to the column.   The flow-
throughs were then discarded and the columns were returned to the 
collection tubes.  500 µL of Buffer QG was added to each of the columns 
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which were then centrifuged again at 17,900 x g for 1 min.  The flow-
throughs were discarded, the columns returned to the collection tubes and 
750 µL of wash buffer PE was added.  The columns were centrifuged for 
a third time at 17,900 x g for 1 min after which the flow-throughs were 
discarded and the columns were centrifuged again in empty collection 
tubes to remove the residual wash buffer.  The columns were transferred 
to sterile 1.5m l eppendorfs and the DNA was eluted by applying 30 µL 
of buffer EB to the centre of each column and incubating for 2 min 
before centrifuging a final time at 17,900 x g for 1 min. 
2.11.6 Ligation reaction 
The purified BCA2 insert and EGFP destination vector DNA was 
quantified so that a 3:1 molar ratio of insert:vector DNA could be 
prepared for the ligation reaction. 
The following calculation was performed: 
                      
                        
                   
                 
     
                        
                       
    
Substituting in values for HA-BCA2 and EGFP vectors: 
ng vector required = 100   moles of insert required = 3 
kb size of insert = 1    moles of vector required = 1 
kb size of vector = 4.7 
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Two ligation reactions were set up, each containing 63.8 ng of BCA2 
DNA and 100 ng of either EGFP-N1 or EGFP-C1.  2 µL of 10x reaction 
buffer was added to each DNA mix and the volume was brought to 19 µL 
with sterile dH2O.  1 µL of T4 DNA ligase was added and the reaction 
was left to proceed at room temperature for 10 min.   
2.11.7 Transformation of competent E.coli / amplification of EGFP-
BCA2 and BCA2-EGFP 
400 µL of competent DH5α cells were defrosted on ice.  90 µL of cells 
were added to four separate, sterile eppendorfs containing 0.1 µL and 
1 µL of either EGFP-BCA2 (C1) or BCA2-EGFP (N1) DNA.   The cells 
and DNA were incubated for 20 min on ice then heat-shocked for 90 s at 
42
o
C before being returned to ice for 2 min.  600 µL of SOC medium 
was added to each eppendorf and the cells and DNA were incubated at 
37
o
C for 1 hr with constant agitation (150 RPM shaking).  The 
transformed cells were then cultured for 24 hr on 30 μg/mL kanamycin 
LB-agar before colonies were selected and cultured for 16 hr in LB broth 
(containing 30 μg/mL kanamycin).  The cultures were then maxi-prepped 
(as in Section 2.10.4.2).  To check that BCA2 gene had been successfully 
inserted, the plasmid subclones were separated by agarose gel 
electrophoresis in parallel with the empty EGFP vectors.  Prior to 
separation on a 1% gel, all the plasmids were digested with EcoR1 
restriction enzyme so that a single band would be produced by 
electrophoresis.  Results are shown in Figure 2-3. 
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Figure 2-3:  Agarose gel electrophoresis verification of BCA2 subcloning into 
EGFP vectors.  Purified EGFP-BCA2 (C1) and BCA2-EGFP (N1) constructs were 
linearised along with the insert-free EGFP-N1 and C1 vectors. 
Successful incorporation of BCA2 was apparent in both EGFP N1 and 
C1 vectors. The molecular weight increase in the BCA2 constructs was 
approximately 1 kb which matches the size of the BCA2 gene.  
2.12 BCA2 insert sequencing in pCMV-HA and EGFP –N1 and -
C1 plasmids 
Sequencing was performed in Cardiff University Central Biotechnology 
Services (CBS) facility under the supervision of Dr. Keith Hart and 
Andrew Francis. 
2.12.1 PCR – Insert amplification  
PCR reactions were set up by mixing 5 µL of Better Buffer with 1 µL of 
BigDye® 3.1 RRM, 3.2 µL of 1 µM primer solution, 1 µL of 250 ng/µL 
DNA and 4.8 µL of dH2O.  Table 2-7 describes DNA and primers used. 
Table 2-7: Sequencing primers 
Sample DNA Primer 
A HA-BCA2 pCMV Forward - pCMV 631-657: 
5’-ATCCGGTACTAGAGGAACTGAAAAAC-3’ 
B HA-BCA2 pCMV Reverse - M13 reverse: 
5’-AAACAGCTATGACCATG-3’ 
C EGFP-BCA2 (C1) Forward - pEGFPC1for: 
5’-GATCACTCTCGGCATGGAC-3’ 
D EGFP-BCA2 (C1) Reverse - pEGFPC1rev: 
5’-CATTTTATGTTTCAGGTTCAGGG-3’ 
E BCA2-EGFP (N1) Forward - pEGFPN1for: 
5’-GTCGTAACAACTCCGCCC-3’ 
F BCA2-EGFP (N1) Reverse - pEGFPN1rev: 
5’-GTCCAGCTCGACCAGGATG-3’ 
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The reaction mixtures were placed on a Veriti Thermocycler and 
amplified using the following programme: 
1.  Initial denaturation step: 96°C for 1min 
2.  Denaturation cycle step: 96°C, for 10 s 
3.  Primer annealing step:  50°C, for 5 s 
4.  Strand elongation step:  60°C, for 4min 
2.12.2 Dynabeads® sequencing clean-up 
20 µL of homogenous Dynabeads® solution was added to each 
completed PCR reaction sample and was thoroughly mixed by pipetting.  
The samples were then incubated at room temperature for 15 min before 
being placed on a magnetic PCR plate.  The supernatants were carefully 
removed with clean pipette tips and 30 µL of 85% ethanol was added to 
each tube.  The samples were returned to the PCR plate for 1min before 
the supernatants were again removed and discarded.  The samples were 
air-dried for 5 min then 30 µL of sterile dH2O was added to each tube 
and mixed by pipetting till homogenous.  The samples were left for 2 min 
to allow the cleaned PCR products to leach into the water then 25 µL of 
the eluted DNA was transferred into new eppendorfs for sequencing.   
2.12.3 Sequencing preparation 
The cleaned PCR products were dried for 15 min in a centrifugal 
evaporator before being resuspended in 10 µL of formamide and 
sequenced on an ABI PRISM® 3100. 
Repeat – 25 cycles 
total 
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2.12.4 Sequencing analysis 
The .seq results files generated by sequencing were analysed using open 
source Chromas Lite software (http://technelysium.com.au/) 
2.13 Transfection 
2.13.1 DNA transfection 
Plasmid constructs 
- pCMV-HA-BCA2 (HA-BCA2; (Miyakawa et al. 2009) was used in 
BCA2 over-expression experiments.  
 
- pCMV6-AC-HA with no insert DNA was used as a vector control  
  in HA-BCA2 transfection experiments. 
 
- pEGFP-C1 containing Rab7, Rab5 and Rab21 (Simpson et al. 2004) 
were used in the double-transfection / co-localisation experiments. 
Methods 
The following methods all describe volumes and quantities per well of a 
12-well plate (quantities were multiplied by 2.4 for transfections in 6-
well plates and divided by 10 for 96-well plates to account for 
differences in surface area): 
2.13.1.1 Fugene 6 transfection – HA-BCA2 
100,000 MCF-7, 100,000 MCF-10A, 67,000 HeLa or 70,000 MDA-MB-
231 cells were seeded onto coverslips in a 12-well plate and incubated 
for 24 hr (37
o
C, 5% CO2) in complete media.  After 24 hr the cells were 
50-60% confluent.   The Fugene 6 transfection mixture was prepared by 
mixing 3 μL of Fugene 6 with 97 μL of SFM and incubating at room 
temperature for 5 min.  The diluted Fugene 6 was then added to 1 μg of 
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plasmid DNA in 98 μL of SFM.   The mixture was incubated at room 
temperature for 30 min then 200 μL of the FuGENE 6:DNA complex 
was added dropwise cells.  The media was changed for fresh complete 
media after 5 hr.  The transiently transfected cells were fixed and labelled 
with antibodies and probes 24 hr later. 
2.13.1.2 Lipofectamine 2000 transfection 
140,000 MCF-7 or 90,000 MDA-MB-231 cells were seeded onto 
coverslips in a 12-well plate and incubated for 24 hr (37
o
C, 5% CO2) in 
RPMI supplemented with 10% FBS.  After 24 hr the cells were ≈80% 
confluent.   The Lipofectamine 2000 transfection mixture was prepared 
by mixing 3 μL of Lipofectamine 2000 with 97 μL of SFM and 
incubating at room temperature for 5 min.  The diluted Lipofectamine 
2000 was then added to 1 μg of plasmid DNA in 98 μL of SFM.   The 
mixture was incubated at room temperature for 30 min then 200 μL of 
the Lipofectamine 2000:DNA complex was added dropwise to  the cells.  
The media was changed for fresh RPMI after 4 hr.  The transiently 
transfected cells were fixed and and labelled with antibodies and probes 
after 24 hr. 
2.13.2 siRNA Transfection 
The following method describes volumes and quantities per well of a 6-
well plate. 
2.13.2.1 Single-siRNA sequence depletion method for BCA2 
and flotillin 1 
250,000 MCF-7 cells were seeded in 6-well plates and grown to 60% 
confluence in RPMI supplemented with 10% FBS.  Cells were 
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transfected 24 hr after plating with siRNA (sequences below).  The 
transfection reagent was prepared by mixing 4.8 μL of oligfectamine in 
19.2 μL Opti-MEM to a final volume of 24 μL.  1.2 μL of a 50 μM 
siRNA solution was diluted in 214.8 μL of Opti-MEM® I to a final 
volume of 216 μL.  The siRNA and oligofectamine were mixed gently 
and incubated at room temperature for 30 min.  During this time the 
culture media in the well plates was aspirated, the cells were washed 
once with SFM then the media was replaced with 960 μL of SFM.  240 
μL of the oligfectamine:siRNA complex was then added to each well to 
transfect  the cells.   After 4 hr incubation (37ºC, 5%CO2): 600μL of 30% 
serum RPMI was added to the culture medium without removing the 
transfection mixture.  Lysates of the siRNA depleted cells were collected 
after 48 hr total transfection. 
siRNA sequences 
Non-targeting siRNA control (GFP) 
Sense sequence 5’-GGCUACGUCCAGGAGCGCAdTdT-3’ 
 
Flotillin-1 siRNA – published sequence 
Sense sequence  5'-AGAUGCACGGAUUGGAGAA-dTdT-3’ 
 
BCA2-1 siRNA – standard MWG sequence    
Sense sequence  5’-CUACCGGAAUAUAUAUGUC-dTdT-3’ 
 
BCA2-K siRNA – published sequence 
Sense sequence  5’-CGUCUGAAUAGAAUUAAUU-dTdT-3’ 
 
2.13.2.2 SMARTPOOL siRNA depletion of BCA2 
250,000 MCF-7 cells were seeded into 6 well plates. After 24 hr the cells 
were ≈40% confluent.  The transfection mixture was prepared by mixing: 
 135 
 
2.4 µL Dharmafect1 transfection reagent in 237.6 µL of SFM and 
incubating at room temperature for 5 min.  Meanwhile 12 µL of 5 µM 
siRNA (either non-targeting GFP siRNA or BCA2 Dharmacon ON-
TARGET plus SMARTpool siRNA) was mixed into 228 µL SFM.  The 
diluted Dharmafect1 was then added to the diluted siRNA and the 
mixture was incubated at room temperature for 30 min at room 
temperature.  The cell media was aspirated and replaced with 1920 μL of 
compete media.  After 30 min incubation 480 µL transfection mixture 
was added to each well, giving a final siRNA concentration of 25 nM.  
Cells were incubated with the siRNA at 37°C in 5 % CO2 for 48 hr 
before further experiments were performed. 
2.14 Cell viability assay 
Cell viabilities were determined using the CellTiter-Blue® assay in 
accordance with manufacturer’s instructions.  3,500 HeLa cells were 
seeded into black 96-well plates and incubated overnight at 37ºC, 5% 
CO2.  The following day cells were transfected with 0.1 μg HA-BCA2 or 
empty vector control using 0.3 μL of Fugene 6 (see 2.13.1.1).  24 hr after 
transfection cells were serum starved in SFM for 1 hr then incubated for 
48 hr with 100 µL of either: complete media, reduced-serum (0.5% FBS) 
media or reduced-serum media containing 20 ng/ml EGF.  After 44 hr 
incubation, 20 μL of CellTiter-Blue reagent was added to each of the 
wells and the plates were returned to the incubator.  After 4 hr incubation 
with the CellTiter-Blue reagent, the fluorescence (544Ex/590Em) was 
analysed using a Fluostar Optima fluorescent plate reader. 
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2.15 Generation of stable cell lines  
2.15.1 Preparation of vector constructs 
2.15.1.1 Truncation mutant design 
Truncation mutants were designed for BCA2 based on the location of key 
domains predicted by the HHPred online bioinformatics software:  
Homology detection & structure prediction by HMM-HMM comparison. 
http://toolkit.tuebingen.mpg.de/hhpred.  A truncation mutant lacking the 
N-terminal zinc finger was designed (-Zn-BCA2) along with a mutant 
lacking the C-terminal RING-H2 domain (-RING-BCA2).  The results of 
the homology detection and structure prediction by HMM-HMM 
comparison are presented in Appendix I.  Diagrams of truncation mutants 
that were designed based on the domain prediction results are presented 
in Figure 2-4.  
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Figure 2-4: Schematic diagram of BCA2, functional truncation mutants developed based on predicted domains  
1
3
7 
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2.15.1.2 PCR primer design 
PCR primers were then designed to amplify wild-type HA-BCA2 and the 
two truncation mutants from the pCMV-HA-BCA2 plasmid.  To enable 
directional cloning into the pEF5/FRT/V5-D-TOPO® vector, “CACC” 
was added to the 5’ end of the forward PCR primers.  To prevent the 
vector’s optional V5 C-terminal tag from being added to the translated 
protein, reverse primers were designed with TGA stop codons at the 5’ 
end.  The HA-sequence was reintroduced to the N-terminal truncation 
mutant by including the HA-sequence in the forward primer for this 
partial gene. The primers and their target sites in the HA-BCA2 sequence 
are presented in Figure 2-5. 
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HA-BCA2 sequence & primer sites 
 
ATGTACCCATACGATGTTCCAGATTACGCTCTTATGGCCATGGAGGCCCGAATTCGGTC
GACCGAGATCCGGATGGCGGAGGCTTCGGCGGCCGGGGCGGACTCGGGCGCCGCTGTAG
CCGCCCACCGGTTTTTCTGCCACTTTTGCAAGGGCGAGGTCAGCCCCAAACTACCGGAA
TATATATGTCCCAGATGTGAATCAGGCTTTATTGAAGAAGTGACAGATGATTCCAGTTT
TTTAGGTGGTGGCGGCAGTCGGATAGACAATACCACAACAACACATTTTGCAGAGCTTT
GGGGCCATTTGGATCACACGATGTTTTTTCAAGATTTTAGACCCTTTCTAAGTAGCAGT
CCACTGGACCAAGATAATAGAGCCAATGAAAGGGGTCACCAGACTCACACTGACTTCTG
GGGAGCAAGACCTCCACGGTTGCCATTGGGTCGGAGATACAGATCTCGAGGAAGTTCTC
GTCCTGACAGATCTCCAGCTATTGAAGGAATACTACAACACATCTTTGCAGGATTCTTT
GCAAATTCTGCCATTCCTGGATCTCCACACCCTTTTTCCTGGAGCGGGATGCTGCACTC
CAACCCTGGGGACTATGCCTGGGGTCAGACAGGGCTTGATGCCATTGTAACCCAGCTTT
TAGGACAACTGGAAAACACAGGCCCTCCCCCAGCTGACAAGGAAAAGATCACATCTCTT
CCAACAGTGACAGTAACTCAGGAACAAGTTGATATGGGTTTAGAGTGTCCAGTATGCAA
AGAAGATTACACAGTTGAAGAGGAAGTCCGGCAGTTACCTTGCAATCACTTCTTTCACA
GCAGTTGTATTGTGCCGTGGCTAGAACTGCATGACACATGTCCTGTATGTAGGAAGAGC
TTAAATGGTGAGGACTCTACTCGGCAAAGCCAGAGCACTGAGGCCTCTGCAAGCAACAG
ATTTAGCAATGACAGTCAGCTACATGACCGATGGACTTTCTGA 
Key: 
HA-Tag                  CACC-HA-BCA2-50for primer site  
BCA2             HA-BCA2-225rev primer site 
CACC-HA-BCA2for primer site                 HA-BCA2rev primer site 
 
Primers for WT-BCA2 
CACC-HA-BCA2for  
5’-CACCATGTACCCATACGATGTTCC-3’       Tm = 64.6
o
C  
HA-BCA2rev  
5’-TCAGAAAGTCCATCGGTCATGTAGC-3’      Tm = 64.6
o
C  
    
Primers for –Zn-BCA2 (a.a. 50 – 304)  
CACC-HA-BCA2-50for  
5’-CACCATGTACCCATACGATGTTCCAGATTACGCTACAGATGATTCCAGTTT-
TTTAGGTGG-3’                         Tm = 61.5
oC   
HA-BCA2rev   
5’-TCAGAAAGTCCATCGGTCATGTAGC-3’      Tm = 64.6
oC  
    
 
Primers for -RING truncation mutant (a.a. 1-225) 
CACC-HA-BCA2for  
5’-CACCATGTACCCATACGATGTTCC-3’       Tm = 64.6
oC   
HA-BCA2-225rev  
5’- TCAACCCATATCAACTTGTTCCTGAG-3’    Tm = 63
oC  
  
Figure 2-5: Primers for PCR subcloning of wild-type and truncation mutant 
BCA2.  A) HA-BCA2 sequence with colour coded primer binding sites.  Primers for 
PCR amplification of B) HA-BCA2 Wild-Type. C) -Zn-finger mutant and D) –RING 
mutant HA-BCA2. 
  
A 
B 
C 
D 
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2.15.1.3 Insert generation by PCR 
In order to amplify the wild-type HA-BCA2 and the truncation mutants, 
the following mixture was set up for each PCR reaction: 
PCR reaction mixture   Volume     Final concentration 
5x Hot star PCR buffer   10 µL   1x 
100 µM Fwd primer*   0.5 µL   1 µM 
100 µM Rev primer*   0.5 µL   1 µM 
HotStar Hifidelity Polymerase  1 µL   2.5 units 
Nuclease-free dH2O   37 µL   - 
50 ng/ µL HA-BCA2 template  1 µL   1ng/µL 
Total volume 50 µL  
*The following forward and reverse primer combinations were used: 
For WT-BCA2:  
CACC-HA-BCA2for 
HA-BCA2rev 
 
For –Zn mutant-BCA2:  
CACC-HA-BCA2-50for primer site  
HA-BCA2rev 
 
For –RING H2 mutant-BCA2:  
CACC-HA-BCA2for 
HA-BCA2-225rev 
The PCR reaction was then performed according to the following 
protocol: 
Thermocycler protocol 
- Initial denaturation:    95oC ... 5min  
 
- Cycles (x30):     
• 94oC … 15s     denaturation  
• 55 oC …60s     annealing  
• 72oC … 60s     elongation  
 
- Final elongation step:     72oC …  10 min  
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Following PCR amplification 500ng of DNA was then loaded onto a 1% 
agarose gel and separated at 80 V for 2 hr in TBE.  The resulting gel was 
imaged and is presented in Figure 2-6.  Single bands at the appropriate 
molecular weight for wild-type HA-BCA2 (~1 kb), the two truncation 
mutants (~0.75 kb) were clearly visible. 
 
Figure 2-6: Agarose gel separation of wild-type and mutant HA-BCA2 PCR 
products. 
2.15.1.4 TOPO cloning 
The PCR products were TOPO cloned into the pEF5/FRT/V5-D-TOPO® 
using a 1:1 molar ratio of insert:vector DNA.   The following values and 
calculations were used: 
kb size of vector = 5.831 
kb size of W.T. HA-BCA2 = 0.987 
kb size of –Zn HA-BCA2 = 0.777 
kb size of –RING H2 HA-BCA2 = 0.768 
ng of vector used = 20 
 
ng of insert needed  =    
ng of vector used     x     kb size of insert      x   mol. insert required 
        kb size of vector          mol. vector required 
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W.T. HA-BCA2 
 
ng of insert needed   =  20    x    0.987    x   1 
                     5.831  1 
          = 3.39 ng  
-Zn HA-BCA2 
 
ng of insert needed   =  20    x    0.777    x   1 
                    5.831  1 
          = 2.67 ng 
-RING HA-BCA2 
 
ng of insert needed   =  20    x    0.768    x   1 
                    5.831  1 
          = 2.63 ng  
 
The PCR products were diluted in nuclease-free water to the following 
concentrations: 
W.T. HA-BCA2   = 3.39 ng/ µL 
-Zn HA-BCA2   = 2.67 ng/ µL 
-RING H2 HA-BCA2  =2.63 ng/ µL 
 
The TOPO cloning was performed by setting up the following reaction 
mixture and incubating for 20 min at room temperature: 
TOPO reaction mixture 
PCR product  1 µL 
Salt solution  1 µL 
Nuclease-free dH2O 3 µL 
TOPO vector   1 µL 
Final vol.  6 µL 
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2.15.1.5 Transformation of One Shot® TOP10 competent cells 
2 µL of the TOPO cloning reaction mixture was added to a 50 µL vial of 
One Shot® TOP10 competent cells and mixed by gentle stirring before 
incubation on ice for 30 min.  The cells were then heat-shocked in a 
water bath at 42
o
C for 30 s and transferred to ice for 2 min.  SOC media 
(250 µL) was added to each of vials which were then tightly sealed and 
transferred to the shaking incubator for 1 hr at 37
o
C, 200 RPM.  50 µL 
and 200 µL of each transformed cell suspension were spread onto 
separate pre-warmed LB agar plates containing 100 µg/mL ampicillin.  
Untransformed cells and cells previously transformed with HA-BCA2 
were also spread onto ampicillin-plates to act as negative and positive 
controls respectively.  The inoculated selection plates were incubated 
overnight at 37
o
C, 5% CO2.   
The following day, 30-50 colonies were seen on the plate for WT-BCA2 
and both mutants.  No growth was observed on the selection media 
inoculated with untransformed bacteria (negative control) and lawn of 
bacterial growth was present on non-selective LB agar (positive control).  
2.15.1.6 Amplification and purification of plasmids 
Half of an isolated colony was lifted with a sterile pipette tip and placed 
into 5 mL of antibiotic-containing LB broth in a sterile universal with the 
lid loosely screwed on.  The other half of the isolated colony was then 
used to check the presence and orientation of the insert by PCR (see 
section 2.15.1.7 for method). 
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The plasmids were amplified by incubating the 5 mL cultures overnight 
at 37
o
C with 200RPM shaking.  Plasmid extraction and purification was 
performed via a miniprep procedure, according to manufacturer’s 
instructions and as described previously in section 2.10.4.1.  The 
inoculated universals were stored at 4
o
C for later Maxiprep amplification 
of successful transformants. 
2.15.1.7 PCR analysis of Transformants 
In order to determine the presence and orientation of the inserts in the 
transformants, PCR analysis was performed.  In PCR verification of 
insert orientation two reactions are set up.  One PCR reaction contains a 
T7 primer and an insert sequence-specific forward primer.  The second 
PCR reaction contains T7 primer and a sequence specific reverse primer.  
Figure 2-7 shows how correct and incorrect insert orientations would 
appear following PCR and agarose electrophoresis of samples. The figure 
demonstrates how results are interpreted: a correctly orientated insert 
would only be amplified with the T7 primer and a reverse primer. 
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Figure 2-7: The principle of PCR verification of insert orientation 
Two PCR reactions were performed on the half-colonies (from section 
2.15.1.6).  Half-colonies from the previous section were resuspended in 
the following PCR reaction mix:  
Hot star PCR buffer  10 µL 
T7 primer   1 µL 
Fwd or Rev insert primer 1 µL  Add ½ colony 
HotStar Polymerase  1 µL 
Nuclease-free water  37 µL 
The thermocyler was set up and the samples were run using the following 
PCR programme: 
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Thermocycler protocol 
- Initial denaturation:   94oC ... 10min      (lyses cells & 
deactivates nucleases) 
 
- Cycles (x30):     
• 94oC … 15s     denaturation  
• 55 oC …60s     annealing  
• 72oC … 60s     elongation  
 
- Final elongation step:    72oC … 10 min  
The PCR products were mixed with loading buffer separated by 
electrophoresis on a 1% agarose gel for 3 hr (80 V) alongside a DNA 
ladder to enable band size determination.  The results of the PCR analysis 
are presented in Figure 2-8. 
 
Figure 2-8: Agarose gel of PCR transformant analysis.  The presence of a band in 
the “T7 + Fwd” primer lane indicates a correctly orientated insert.  Samples from the 
lanes indicated by green arrows were selected for batch culture amplification 
PCR verification of HA-BCA2 and mutant constructs confirmed that the 
TOPO cloning had been successful. 
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2.15.1.8 Batch Culture and Purification of Plasmids 
Add 5 mL of ampicillin-containing LB broth was added into the 
previously inoculated universal tubes containing the successful 
transformants.  The lid was screwed on loosely and the cultures were 
incubated for 4 hr at 37
o
C with 200 RPM shaking.   The starter cultures 
were transferred to large (1 L flasks) containing 100 mL ampicillin LB-
broth.  Sterilised sponge bungs were placed in flask openings and the 
batch cultures were then incubated overnight at 37
o
C with 200 RPM 
shaking.   
Plasmid extraction and purification was performed via the maxiprep 
procedure (previously described in 2.10.4.2) according to manufacturer’s 
instructions. 
2.15.1.9 Restriction analysis of transformants 
Following maxi-prep, restriction analysis was performed to re-verify the 
presence and correct orientation of the insert.    
For restriction analysis two restriction enzymes were selected: one to cut 
the vector and one to cut the insert.  The first enzyme to be chosen was 
one that cut at a single site, only in the destination vector.  The second 
enzyme to be chosen was one that cut once, asymmetrically and only in 
the insert.   The vector information sheet (Appendix G) and the online 
“NEB cutter” tool (http://tools.neb.com/NEBcutter2/index.php) were 
used to identify suitable sites for restriction analysis of the HA-BCA2 
and mutant constructs.  The information used in restriction enzyme 
selection is summarised in Figure 2-9.  Not1 was chosen as the first 
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(vector) restriction enzyme and BstEII was identified as a suitable 
candidate for the second enzyme (to cut the insert). 
   
Figure 2-9: Restriction enzyme selection for restriction analysis validation of 
correct insert orientation. 
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The predicted band sizes that would be generated by correctly and 
incorrectly orientated inserts were calculated using the vector map and 
the insert sequence.  This process is described and summarised in Figure 
2-10. 
 
Figure 2-10: Predicted relative and absolute band sizes for restriction analysis of 
HA-BCA2, –Zn and –RING mutant constructs. A) The relative band sizes created by 
restriction analysis of a correctly orientated insert. B) The relative band sizes for an 
incorrectly orientated insert.  C) The predicted pattern produced by agarose 
electrophoresis of differently orientated inserts. D) The calculated sizes for wild-type 
and truncation mutants of HA-BCA2. 
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The approximate sizes of the small fragments produced by correctly 
orientated insets were ~0.7 kb, ~0.65 kb and ~ 0.4 kb for the WT-BCA2, 
-Zn-BCA2 and -RING-BCA2 respectively. 
Sequential double digests of the HA-BCA2, -Zn and-RING mutant 
constructs were performed as follows: 2 μg of vector construct was 
digested with an eighty-fold excess of Not1 at 37
o
C followed by an 
eighty-fold excess of BstEII at 60
oC. For each restriction reaction 5 μL 
NEBuffer 3.1 was mixed with 31 μL of sterile dH2O and 4 μL of DNA. 8 
μL of Not1 was added to give a total volume of 48 μL and each reaction 
mixture was incubated in a water bath set to 37
o
C for 1 hr. After 1 hr, 2 
μL of BstEII were added and the reaction mixtures were transferred to a 
water bath set to 60
o
C for a further hour. 
The complete digest was then mixed with loading buffer and separated 
on a 1% agarose gel at 80 V for 3 hr alongside a DNA ladder to enable 
band size determination (Fig. 2-11). The banding pattern produced by the 
separated digest products was compared with predicted band sizes (Fig. 
2-10). 
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Figure 2-11: Restriction analysis of HA-BCA2 (wild-type), –Zn and –RING mutant 
constructs separated by agarose gel electrophoresis.  Verification of insert 
orientation was determined by the size of the small, highlighted fragments.  
The results of the restriction analysis confirmed that the inserts were 
correctly orientated in all the constructs.  The constructs could therefore 
be used to produce stable cell lines. 
 
2.15.2 Producing the stable cells 
Due to the intensiveness of the tissue culture stages in terms of labour, 
time and resources, only one of the constructs could be developed into a 
stable cell line at a time.  The wild-type HA-BCA2 construct was 
selected for the first stable cell line development work. 
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2.15.2.1 Parental cell line 
Flp-In HeLa S3 parental cells (along with the pOG44 vector) were a kind 
gift from Prof. Michael Clague and Prof. Sylvie Urbé from the 
Department Cellular and Molecular Physiology at Liverpool University.   
Flp-In HeLa were cultured in complete media (DMEM, 10% FBS 
supplemented with 250 µg/mL Zeocin selection antibiotic). 
2.15.2.2 Genejuice transfection of Flp-In HeLa with Wild Type 
BCA2 
400,000 Flp-In S3 HeLa cells were seeded into 5 wells of a 6-well plate 
and incubated for 24hr (37ºC, 5% CO2) in 2 mL DMEM supplemented 
with 10% FBS and 250 μg/mL of Zeocin.  After 24 hours the cells were 
≈60% confluent.   The Genejuice transfection mixture was prepared by 
adding 3 μL of Genejuice to 100 μL of SFM, vortexing on medium speed 
for 10s then incubating at room temperature for 5 min.  The diluted 
Genejuice was then added to 0.5 μg of WT construct and 0.5 μg of 
pOG44 in SFM to 100 μl. The mixture was incubated at room 
temperature for 30min before 200 μL of the Genejuice:DNA complex 
was used to transfect  the cells in 3 of the wells.  After 4 hr the media was 
changed for fresh complete media.   After 24 hours, the cells in each well 
were split 1/6 and plated onto two 10 cm dishes containing 10 mL of 
complete, Zeocin-free media.  1/6 splits were also made from a well of 
untransfected cells to act as negative (i.e. hygromycin sensitive) controls.  
The cells were incubated for 3 hr at 37ºC, 5% CO2 before the media was 
replaced with hygromycin (400 µg/mL) supplemented, complete media. 
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2.15.2.3 Growth and maintenance of cells 
The cells were maintained in complete selection media (DMEM 
containing 10% FBS and 400 μg/mL Hygromycin B) which was changed 
every 3 days till day 18 of the experiment.  During the media changes the 
cells were periodically imaged to document their progress. Cells were 
imaged with a digital camera adapted to fit an inverted light microscope.  
Untransfected, non-resistant cells were gradually killed by the 
hygromycin and resistant clone colonies began to form.  After nineteen 
days were picked and transferred to 24 well plates as described below.  
2.15.2.4 Colony picking 
Marker pen was used to circle usable colonies (those with a diameter 
large enough to fill most of a 10x objective field of view and with good 
separation margins from other colonies).  The colonies on plates that 
were too dense to allow individual colonies to be picked were discarded. 
Before starting: 500 µL of hygromycin media (400 µg/mL) was added to 
the wells of a 24 well plate and the plate was placed in the incubator at 
37ºC.  The trypsin was kept cool in an ice bath in the tissue culture hood.  
One 10 cm dish was processed at a time: stable colonies were washed in 
10 mL autoclaved and pre-warmed PBS.  All traces of PBS were 
removed and 1.5 mL of ice-cold trypsin was added to and swirled across 
the dish.  1 mL of trypsin was then removed, leaving a thin film across 
the cells.  The pipette was set to 10 µL, ~5 µL of trypsin was taken up 
into a filter tip pipette.  Approximately 2 µL of trypsin were then added 
directly onto a colony which was then quickly scratched off with the 
pipette tip.  The colony was then transferred to the 24-well plate and 
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gently mixed into to the hygromycin media.   After 6 colonies had been 
picked and transferred to wells a 1 mL pipette (set at 350 µL to avoid 
bubbles) was used to pipette the cells up and down in order to break up 
large cell aggregates into smaller clumps.   This was repeated for all the 
remaining cell dishes.  All the plated cells were then incubated at 37
o
C, 
5% CO2.  The colony picking procedure is summarised in Figure 2-12. 
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Figure 2-12: Illustration of procedure for colony picking of stable Flp-in clones. 
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2.15.2.5 Growth and maintenance of stable cell lines 
The cells were left to grow for 7 days in the 24 well plates.  The cell 
density was monitored and recorded  and the media was changed every 
2-3 days.  After 7 days the cells in wells that were >60% confluent were 
split 1:2 into two wells of 12-well plates.  Once the 12-well plate clones 
became70% confluent, one well was used for lysate collection and the 
second well was split into two wells of separate 6-well plates (one well 
for freezing cells down, one for Zeocin sensitivity testing).   
2.15.2.6 Cell freezing 
Once the clones in the 6 well plate had reached 70% confluency the 
hygromycin media was aspirated and the cells were washed with 1 mL of 
PBS. The PBS was removed and the cells were incubated with 450 µL of 
trypsin EDTA at 37
o
C for 3 min.  1 mL of media was then used to 
inactivate the trypsin and the cells in the media suspension were then 
transferred to Eppendorf tubes and centrifuged for 3 min at 900g.  The 
supernatants were aspirated and the cell pellets were gently resuspended 
in 750 µL of freezing medium (10% DMSO, 10% FBS DMEM) and 
transferred to cryovials.  The cryovials were placed in a Mr. Frosty
TM
 
freezing container at -80
o
C to ensure the cells froze at a slow and steady 
rate of approximately -1
O
C per minute. 
2.15.3 Testing the success of the stable cells 
2.15.3.1 Zeocin sensitivity 
Zeocin sensitivity testing was performed on the clones by seeding at low 
confluency (~10%) into a 6-well plate alongside two wells of HeLa Flp-
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In S3 cells.  The cells were grown in 250 µg/mL Zeocin media for 7 
days.  The media was changed on day 2 and day 5 after seeding. 
Clones were classified according to observed changes in growth rate and 
morphology: 
- Resistant: cells appear healthy and grow at a normal rate, no 
apparent sensitivity 
- Some sensitivity: some cells showing morphological changes 
(blebbing, cytoplasmic granulation, cell enlargement, increased 
heterogeneity.  Slower growth rate. 
- Sensitive: Extensive changes to cell size, morphology and/or 
growth rate 
- Highly sensitive: Extensive cell death.   
Sensitive Zeocin clones were then tested for HA-BCA2 expression by 
Western blotting for HA. 
2.15.3.2 HA-BCA2 expression analysis 
Lysates were made of the 18 clones growing in T25 flasks by seeding the 
cells in 6-well plates and collecting lysates on ice in 100 µL of NP-40 
lysis buffer containing protease inhibitor cocktail.  Lysates containing 50 
µg of total protein were separated on a 10% acrylamide gel by SDS-
PAGE.  Lysates of untransfected Flp-In HeLa and HeLa cells transiently 
transfected with HA-BCA2 were run alongside the clone lysates to act as 
a negative and positive control respectively.  After separation the samples 
were transferred to PVDF.  After Ponceau S staining to verify even 
loading and transfer the the PVDF membrane was blocked for 1 hr at 
room temperature in 5% milk in PBS containing 0.025% Tween (PBST).  
The membrane was incubated with mouse anti ~HA was diluted 1:500 in 
2% milk in PBST.  This primary antibody incubation step was performed 
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overnight in a humidified chamber at 4
o
C.  After 3x 5 min washes in 
PBST the PVDF strips were incubated at room temperature for 1 hr with 
anti mouse secondary antibody diluted 1:5000 in 2% milk in PBST.  The 
strips were washed a further 3x 5 min in PBST before Clarity ECL 
reagent was applied for 5 min and the resulting signal was detected using 
the Chemi-doc imaging system.   
2.15.3.3 Further HA-BCA2 expression analysis 
Three passages after resurrecting the cells lysates were taken of the 
clones that had indicated positive BCA2 expression.  Lysates were 
collected from 6-well plates by scraping into 100 µL lysis buffer 
(including protease and phosphatase inhibitors) on ice.  As previously 
described lysates were prepared, separated by SDS-PAGE, transferred to 
PVDF then blotted for HA. 
2.15.3.4 Induction/enhancement of HA-BCA2 expression 
150,000 clone cells were plated into 6-well plates and incubated at 
37
o
C/5% CO2 overnight.  The following morning cells were treated either 
with diluents controls or the following promoter enhancing drugs for 
48 hr: 
- 100 µM Butyric acid – 48 hr treatment (Tsubaki et al. 2002) 
Diluent control = dH2O 
 
- 1 µM 5-azacytidine – 48 hr treatment (Escher et al. 2005) 
Diluent control = acetic acid:water (1:1 v/v) 
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After 40 hours incubation a third (as yet untreated) set of wells were 
treated with 10 µM of the proteasome inhibitor MG132 or a DMSO 
diluent control. Incubation with MG132 was for 8 hr (Wang et al. 2013)   
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Chapter 3: In silico studies of BCA2 in Breast Cancer and 
Identification of Co-expressed Genes 
3.1 Biomarker and survival analysis
The expanding research use of microarray technology has lead to the 
creation of online repositories for gene expression data.  Microarray 
databases are free, searchable resources that allow users to access large 
quantities of experimental data for analytical purposes.   In this project 
publically available gene microarray databases were used for three main 
objectives.  Firstly, clinical gene expression data was used to evaluate 
the impact of BCA2 on patient survival in breast cancer, importantly 
also according to subtype.  Secondly, coexpression analysis was 
performed to identify genes which may be coregulated with BCA2 
and/or have similar cellular functions.  Thirdly, microarray data from 
specific experiments were examined in order to identify changes in 
BCA2 expression that may be biologically relevant and warrant further 
study.  The experimental datasets examined were primarily those 
pertaining to breast cancer development, oestrogen stimulation, 
therapeutic resistance and oncogene overexpression (including RTKs).       
3.1.1 KM Plotter 
The KM Plotter (http://www.kmplot.com/) is an online analysis tool 
that integrates microarray expression data with clinical information 
from 4,142 breast tumours.  Users can examine the impact on survival 
of different levels of gene expression for over 22 thousand target genes 
(Gyorffy et al. 2010). Median gene expression is used to split the data 
into high and low expressing groups and survival curves are generated 
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across all breast cancers or for analyses restricted according to different 
parameters such as oestrogen receptor (ER) status, molecular subtype, 
grade etc. The hazard ratio for RFS with 95% confidence intervals and 
logrank P value are automatically calculated for low vs. high 
expression.  The effect of BCA2 expression was analysed using the 
optimal “JetSet” probe: AffymetrixID 212742_at (Li et al. 2011).  
Results of the survival analyses performed as part of this project are 
shown in Figure 3-1. 
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Figure 3-1: Kaplan-Meier survival curves for high vs. low BCA2 mRNA 
expression created using KM Plotter (Gyorffy et al. 2010).  Probability of relapse 
free survival in high (red) or low (black) BCA2 expressing breast cancer is compared. 
A) Survival across all tumours. B) Survival stratified according to tumour grade C) 
Survival in ER+ vs. ER- disease. D) Survival in lymph node (LN)+ vs. LN- disease. 
E) Survival stratified according to molecular subtype. 
Kaplan-Meier plots for high versus low BCA2 expression show that BCA2 
only significantly impacts on relapse free survival in luminal B and HER2 
subtypes of breast cancer (Fig. 3-1 E).  High levels of BCA2 in luminal B 
disease are associated with poorer prognosis, with a hazard ratio (HR) for 
RFS of 1.28 and a P value of 0.016.  Significantly reduced relapse free 
survival was also demonstrated in high BCA2 expressing HER2-type 
disease (HR = 1.57, P = 0.036).  
 168 
 
3.1.2 GOBO: Gene expression-based outcome 
The online biomarker assessment tool GOBO (http://co.bmc.lu.se/gobo) 
was also used to generate Kaplan-Meier relapse free survival plots 
based on BCA2 mRNA expression with the 212742_at Jetset probes (Li 
et al. 2011).  GOBO is fundamentally similar to KM Plotter: microarray 
data and associated clinical information enable the user to investigate 
the potential prognostic significance of genes of interest (Ringnér et al. 
2011).  The GOBO analytical tool uses a smaller patient data set (1881 
samples) than KM Plotter but has the advantage that it can be 
subdivided into >2 groups for outcome analysis, based on magnitude of 
gene expression.  The greater expression stratification capability of 
GOBO means that graded relationships between gene expression and 
survival can be explored.   
For the BCA2 survival analyses, relapse free patient survival was 
compared for samples separated into high, medium and low BCA2 
expressing tumours.  Kaplan-Meier plots were created across all 
tumours and for groups subdivided according to: ER-status, molecular 
subtype, histological grade, and lymph-node status.  Logrank P values 
were calculated across the three expression levels.  Survival curves for 
graded BCA2 expression are shown in Figure 3-2.  
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Figure 3-2: Kaplan-Meier survival curves for high vs. low BCA2 mRNA 
expression created using GOBO (Ringnér et al. 2011).  Probability of relapse free 
survival in high (blue), medium (red) or low (grey) BCA2 expressing breast cancer is 
compared. A) Survival across all tumours. B) Survival stratified according to tumour 
grade C) Survival in ER+ vs. ER- disease. D) Survival in LN+ vs. LN- disease. E) 
Survival stratified according to molecular subtype.  
The GOBO expression data indicated that higher BCA2 expression was 
associated with better prognosis in breast cancer (Fig. 3-2 A, p = 0.00045).  
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Significantly improved relapse free survival was also demonstrated in 
higher BCA2 expressing disease of tumour grade 3 (Fig. 3-2 B, p = 
0.01665), ER positive status (Fig. 3-2 C, p = 0.00074) and LN positive 
status (Fig. 3-2 D, p = 0.00910).  Intermediate BCA2 expression was 
associated with better prognosis in luminal B type disease with high and 
low expression being associated with poorer prognosis (Fig. 3-2 E, p = 
0.01464). 
In addition to producing Kaplan-Meier curves, GOBO also allows 
comparisons of gene expression between different molecular subtypes 
of breast cancer. Expression levels are compared using box-plots and 
analysis of variance (ANOVA) statistics.  Average BCA2 expression 
levels were compared in patient breast tumours stratified according to 
molecular subtype, ER status and tumour grade (Fig. 3-3).   
 
Figure 3-3: Comparative BCA2 expression analysis in GOBO datasets of patient 
tumours categorised according to molecular and clinical features. Relative BCA2 
expression levels in patient data subdivided into A) different molecular subtypes of 
breast cancer, B) ER+ vs. ER- disease and C) tumour grade. 
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BCA2 was expressed at statistically significantly different levels across 
patient breast tumours of different molecular subtype (p < 0.00001, 
Fig. 3-3 A), and ER-status (p = 0.00441, Fig. 3-3 B) but not grade 
(p = 0.28622, Fig. 3-3 C).  Higher BCA2 levels were associated with 
the luminal A subtype (Fig. 3-3 A) and with ER+ breast cancer 
(Fig. 3-3 B).  There was no significant difference in expression levels 
between tumour grades (Fig. 3-3 C, p = 0.28622). 
Mean BCA2 expression in a publically available dataset from a panel of 
51 cell lines was analysed using GOBO (Fig. 3-4 A).  A statistical 
comparison was also made between groups of cell lines divided 
according to basal or luminal type (Fig. 3-4 B).  A third analysis looked 
at BCA2 expression across cell line groups defined by HER2 positivity, 
hormone receptor positivity and triple negative-type (Fig. 3-4 C).  
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Figure 3-4: Comparative BCA2 expression analysis in GOBO dataset of 51 normal and malignant breast cell lines categorised according to subtype. A) Log2 BCA2 
expression levels across individual cell lines.  B) Mean Log2 BCA2 expression compared between basal A, B and luminal A subtypes.  C) Mean Log2 BCA2 expression 
compared between triple negative, HER2 positive and hormone receptor positive disease. In A and B: Red = Basal A, Grey = Basal B and Blue = Luminal.  
1
7
3 
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Mean BCA2 levels appeared to be higher in breast/breast cancer cell 
lines categorised as luminal (e.g. MCF-7 and T47D) though the 
difference in expression compared with basal A (e.g. MDA-MB-468) and 
basal B (e.g. MDA-MB-231) types was non-significant (p = 0.09616).  
Highest mean BCA2 expression was associated with hormone receptor 
positivity and lower mean BCA2 expression levels were seen in the triple 
negative and HER2
+
 cell lines.  The difference in BCA2 expression 
between triple negative, HER2 and hormone receptor positive cell line 
classes was statistically significant (p = 0.02912).   
3.1.3 Gene co-expression using MEM: Multi experiment matrix 
Co-expression is an important principle of gene expression analysis and 
relates to the theory that genes which are co-expressed may have shared 
transcriptional control mechanisms and/or similar functional roles. The 
usefulness of this rationale has been demonstrated in a number of studies 
on gene co-expression and function (Stuart et al. 2003; Wolfe et al. 
2005).   
Based on the “guilt by association” theory, genes whose expression was 
highly correlated with BCA2 were identified using the MEM tool 
(http://biit.cs.ut.ee/mem/).  The MEM ranks genes according to 
expression similarity across 1794 human microarray datasets using an 
algorithm based on Pearson’s correlation (Adler et al. 2009).  
The full list of 48 genes whose expression was most highly correlated 
with BCA2 can be found in Appendix B.  Chromosome locations of the 
co-expressed genes were researched using Genecards 
 175 
 
(http://www.genecards.org/).  The purpose of describing gene loci was to 
identify genes that were potentially co-expressed with BCA2 due to 
cytogenetic aberrations such as increased copy number.  Of the 48 co-
expressed genes, 6 were localised to the same chromosome arm as BCA2 
(Chr.1q) and 7 were from Chr.7q (Table 3-1).  The remaining genes were 
distributed fairly evenly among the other chromosome arms.    
Table 3-1: Genes co-expressed with BCA2 from the long arm of chromosome 1 
(grey) or the long arm of chromosome 7 (white) 
Chr1q gene Gene locus Full gene name 
POLR3C 1q21.1 
Polymerase (RNA) III (DNA directed) 
polypeptide C (62kD) 
TIMM17A 1q32.1  
Translocase of inner mitochondrial 
membrane 17 homolog A (yeast)  
TMCO1 1q22-q25  
Transmembrane and coiled-coil 
domains 1  
UBE2Q1 1q21.3   
Ubiquitin-conjugating enzyme E2Q 
family member 1 
TROVE2 1q31  TROVE domain family, member 2  
HAX1 1q21.3  HCLS1 associated protein X-1 
SBDS 7q11.21 
Shwachman-Bodian-Diamond 
syndrome pseudogene 1 
BCAP29 7q22.3  B-cell receptor-associated protein 29  
AP2B1 17q11.2-q12  
Adaptor-related protein complex 2, 
beta 1 subunit  
ANKIB1 7q21.2 
Ankyrin repeat and IBR domain 
containing 1  
DLD 7q31-q32  Dihydrolipoamide dehydrogenase 
METTL2B 7q32.1 Methyltransferase like 2A  
PSMD12 17q24.2 
Proteasome (prosome, macropain) 
26S subunit, non-ATPase, 12  
Functional annotation clustering analysis of the 48 co-expressed genes 
was performed using DAVID (http://david.abcc.ncifcrf.gov/).  The 
strongest gene ontology (keyword) associations were primarily functions 
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relating to intracellular protein and vesicle transport (see Table 3-2).  A 
more detailed table of results from the DAVID functional clustering 
analysis is also included in Appendix C. 
Table 3-2: Genes co-expressed with, and ontologically related to, BCA2.  Gene loci 
and protein names and functions were compiled from the Genecards database. 
Gene Locus Protein Function 
BCAP29 7q22.3 
B-cell receptor-
associated protein 29 
Transport of membrane proteins 
from endoplasmic reticulum to 
Golgi.  May be involved in caspase-
8 mediated apoptosis. 
RAB18 10p12.1 Rab18 
Transport of proteins from 
endoplasmic reticulum to Golgi.  
COPB1 11p15.2 
Coatomer protein 
complex, subunit 
beta 
Part of the coatamer complex.  
Involved in protein transport from 
Golgi to endoplasmic reticulum. 
TIMM17A 1q32.1  
Mitochondrial inner 
membrane 
translocase 
Protein translocation across inner 
mitochondrial membrane. 
TRAM1 8q13.3  
Translocation 
associated membrane 
protein 1 
Glycosylation and translocation of 
secretary proteins across the 
endoplasmic reticulum 
TNPO1 5q13.2 Transportin 1 
Receptor for nuclear localisation 
signals. Nuclear import of proteins. 
VPS37A 8p22  
Vacuolar protein 
sorting associated 
protein 37A 
Part of the ESCRT-I complex, 
required for sorting of 
ubiquitinated, endocytosed 
receptors into internal vesicles of 
MVBs. 
VAMP7 
Xq28 / 
yq12 
Vesicle-associated 
membrane protein 7 
Targeting, fusion and transport of 
vesicles with late endolysosomes. 
ARL1 12q23.2  
ADP-ribosylation 
factor-like 1 
Regulation of Golgi structure and 
function. 
AP2B1 
17q11.2-
q12  
Adaptor-related 
protein complex 2, 
beta 1 subunit 
Part of assembly protein complex 2 
(AP2), which links clathrin to 
receptors in coated vesicles. 
YWHAQ 2p25.1 14-3-3 θ / τ 
Adaptor protein, binds to 
phosphoserine/threonine motifs 
and modulates protein activity and 
localisation. E.g. Protein kinase C θ. 
VIMP 15q26.3 Selenoprotein S 
Transfer of misfolded proteins 
from the endoplasmic reticulum to 
the cytosol for proteasomal 
degradation. 
HAX1 1q21.3  
HCLS1 associated 
protein X-1 
Clathrin mediated endocytosis of 
integrin αvβ6. 
SLC25A32 8q22.3 
Mitochondrial folate 
carrier 
Transports folate across the inner 
membranes of mitochondria 
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3.2 Gene expression changes: BioGPS 
BioGPS (http://www.biogps.org/) is an open-access, online portal that 
allows users to find and extract gene expression information from a large 
selection of publically available datasets.  BCA2 expression information 
was obtained via the BioGPS portal from the following datasets: 
 GSE15192: Differences between CD44+/CD24- and CD44-
/CD24+ subpopulation of immortalized human mammary 
epithelial cells 
 GSE5116: Genomic Pathways of 17-beta-Estradiol Induced 
Malignant Cell Transformation in Human Breast Epithelial Cells  
 GSE4668: Expression data from hormone-starved MCF7/BUS 
cell culture 
 GSE20361: Dynamic changes during adaptation to estrogen 
deprivation in MCF7 cell line 
 GSE14986: Antiestrogen-resistant subclones of MCF-7 human 
breast cancer cells are derived from a common clonal drug-
resistant progenitor 
 GSE10696: Expression analysis in A431_wt vs A431_GR cells 
 GSE14987: Expression data from ERBB2 over-expression and 
EGF stimulation in MCF10A cells 
 GSE13274: Ad-HER-wt and Ad-HER2-ki infected HMECs 
 GSE3151: Oncogenic signalling dataset 
The gene expression values in BioGPS datasets were generated in 
Affymetrix microarray experiments and relate to probe set fluorescence 
intensity.  Gene expression data used in this chapter were obtained with 
Human Genome U133A (HG-U133 plus 2.0) arrays (GPL570 platform) 
and the 212742_at (JetSet) probe for optimal RNF115/BCA2 detection.  
Where available, data using the 226468_at probe set were also analysed 
to determine whether a consistent direction of expression change was 
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detected.  This afforded further confidence that observed changes in 
BCA2 expression were robust and reliable. 
In place of expression call data, log2 BCA2 expression was calculated 
and positive values were deemed “present”.  If in the experimental 
conditions BCA2 expression fell below control levels then log2 was 
calculated for the lowest data point to ensure the mRNA levels were still 
detectable (present). 
Fluorescence intensity values were converted to relative expression ratios 
(fold-change) compared to control.  The fold-change values were then 
log2 transformed and means and 95% confidence intervals were 
calculated.  The statistical significance of differences between groups 
was assessed by one of two approaches.  For analyses comparing two 
sample populations/means, the student’s independent T-test was chosen 
to determine significance.  For groups of three or more, one-way analysis 
of variance (ANOVA) for independent samples was carried out.  
ANOVA was followed, where appropriate, by Tukey’s post-hoc testing.  
The log2 fold-change data and statistical test results are presented 
graphically in section 3.2.1 onwards.   
A standard threshold of 1.5 (absolute) fold-change between the control 
and the test groups was considered the cut-off for biological relevance.  
Absolute fold-change values are presented in table format; red values 
indicate ≥1.5 fold induction, green values denote ≥ 1.5 fold suppression. 
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3.2.1 BCA2 expression in CD44+/CD24- and CD44-/CD24+ 
subpopulations of immortalized human mammary epithelial cells 
A subpopulation of normal and malignant breast epithelial cells have 
been implicated in tumour initiation and have demonstrated stem cell like 
properties (Al-Hajj et al. 2003).  This subpopulation is defined by a 
CD44
+
/CD24
-/low
 phenotype and in breast cancer is most often found in 
basal breast cancers that have undergone a degree of epithelial to 
mesenchymal transition (Sheridan et al. 2006; Honeth et al. 2008).  
In order to determine whether BCA2 was differentially expressed in 
putative stem cells, the GSE15192 dataset was examined.  This dataset 
was generated by gene expression profiling of CD44
+
/CD24
-
 and CD44
-
/CD24
+
 subpopulations of MCF-10A cells.  The subpopulations were 
identified and sorted by flow cytometry in 4 independent experiments.  
More detailed descriptions of the methods employed are provided in the 
source publication (Bhat-Nakshatri et al. 2010).  BCA2 expression data 
were extracted from the dataset, detectable expression was confirmed, 
then mean relative log2 fold-change between the cellular subpopulations 
was calculated and statistically compared.  This fold-change in BCA2 
expression in CD44
+
/CD24
-
 versus CD44
-
/CD24
+
 subpopulations are 
presented and compared in Figure 3-5. 
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Figure 3-5: BCA2 mRNA expression in CD44-/CD24+ and progenitor-like 
CD44+/CD24- subpopulations in human mammary epithelial cells. Global gene 
expression in MCF-10A subpopulations was measured by microarray (Bhat-Nakshatri 
et al. 2010) and deposited online (GSE15192).  A) Log2 mRNA expression analysis of 
controls confirmed detectable BCA2 expression with both probesets. Mean log2 fold 
change in BCA2 expression between the cell subpopulations was determined from B) 
the 212742_at probe set data and C) 226468_at set. Error bars represent 95% 
confidence intervals **** Statistical significance p ≤ 0.0001. ** Statistical significance 
p ≤ 0.01.  D) Absolute fold change in BCA2 expression in the stem cell subpopulation.  
Red values indicate fold induction ≥ 1.5. 
BCA2 expression was confirmed by log2 analysis (Fig. 3-5 A).  Students 
independent T-test of the two subpopulation means IN Fig 3-5 B revealed 
that the CD44+/CD24- (stem-like) cells expressed significantly higher 
BCA2 levels than the CD44-/CD24+ cells when measured with both the 
212742_at probe set (p = 0.0001) and the 226468_at set (p = 0.0012, Fig. 
3-5 C).  BCA2 expression measured with the JetSet probe showed a fold 
increase of 1.66 in the putative stem cell population (Fig. 3-5 D).  The 
fold induction indicated by the 226468_at probe set was 1.36, below the 
threshold for biological significance but the directional trend (i.e. 
increase) in BCA2 expression was still apparent. 
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3.2.2 BCA2 expression during oestradiol induced oncogenic 
transformation of human breast epithelial cells 
17β-oestradiol (E2) has been demonstrated to induce malignant 
transformation in human breast epithelial cells (Fernandez et al. 2005).   
The GSE5116 dataset is comprised of gene expression profiling of 
MCF-10F cells that were progressively transformed by E2 
supplementation in 3 independent experiments (Huang et al. 2007).  
MCF-10F cells are an ER negative, immortalised, non-tumourigenic 
breast epithelial cell line.  After 7-9 passages with bi-weekly E2 
supplementation cells were subjected to further testing and selection and 
were classified according to their malignant properties.  Cells that 
demonstrated high colony forming efficiency and spheroid (rather than 
duct) formation in collagen-matrix were categorised as transformed 
(trMCF).  trMCF cells that were then able to cross the membrane in 
Matrigel invasion assays were classified as invasive bsMCF cells.  
Clones derived from the bsMCF cells were classed as bcMCF cells.  The 
final classification of cell transformation was caMCF.  These were cells 
harvested from tumours that had formed after injection of bsMCF and 
bcMCF cells into severe combined immunedeficient (SCID) mice.  RNA 
was extracted from MCF-10F, trMCF, bcMCF and caMCF cells at three 
different passages and global gene expression was assessed by 
microarray.  Using the GSE5116 dataset generated by these studies, 
BCA2 expression changes during malignant transformation were 
examined and results are presented in Figure 3-6.     
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Figure 3-6: BCA2 mRNA expression in progressively transformed mammary 
epithelial cells.  Global gene expression in MCF-10F and derived cell lines was 
measured by microarray (Huang et al. 2007) and deposited online (GSE5116).  A) Log2 
mRNA expression analysis of controls confirmed detectable BCA2 expression with 
both probesets.  Mean log2 fold change in BCA2 expression was determined from data 
obtained with B) the 212742_at probe set and C) the 226468_at probe set. * Statistical 
significance p ≤ 0.05. Error bars represent 95% confidence intervals. D)  Absolute fold 
change in BCA2 expression in the transformed cell lines relative to MCF-10F control.  
Red values indicate fold induction ≥ 1.5 
BCA2 expression was confirmed by log2 analysis (Fig. 3-6 A).  BCA2 
fold-change measured with both probe sets exhibited a general trend of 
increasing BCA2 expression with increasing malignant transformation. 
The difference between groups measured using the 212742_at probe set 
(Fig. 3-6 B) was statistically significant by one-way ANOVA F(3, 8) = 
4.76, p = 0.0345.  Tukey post-hoc tests revealed that the increase in 
BCA2 expression was only statistically significant between the MCF-10F 
control cells and caMCF breast cancer cells (p < 0.05).   The increase 
was above the threshold for biological relevance as the caMCF cells were 
associated with a 1.62 fold induction in BCA2 expression (Fig. 3-6 D).  
Although BCA2 fold-change measured with the 226468_at probe set 
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appeared to follow a similar trend of increasing BCA2 expression with 
increasing transformation (Fig. 3-6 C), the difference between groups 
was not statistically significant by one-way ANOVA (F(3, 8) = 1.04, p = 
0.4257).  The lack of statistical significance may relate to the increased 
variability of the expression data obtained with the 226468_at probe set 
compared with 212742_at.   
3.2.3 Response of BCA2 expression to oestrogen deprivation and 
supplementation.   
BCA2 expression has been shown to be regulated by the oestrogen 
receptor and by E2 stimulation in breast cancer cells (Kona et al. 2012).   
To analyse BCA2s transcriptional responsiveness to E2, two datasets 
from oestrogen stimulation and/or deprivation were examined from the 
BioGPS portal.  Data from the GSE4668 set were obtained from 5 
independent experiments in which MCF7/BUS cells (clonal cells derived 
from the MCF-7 cell line) were stimulated with sub-saturating 
concentrations (0-100 pM) of E2 for 48 hr.  E2 induced changes in gene 
expression compared to unstimulated cells were evaluated by microarray 
(Coser et al. 2003).  Levels of BCA2 expression following different E2 
doses are presented in Figure 3-7 A.  Also included in the GSE4668 
dataset are the results of three independent microarray experiments in 
which cells were deprived of oestrogen for 0, 24, and 48 hr.  BCA2 
relative expression data for hormone starved MCF-7/BUS cells is shown 
in Figure 3-7 B.   
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Figure 3-7: BCA2 mRNA expression in oestrogen stimulated and oestrogen 
deprived MCF-7/BUS cells.  Global gene expression was determined by microarray 
(Coser et al. 2003) and deposited online (GSE4668).  A) Log2 mRNA expression 
analysis of controls confirmed detectable BCA2 expression in both experiments. Mean 
log2 fold change in BCA2 expression was calculated. B) BCA2 expression in MCF-
7/BUS cells treated with increasing dose of E2. C) BCA2 expression over an E2 
deprivation time course of 0 – 48 hours.  D and E) Associated absolute fold-changes in 
BCA2 expression are shown below resepective experiment graphs. 
BCA2 expression was confirmed by log2 analysis (Fig. 3-7 A) 
expression was also checked and confirmed for the lowest expression 
point (100 pM E2). The data in Figure 3-7 B and C indicate that BCA2 
mRNA levels are not significantly altered by either oestrogen stimulation 
or starvation. There was no significant difference between MCF-7/BUS 
cell groups stimulated by different oestrogen concentrations (Fig. 3-7 B).  
Statistical significance was evaluated by one-way ANOVA F(4, 20) = 
0.71 , p = 0.5946.  There was also no significant difference in the mRNA 
levels of BCA2 after 24 or 48 hours of hormone starvation (Fig. 3-7 C): 
one-way ANOVA F(2, 6) = 3.21 , p = 0.1127.  None of the absolute fold-
changes indicated a biologically significant alteration in BCA2 
expression (Fig. 3-7 D and E).   
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Data in Figure 3-8 were extracted from the GSE20361 data set.  The data 
in this set come from microarray analysis of a series of RNA extracts 
taken from long-term oestrogen deprived (LTED) MCF-7 cells over a 
180 day period (Aguilar et al. 2010).   
 
Figure 3-8: BCA2 mRNA expression in long term oestrogen deprived MCF-7 cells.  
Global gene expression was determined by microarray (Aguilar et al. 2003) and 
deposited online (GSE20361).  A) Log2 mRNA expression analysis of controls 
confirmed detectable BCA2 expression with both probesets. Mean log2 fold change in 
BCA2 expression over a time course of oestrogen deprivation in MCF-7 cells was 
calculated from the: B) the 212742_at probe set and C) the 226468_at probe set.  D) 
Associated absolute fold-changes in BCA2 expression are shown below resepecive 
experiment graphs. 
BCA2 expression was confirmed by log2 analysis of controls (Fig. 3-8 
A) and expression was also checked and confirmed for the lowest 
expression point (day 30). Statistical testing could not be performed on 
the LTED culture as only single experiment values were given.  The 
amount of BCA2 appeared to be decreasing up to 30 days but then 
returned to baseline levels between 30 and 90 days.  Overall there was 
relatively little variation in BCA2 expression detected by either the 
212742_at or 226468_at probe sets over the time course (Fig. 3-8).   
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3.2.4     BCA2 expression in tamoxifen and fulvestrant resistant 
breast cancer cell lines 
BCA2 regulation by E2 and the ER has been shown to be impaired in 
vitro by tamoxifen anti-oestrogen treatment (Kona et al. 2012).  It was 
therefore hypothesised that levels of the E3 ligase may be altered in cell 
lines with acquired anti-oestrogen therapeutic resistance.  To investigate 
this hypothesis, the GSE14986 dataset was interrogated.  This dataset 
contains microarray data for the MCF-7 cell line along with MCF-7 
derived cell lines with acquired resistance to anti-E2 (tamoxifen) and 
anti-ER (fulvestrant) therapies.  Details of the production and selection 
process of the drug resistant clonal cell lines are given in the source 
publication (Coser et al. 2009). Mean relative BCA2 levels in MCF-7, 
low cell density control, tamoxifen resistant (TAMR) and fulvestrant 
resistant (FASR) cells are presented and compared in Figure 3-9. 
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Figure 3-9: BCA2 mRNA expression in MCF-7 breast cancer cells and derived cell 
lines with acquired hormone therapy resistance.  Global gene expression profiles of 
MCF-7 and hormone refactory celll lines were obtained by microarray (Coser et al. 
2009) and deposited under the dataset identifier GSE14986.  A) Log2 mRNA 
expression analysis of controls confirmed detectable BCA2 expression with both 
probesets.  Mean log2 fold change in BCA2 expression was compared between the cell 
lines using (B) the 212742_at probe set data and C) the 226468_at set.  ** Statistical 
significance p ≤ 0.01.  Error bars represent 95% confidence intervals. D)  Absolute fold 
change in BCA2 expression in the resistant cell lines relative to MCF7 control. 
BCA2 expression was confirmed by log2 analysis of controls (Fig. 3-9 
A) and expression was also checked and confirmed for the lowest 
expression point (TAMR). Both tamoxifen and fulvestrant resistant cell 
lines demonstrated slight reductions in BCA2 expression levels, though 
the suppression appeared to be greater in the TAMR cells.  The 
differences between the MCF-7 cells and the resistant cell lines were 
statistically significant for the 212742_at probe set (Fig. 3-9 A): one-way 
ANOVA F(3, 11) = 29.01, p < 0.0001.  Tukey post-hoc testing indicated 
that the difference in BCA2 expression was statistically significant 
between the MCF-7 cells and the cell lines resistant to tamoxifen 
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(TAMR, p < 0.01) and to fulvestrant  (FASR, p < 0.01).  Despite the 
differences being statistically significant however, the fold suppression of 
1.44 in the TAMR and 1.23 in the FASR cells were below the 1.5 
threshold for biological relevance (Fig. 3-9 C).   
None of the differences between groups tested with the 226468_at probe 
set (Fig. 3-9 B) were statistically significant as determined by one-way 
ANOVA F(3, 11) = 1.52, p = 0.2640.   
3.2.5 BCA2 expression in EGFR overexpressing and derived 
gefitinib resistant cell lines 
There is literature to suggest that BCA2 has a functional role in EGFR 
endocytosis and downregulation (Mizuno et al. 2003; Sakane et al. 2007; 
Smith et al. 2013).  However, reports are conflicting in terms of the 
protein’s mechanism of action and the ultimate effects on receptor 
trafficking.  In light of BCA2’s putative endocytic function and the 
known association between EGFR inhibitor resistance and altered 
endocytosis (Hopper-Borge et al. 2009), changes in BCA2 expression 
were examined in a dataset of EGFR inhibitor (gefitinib) sensitive and 
resistant cell lines.  The GSE10696 dataset was generated from a study 
comparing the EGFR overexpressing A431 skin epithelial cell line with a 
model of acquired resistance (A431_GR).  The A431_GR cell line was 
developed from parental A431 cells by chronic gefitinib exposure and 
resistant cell selection. More methodological details are described in 
(Guix et al. 2008).  The results of the BCA2 expression analyses are 
presented in Figure 3-10. 
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Figure 3-10: BCA2 mRNA expression levels in parental (naturally EGFR 
overexpressing) cancer cells and a derived cell line model of gefitinib resistance.  
Global gene expression in A431 and acquired gefitinib resistant A431 cells was 
measured by microarray (Guix et al. 2008).  A) Log2 mRNA expression analysis of 
controls confirmed detectable BCA2 expression with both probesets. Mean log2 fold 
change BCA2 expression from B) the 212742_at probe set and C) the 226468_ was 
compared between the EGFR inhibitor sensitive (parental) cell line and the acquired 
resistance model.  *** Statistical significance p ≤ 0.001.  ** Statistical significance 
p ≤ 0.01. Error bars represent 95% confidence intervals.  D)  Absolute fold change in 
BCA2 expression in the gefitinib resistant cell lines relative to A431 control. Red values 
indicate fold induction ≥ 1.5 
BCA2 expression was confirmed by log2 analysis (Fig. 3-10A). For both 
BCA2 probe sets an elevation of BCA2 expression was evident in the 
gefitinib resistant cells compared with wild type A431 cells.  Student’s 
independent T-tests indicated the difference in expression between the 
two cell types was statistically significant for 242742_at probe set (Fig. 
3-10 B, p = 0.0062) and for the 226468_at (Fig. 3-10 C, p = 0.0001). 
The 242742_at probes indicated an absolute fold induction of 1.24 of 
BCA2 in the resistant compared with wild type cells, the 226468_at 
probes on the other hand showed a 1.62 fold increase (Fig. 3-10 D).   
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3.2.6 BCA2 expression following HER2 overexpression in 
mammary epithelial cells 
Despite strong evidence for a role in breast cancer and literature to 
indicate that BCA2 has a regulatory role in EGFR endocytosis, no 
published work to date has explored possible effects of BCA2 on HER2.  
Trafficking of HER2 is poorly characterised but the receptor is known to 
form heterodimers with other ErbB family receptors such as EGFR. 
Heterodimerisation with HER2 has been shown to modulate the 
downregulation and trafficking of EGFR (Hendriks et al. 2003).  HER2 
is an internalisation resistant receptor, a property that gives rise to 
sustained activity of downstream signalling pathways (Hommelgaard et 
al. 2004).  Identifying proteins that influence HER2 downregulation may 
therefore potentially provide therapeutic opportunities.   
BCA2 expression data was analysed from two separate microarray 
studies of HER2 overexpression in breast epithelial cells.   The 
GSE14987 dataset examines transcriptional effects of HER2 over-
expression and EGF stimulation in MCF10A cells from 3 independent 
experiments (Wolfer et al. 2010).  The GSE13274 microarray data is 
from human mammary epithelial cells (HMECs) and HMECs transfected 
with HER2 or a kinase inactivated HER2 mutant (Hartman et al. 2010).  
Five independent experiments were performed.   
Comparative BCA2 expression data from the GSE14987 and GSE13274 
datasets are presented in Figure 3-11.  
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Figure 3-11: BCA2 mRNA expression levels in HER2 overexpressing mammary 
epithelial cell lines.  BCA2 expression data, measured by two probe sets, 212742_at 
probe and 226468_at, were extracted from two datasets. A) Log2 mRNA expression 
analysis of controls confirmed detectable BCA2 expression with both probesets and in 
both datasets. B and C were taken from GSE14987 and depict mean log2 fold change in 
BCA2 expression in MCF-10A and HER2 transfected cells ± EGF stimulation (Wolfer 
et al. 2010). E and F) Mean log2 fold change BCA2 expression from the GSE13274 
dataset of HMEC cells transfected with GFP control, HER2 or a kinase-dead HER2 
mutant (Hartman et al. 2010). ** Statistical significance p ≤ 0.01.  * Statistical 
significance p ≤ 0.05. Error bars represent 95% confidence intervals. D and G) 
Associated absolute fold-changes in BCA2 expression are shown below respective 
experiment graphs. Green values indicate fold suppression ≥ 1.5 
BCA2 expression was confirmed by log2 analysis of controls (Fig. 3-11 
A and D) and expression was also checked and confirmed for the lowest 
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expression points for each experiment (HER2 + EGF in the GSE14987 
dataset and C and HER2 in the GSE13274 dataset). 
Both probe sets and both experiments displayed small but statistically 
significant downregulation of BCA2 following HER2 overexpression.  In 
the HER2 overexpressing MCF-10A cells BCA2 mRNA levels measured 
by 212742_at suggested a 1.30 fold downregulation (Fig. 3-11 D).  
Further reduction in BCA2 was apparent in the HER2 transfected cells 
stimulated with EGF: BCA2 expression was reduced by 1.52 fold relative 
to the GFP control transfected cells (Fig. 3-11 B).  One-way ANOVA of 
the 212742_at data (Fig. 3-11 B) indicated that the differences in BCA2 
expression between the groups were statistically significant F(2, 6) = 
28.37, p = 0.0009.  Tukey post-hoc testing returned significant 
differences between the GFP control and HER2 transfected cells, with 
and without EGF stimulation (p < 0.01).  Though the trend seen in Figure 
3-11 B was mirrored in the 226468_at probe set data (Fig. 3-11 C), the 
results of the one-way ANOVA indicated the differences between groups 
were not statistically significant F(2, 6) = 2.30 , p = 0.1813.    
BCA2 expression in the transfected HMECs was only modulated by 
overexpression of the kinase-competent HER2, suggesting the decrease 
in BCA2 may be linked with HER2 function.  The difference between the 
three transfected groups, as detected with probe set 212742_at (Fig. 3-11 
E), was statistically significant: one-way ANOVA F(2, 12) = 18.49, p = 
0.0002.  Tukey post-hoc tests revealed that the difference in expression 
was statistically significant between HER2 transfected HMECs and the 
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GFP transfected controls (p<0.01).  Post hoc tests also showed that 
BCA2 expression in the kinase dead HER2 overexpressing cells was not 
significantly different from the GFP control but was significantly 
different from the HER2 overexpressing cells (p<0.01).  Similar results 
were obtained from analysis of the 226468_at probe data (Fig. 3-11 F).  
One-way ANOVA showed a significant difference in expression across 
the transfected groups F(2, 12) = 6.51, p = 0.0122.  Post-hoc tests showed 
that the expression differences were statistically significant between the 
HER2 transfected HMECs and the GFP control and HER2-ki transfected 
groups (p < 0.05).    
The absolute fold changes in BCA2 expression in the HER2 transfected 
cells were above the threshold for biological relevance for both probe 
sets.  The 212742_at probe set indicated a 1.64 fold suppression of BCA2 
expression and the 226468_at probset showed 1.65 fold downregulation 
compared with the GFP control and any change in expression was lost 
with the kinase dead mutant (Fig. 3-11 G).  
3.2.7 BCA2 expression following overexpression of selected 
oncogenes in mammary epithelial cells 
BCA2 stability has previously been shown to be enhanced by Akt 
phosphorylation (Bacopulos et al. 2012).  Since BCA2 expression also 
appeared to be altered by HER2 overexpression (Fig. 3-11), the effect of 
overexpressing oncogenic signalling proteins on BCA2 levels was 
examined.  BCA2 expression data was extracted from the GSE3151 set 
containing samples of GFP control, c-Myc, Src and H-Ras transfected 
HMEC cells.  The samples were taken from 7-10 independent 
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experiments.  For more details regarding the transfection and RNA 
extraction methods see the source publication (Bild et al. 2005).  Fold-
changes in BCA2 between GFP transfected control and oncogene 
overexpressing cells are presented in Figure 3-12. 
 
Figure 3-12: BCA2 mRNA expression levels in breast epithelial cells transfected 
with GFP (control) and selected oncogenes.  Global gene expression in HMEC cells 
transfected with GFP, Myc, Src or H-Ras was measured by microarray (Bild et al. 
2005).  A) Log2 mRNA expression analysis of controls confirmed detectable BCA2 
expression with both probesets.  Mean relative expression data from B) the 212742_at 
probe set and C) the 226468_ was comparing BCA2 levels in the GFP control cells and 
the oncogene transfects.  ** Statistical significance p ≤ 0.01.  * Statistical significance 
p ≤ 0.05. Error bars represent 95% confidence intervals.  D)  Absolute fold change in 
BCA2 expression in the oncocgene overexpressing cells relative to control. Green 
values indicate fold suppression ≥ 1.5. 
BCA2 expression was confirmed by log2 analysis of controls (Fig. 3-12 
A) and expression was also checked and confirmed for the lowest 
expression points for each experiment (H-Ras). 
H-Ras was the only overexpressed oncogene to induce a statistically and 
(potentially) biologically significant change in BCA2 expression. The H-
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Ras induced reduction in BCA2 levels was observed with both probe 
sets.  One-way ANOVA of the 212742_at probe set data (Fig. 3-12 B) 
demonstrated the difference in fold-change between groups was 
significant: F(3, 33) = 16.72 , p < 0.0001.  Post-hoc tests showed that 
only the H-Ras transfected cells expressed significantly lower levels of 
BCA2 than the GFP transfected HMECs (p < 0.01).  The results with 
second probe set demonstrated a similar trend: the one-way ANOVA was 
significant F(3, 33) 7.08, p = 0.00084 and BCA2 levels in the H-Ras 
transfected cells were significantly reduced (Fig. 3-12 C, p < 0.01).   
The absolute fold suppression in BCA2 levels (Fig. 3-12 D) was above 
the biological significance threshold of ≥ 1.5 fold for both the 212742_at 
probe set (fold reduction = 1.69) and the 226468_at set (fold reduction = 
1.86). 
3.3 Discussion 
Presented in Figure 3-2, is evidence that high levels of BCA2 may be 
associated with improved relapse-free survival and novel findings of 
better outcome with higher BCA2 expression in ER-positive, grade 3, 
and LN-positive disease.  One previous study linked high levels of BCA2 
to increase in disease-free survival for regional recurrence and reduced 
lymph node metastasis (Burger et al. 2005).  The relationship between 
BCA2 and the positive prognostic indicators was not thought to be 
functional consequence of BCA2 expression.  BCA2’s association with 
reduced recurrence and metastasis was attributed to the high incidence of 
BCA2 upregulation in ER+ breast cancer, the most readily treatable form 
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of the disease.  The data created using the GOBO online tool (Fig. 3-2) 
suggest that BCA2 may in fact have an independent functional impact on 
breast cancer prognosis rather than simply bystander correlation with 
other positive prognostic indicators.  This can be inferred as the 
relationship between BCA2 expression and good prognosis is retained in 
the ER+ group following stratification.  
The association of BCA2 expression with increased relapse free survival 
in breast cancer has not been previously reported by subtype but is 
examined here.  A potential relationship between BCA2 and HER2 is 
indicated by a number of figures presented in this chapter.  The KM Plot 
data in Figure 3-1 E indicate that high levels of BCA2 adversely affect 
relapse free survival in the HER2-type and luminal B type breast cancers.  
This finding was not however fully replicated in the GOBO data (Fig. 3-2 
E).  Luminal B is a subtype of breast cancer that is itself comprised of 
different disease subtypes: some are positive for HER2 expression while 
others are highly proliferative (high Ki67).  The GOBO data may reflect 
the complexity of luminal B breast cancer as moderate BCA2 expression 
was associated with better prognosis but the highest and lowest BCA2 
expressing groups were associated with reduced RFS.  In the HER2 
subtype, high BCA2 expression was associated with improved prognosis 
but moderate and low BCA2 expressing disease were both associated 
with reduced RFS.  Overall, the survival data in Figures 3-1 and 3-2 
indicate a complex, context dependent, relationship between BCA2 and 
breast cancer outcome.   
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It is worth noting that the differences in survival impact of BCA2 
between the GOBO and KM Plotter biomarker tools, in particular with 
respects to luminal B and HER2+ disease, could be due to the difference 
in sizes of the data sets analysed. GOBO has just under half the number 
of patient samples as KM Plotter overall, but for the expression studies in 
the luminal B subtype over 1000 samples were used in the KM Plotter 
analysis compared with ~200 from the GOBO database (Figs. 3-1 E and 
3-2 E).  It may be that with more samples a statistically significant effect 
would be seen in the GOBO cohort.    
Elevated BCA2 expression and adverse impact on survival in HER2 
positive breast cancers may relate more to BCA2’s putative role in EGFR 
regulation than to a specific HER2 effect.  EGFR overexpression is most 
commonly seen in basal-type breast cancer (Nielsen et al. 2004) but 
elevated levels of EGFR and other RTKs are also seen in HER2+ and 
luminal B subtypes (see Table 1-1).  However, in general BCA2 is most 
prevalent in ER
+
 / luminal A cancers with no HER2 or EGFR suggesting 
generally an inverse association.  Interestingly the data from the 
microarray in Fig. 3-11 also suggest that BCA2 levels may be negatively 
regulated by HER2.  Figure 3-11 shows data from two separate studies 
that show a modest (~1.3-1.6 fold) decrease in BCA2 levels following 
HER2 overexpression.  The decrease is, however, statistically significant, 
possibly enhanced by EGF stimulation (Fig. 3-11 B) and appears to 
require HER2 kinase activity (Fig. 3-11 E).  Experiments to directly 
analyse BCA2 protein levels in response to HER2 overexpression would 
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need to be performed to verify the effect.  The data in Figure 3-11 
therefore suggest a potentially interesting investigative avenue.       
The reduction in BCA2 expression following HMEC transfection with H-
Ras (Fig. 3-12) is also in keeping with the data showing a decrease in 
BCA2 following HER2 overexpression and EGF stimulation (Fig. 3-11).  
This also offers a potential insight into how HER2 may exert influence 
on BCA2 levels: via enhanced Ras activity.  Specific experiments 
examining downstream transcription factor activity and BCA2 expression 
would need to be conducted to confirm these effects and to elucidate a 
mechanism. 
The small molecule drug gefitinib (IRESSA®) has exhibited activity 
against EGFR overexpressing breast cancers but therapeutic resistance 
remains a significant problem (Normanno et al. 2009).  The development 
of therapeutic resistance has been linked to alterations in the endocytic 
downregulation of EGFR (Hopper-Borge et al. 2009).  BCA2 has also 
been associated with changes in EGFR degradation (Mizuno et al. 2003; 
Smith et al. 2013; Wymant et al. 2014).  The data in Figure 3-10 showing 
modest but significant upregulation of BCA2 mRNA in gefitinib resistant 
epithelial cells is therefore potentially significant.  If the changes in 
BCA2 levels were also evident at the protein level siRNA depletion 
studies of BCA2 could then be carried out in the resistant cells.  These 
investigations might then reveal whether a) the resistance was, in part, a 
functional consequence of increased BCA2 levels and b) if drug 
sensitivity could be restored by inhibiting BCA2.  The data showing an 
increase in BCA2 in acquired gefitinib resistance provides further 
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evidence for EGFR/BCA2 inverse association.  The resistant cell model 
was produced by long-term gefitinib exposure and since the drug inhibits 
EGFR signalling this blockade may be the cause of the increase in BCA2 
levels, potentially via activation of alternative signalling pathways e.g. 
IGF-1R (van der Veeken et al. 2009).  The data add weight to the 
hypothesis suggested by data in Figures 3-11 and 12 that BCA2 levels 
are inversely proportional to ErbB expression/signalling. 
The relationship between BCA2 and the oestrogen receptor was 
examined in a few of the studies presented in this chapter.  In line with 
previously published findings, elevated BCA2 levels were seen in 
hormone receptor positive clinical breast cancer subtypes and cell lines 
(Figs. 3-3 B, 3-4 B and C).  Unexpectedly however, the data from the E2 
stimulation and starvation experiments shown in Figure 3-7 and 3-8 all 
demonstrated no significant change in BCA2 levels with either probe set 
or any of the experimental conditions.  This might suggest that while the 
BCA2 may be transcriptionally modulated by the oestrogen receptor 
(Kona et al. 2012), it may not be the only BCA2 regulating factor.  A 
number of other transcription factor binding sites have been predicted in 
the BCA2 promoter region, including NFκB, AP-1 and the progesterone 
receptor (Burger et al. 2010).  This may explain how BCA2 levels could 
be maintained in the absence of E2 and in ER- cell lines.   Another 
explanation for the null effect of E2 on BCA2 expression seen in Figure 
3-7 may be the suboptimal hormone dose used in the experiment.  
Experiments previously showing transcriptional regulation of BCA2 by 
the ER involved stimulation with 10 nM of E2 (Kona et al. 2012), 
 200 
 
considerably higher than the maximum dose of 100 pM used by Coser et 
al. (2003).  The data in Figure 3-7 may therefore reflect the fact that 
BCA2 is transcriptionally regulated by ER but is not highly oestrogen-
sensitive i.e. a larger stimulating E2 dose is required to induce an effect 
on BCA2 levels.   
The limited effects of long-term oestrogen withdrawal on BCA2 mRNA 
expression (Fig. 3-8) may reflect that fact that E2 withdrawal can 
promote the development of resistance.  Resistance developed at 90 days 
(Aguilar et al. 2010) and endocrine resistance is a phenomenon 
associated with upregulation of ER and increased RTK expression and 
signalling (Gee and Hutcheson 2005).  In light of other findings, increase 
in ER would increase BCA2 expression (Kona et al.  2012) while 
upregulation of RTKs and downstream signalling would reduce BCA2 
levels (Fig. 3-10 to 3-12) thus (potentially) producing a net null-effect on 
BCA2 expression. 
BCA2 appeared to be slightly downregulated in tamoxifen and 
fulvestrant resistant cell lines (Fig. 3-9).  However, the reductions of 
~1.22-1.44 fold (depending on the probe used) were below the 1.5 fold-
change cut off for biological significance/relevance.  Nonetheless this 
may still be worth exploring at the protein level given BCA2’s well 
documented relationship with the oestrogen receptor (Burger et al. 2005; 
Burger et al. 2010; Kona et al. 2012). Investigation of BCA2 in the 
TAMR and FASR models of acquired resistance may also be warranted 
since increased growth factor signalling has a role in the development of 
anti-oestrogen resistance (Gee et al. 2005; Nicholson et al. 2007) and 
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since BCA2 is shown here to be suppressed by HER2/EGFR expression 
and signalling (Figs. 3-10 to 3-12). 
The steady increase of BCA2 levels seen in increasingly transformed 
mammary epithelial cells (Fig. 3-6) could point to a role for BCA2 in 
breast cancer development.  However, the results could also be explained 
by the E2 supplementation used to induce the oncogenic transformation.  
The MCF-10F cells are ER
-
 but BCA2 induction has been previously 
demonstrated in an E2 stimulated, triple negative cell line (Kona et al. 
2012).  The mechanism of BCA2 upregulation in E2 treated, ER
-
 cells 
has not been identified.   
The data in Figure 3-5 potentially suggest a role for BCA2 in cancer 
epithelial to mesenchymal transition (EMT).  EMT is the process by 
which epithelial cells lose their terminally differentiated characteristics 
and acquire/revert to those of stem-like mesenchymal cells  (Mani et al. 
2008). EMT is a key feature of cancer cell invasion and metastasis 
(Chaffer and Weinberg 2011).  The spontaneous development of a 
CD44
+
/CD24
-
 subpopulation in MCF-10A cells in Figure 3-5 is shown to 
be accompanied by a statistically significant increase in BCA2 
expression.  BCA2 mRNA levels are increased ~1.36-1.66 fold in the 
stem-like cells which is a modest elevation but may suggest a role in 
EMT.  If the BCA2 induction was also present at the protein level, the 
findings would support published data showing that BCA2 
overexpression promotes cell migration while siRNA depletion reduces 
invasiveness (Burger et al. 2005; Amemiya et al. 2008).  
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The BCA2 gene locus is 1q21.1, on a chromosome arm associated with 
increased copy number in over half of all primary breast cancers (Bièche 
et al. 1995; Rennstam et al. 2003).  Six of the twenty genes co-expressed 
with BCA2 (Table 3-1) were also from the long arm of chromosome 1, 
more than would be expected by chance.  This could be an indication that 
BCA2 overexpression may in some instances relate to transcriptional 
upregulation in this chromosome region.  Alterations in chromosome 7 
are among the most frequent cytogenetic aberrations found in breast 
cancer  (Bièche et al. 1997).  The enriched co-expression of BCA2 with 
chromosome 7q genes may simply be an indirect consequence of their 
respective involvements in breast cancer or may be indicative of an 
underlying co-regulatory mechanism that is disrupted in mammary 
carciongenesis. 
The presence of 14-3-3θ/τ in the co-expressed gene list (Table 3-2) was 
notable since another 14-3-3 family member (14-3-3σ) has been shown 
to be a BCA2 effector (Bacopulos et al. 2012).  14-3-3 family members 
are conserved adaptor/scaffold proteins that recognise common motifs 
containing phospho- serine or threonine idues (Tzivion et al. 2001).  In 
vitro data previously demonstrated that 14-3-3σ was able to bind to and 
stabilise BCA2 and that the interaction was dependent upon Akt activity 
(Bacopulos et al. 2012).  The evidence of co-expression between BCA2 
and 14-3-3θ/τ may potentially indicate that BCA2 can also be regulated 
by a second 14-3-3 family member.  
The ontological investigation conducted into the co-expressed genes 
(Table 3-2) revealed an enrichment of genes relating to membrane 
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transport, particularly to and from the Golgi apparatus. BCAP29, 
RAB18, COPB1, TRAM1, ARL1, VIMP and VAMP7 all have roles 
associated with anterograde and retrograde Golgi trafficking. BCA2 has 
no documented association with the Golgi body but has been shown to 
associate with late endosomes and lysosomes via an interaction with 
Rab7 (Mizuno et al. 2003).  There are several examples of other late-
endolysosome associated proteins that have additional roles at the Golgi 
body.  VAMP7 for example, forms part of the SNARE complex that 
mediates fusion between late endocytic organelles and other membranes 
(Kent et al. 2012).  VAMP7 also functions at the trans-Golgi Network 
(TGN) where it coordinates trafficking of proteins to the cell surface.  
Through this role VAMP7 has been reported to inhibit endocytosis of 
EGFR (Danglot et al. 2010).  Depletion of VAMP7 was shown to 
prevent transport of the tetraspanin protein CD82 to the plasma 
membrane.  The loss of CD82 from the cell-surface enhanced recruitment 
of AP-2 and the CME machinery which in turn promoted EGFR 
endocytosis.   
A number of Rab proteins have dual endosomal-TGN functions.  One of 
principal functions of Rab7b is thought to be co-ordination of retrograde 
transport from endosomes to the Golgi (Progida et al. 2010).  Rab7a and 
Rab5 have also been shown to be involved in retrograde trafficking via 
endosomal recruitment of the retromer complex (Rojas et al. 2008).  The 
retromer complex facilitates the vesicular transport of transmembrane 
cargo such as the mannose 6-phosphate receptor (M6PR) from late 
endosomes to the TGN.  Return of the M6PR to the TGN is important for 
 204 
 
efficient delivery of acid hydrolases to the lysosomes and as such is 
critical to lysosome function (Arighi et al. 2004).   Rab7 directly binds 
the retromer complex recruiting it to late endosomes and lysosomes.  
Rab5 however, is thought to indirectly promote retromer membrane 
association via PI3K activation (Rojas et al. 2008).  Loss of Rab7 or 
Rab5 activity can inhibit retrograde transport from late endolysosomes to 
the TGN.  BCA2 has been shown to interact with Rab7 and is thought to 
have a role in co-ordinating the late stages of receptor endocytosis 
(Mizuno et al. 2003; Sakane et al. 2007; Smith et al. 2013).  It is 
therefore possible that through Rab7, and like a number of its co-
expressed genes, BCA2 may also have a function in, or an effect on, 
retrograde transport.  
BCA2 was originally discovered by subtractive hybridization cloning in 
breast cancer cell lines.  The protein has since been shown to increase 
breast cancer cell proliferation and invasiveness in vitro and its 
overexpression has been demonstrated in 56% of invasive mammary 
tumours (Burger et al. 2005).  BCA2 has been linked to two receptors of 
major significance in breast cancer: EGFR and the ER (Mizuno et al. 
2003; Burger et al. 2010).   
Through in silico studies in this chapter BCA2’s relationship with breast 
cancer outcome and clinical features has been extended beyond the 
existing literature in the context of breast cancer subtype with both 
positive and negative associations with outcome according to subtype.  
Results of preliminary investigations with publically available microarray 
data also indicate a potential role for altered BCA2 during breast cancer 
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development and in acquired therapeutic resistance to EGFR or ER 
blockade.  These studies additionally suggest a possible functional 
relationship between BCA2 and the HER2 and EGFR oncoproteins and 
their downstream signalling.  Co-expression and ontological studies have 
highlighted the possibility of a connection between BCA2 and protein 
transport from late-endosomes and lysosomes to the TGN.   
While these preliminary in silico findings do not provide robust evidence 
of BCA2-mediated effects, they offer some insight into potentially 
productive avenues for further research.  Analyses to study BCA2 
expression changes at the protein level and to explore the effects of 
localisation (e.g. nuclear versus cytoplasmic BCA2) would add weight 
and depth to the data presented in this chapter. 
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Chapter 4: Method Development for Endocytic Profiling 
and BCA2 Subcellular Localisation in Breast Cell Lines 
BCA2 is thought to be involved in endocytosis in a number of ways. 
Through its interaction with Rab7, BCA2 has been shown to alter EGFR 
endocytosis, though depending on the publication, the interaction has 
been shown to both accelerate and impair degradation of the receptor. 
Mizuno et al. (2003) demonstrated that overexpressed, His-tagged BCA2 
was recruited to late endosomes and lysosomes by EGFP-Rab7. 
Overexpression led to late endosomes and lysosomes becoming clustered 
in the perinuclear region and EGF degradation was shown to be 
inhibited.  The same group then studied the interaction between BCA2 
and Rab7 in a different cell line and examined rates of EGFR degradation 
rather than EGF.  Under these experimental conditions, it was reported 
BCA2 overexpression promoted receptor degradation (Sakane et al. 
2007).  A second group of researchers recently found that BCA2 
depletion inhibited EGFR (and c-Met) degradation by destabilisation of 
the ESCRT-II complex which decreased the number of MVBs (Smith et 
al. 2013).    
BCA2 has also been implicated in regulating HIV infection via 
alterations in endocytosis.  By interacting with tetherin, BCA2 was 
revealed to inhibit HIV particle release and promote lysosomal 
trafficking and degradation of the virions (Miyakawa et al. 2009). A 
more recent paper demonstrated tetherin-independent anti-viral BCA2 
activity.  Here BCA2 was able to interact directly with a critical viral 
protein, HIV-1 Gag, promoting its ubiquitination and lysosomal 
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degradation.  The resulting reduction in HIV-1 Gag protein levels 
prevented virion assembly and release (Nityanandam and Serra-Moreno 
2014).  
Details regarding BCA2’s subcellular localisation and its spatial and 
functional relationship with components of the endocytic pathway are 
limited.  Our initial studies therefore focused on trying to better describe 
the subcellular localisation of BCA2 and to explore differences in 
structure and/or subcellular localisation of endocytic organelles between 
cells thought to express different levels of the protein.     
4.1      The Subcellular Localisation of BCA2 
4.1.1 Endocytic profiling of breast cancer and non-tumourigenic 
breast cell lines 
The endocytic profiles of breast cancer and “near normal” breast cell 
lines were initially determined (Fig. 4-1 to 4-7).  Profiling entailed the 
labelling of key endocytic proteins/organelles with fluorescent probes 
and antibodies.  The aim was to identify any differences in the 
subcellular localisation of key endocytic components between cancerous 
and non-cancerous cell lines and between cell lines expressing different 
levels of BCA2.  MCF-7 and MDA-MB-231 breast cancer cells were 
examined as they have been previously described in literature as “BCA2 
overexpressing” and “BCA2 negative/low” respectively (Brahemi et al. 
2010).  MCF-10A cells were also selected for study as it was 
demonstrated in Figure 3-4 that at the mRNA level this cell line 
expressed lower BCA2 levels than the MDA-MB-231 cells.  
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MCF-10A cells are an immortalised, non-tumourigenic, mammary gland 
epithelial cell line and as such were used as a model of normal breast 
tissue.  MCF-7 cells are a model of luminal A breast cancer while MDA-
MB-231 cells represent basal or “triple negative” disease. 
Actin is a highly abundant cellular protein that exists in two forms: 
globular actin (G-actin) monomers and polymerised actin filaments 
(F-actin).  In addition to having critical roles in cell structure, adhesion 
and migration, actin is thought to have a diverse range of roles in 
endocytosis.  In mammalian cells for example there is data to support a 
role for actin in the internalisation of clathrin-coated  vesicles (Merrifield 
et al. 2002) and in vesicle scission (Merrifield et al. 2005).  There is also 
experimental evidence which implicates actin in intracellular vesicle 
transport: vesicles have been shown to shuttle along actin cables in 
budding yeast (Toshima et al. 2006).   
F-actin can be visualised in cells with the fluorescent phallotoxin: 
rhodamine-phalloidin.  Phalloidin binds to actin filaments with high 
affinity and the attached tetramethyl rhodamine (TMR) fluorophore emits 
an orange-red fluorescence that is proportional to the amount of actin 
present (Huang et al. 1992). 
Early endosomes are critical sorting compartments where multiple 
endocytic pathways intersect.  Endocytic cargo such as receptors and 
their ligands may be trafficked from the early endosome directly back to 
the cell surface, to recycling compartments for slower return to the cell 
surface or into lysosomes for degradation (See Fig. 1-6). Early Endosome 
Antigen 1 (EEA1) is a marker of early endosomes and is a protein that is 
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essential for the tethering and fusing of endocytic vesicles with the early 
endosome (Mu et al. 1995; Simonsen et al. 1998).  
PFA fixed MCF-7, MDA-MB-231 and MCF-10A cells were stained with 
rhodamine phalloidin and labelled for the early endosome marker EEA1 
by IF, the nuclei were counterstained with Hoechst (Fig. 4-1).   
 
Figure 4-1: Actin and early endosome localisation in breast and breast cancer cells. 
Rhodamine phalloidin (red) labelled actin filaments and (green) immunolabelled EEA1. 
Nuclei are stained blue with Hoechst. Arrowheads indicate cortical actin. Scale bars = 
25 µm. 
Figure 4-1 demonstrates considerable similarities between the MCF-7 
and MCF-10A cell lines with respect to the structure and distribution of 
F-actin and early endosomes. The MDA-MB-231 cells showed notable 
differences in their actin and EEA1 labelling. 
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Rhodamine phalloidin staining indicated that the vast majority of the 
F-actin in the MCF-10A and MCF-7 cell lines was contained in sub-
membranous pools of cortical actin (indicated by arrowheads in Fig. 4-1).  
In addition to their cortical actin however, MDA-MB-231 cells contained 
prominent actin stress fibres.  MDA-MB-231 cells also featured several 
pericentral actin foci that showed some colocalisation with EEA1.   
The early endosomes in MDA-MB-231 cells were concentrated in polar, 
perinuclear regions of the cell.  The ubiquitous early endosomes in the 
MCF-7 and in MCF-10A cells however were distributed evenly 
throughout the cells.  
Microtubules are formed from polymerised heterodimers of α and β 
tubulin called protofilaments that assemble into long, hollow fibres.  
Microtubules form part of the cellular cytoskeleton and are involved in 
cell structure, division and motility.  Microtubules also have a role in 
endocytosis: lysosomal clustering occurs around the centrosome/ 
microtubule organising centre (MTOC) and endolysosomal translocation 
has been shown to be microtubule dependent  (Matteoni and Kreis 1987). 
MCF-7, MDA-MB-231 and MCF10A cells were fixed and permeabilised 
with -20ºC methanol, a protocol which has been shown to optimally 
preserve microtubule structure (Wheatley and Wang 1998).  Fixed cells 
were fluorescently immunolabelled for β-tubulin and the nuclei were 
counterstained with Hoechst (Fig. 4-2).   
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Figure 4-2: Microtubule cytoskeleton structure in breast and breast cancer cells. 
Cells were immunolabelled against tubulin (green) and nuclei were counterstained blue 
with Hoechst. Scale bars = 25 µm. 
In all cell lines the microtubules formed a nest-like mesh of interwoven 
microfilaments (Fig.4-2).  The microtubules in the MDA-MB-231 cells 
however appeared less densely fibrous than the cytoskeleton in MCF-7 
and MCF-10A cells.  There were also many more mitotic cells evident in 
the MDA-MB-231 cell line.  
Late endosomes and lysosomes are respectively responsible for the 
sorting and proteolysis of endocytic cargo targeted for lysosomal 
degradation.  These endocytic structures are critically important for the 
cessation of signalling by activated and internalised cell surface 
receptors.   
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A number of antibodies against different late endolysosomal markers 
such as the mannose-6-phosphate receptor (M6PR) and beta-
Galactosidase-1 were tested with different fixation protocols before the 
optimal antibody and method were identified.  Ultimately a protocol for 
LAMP2 IF was successfully created (Fig. 4-3).  LAMP2 is a glycoprotein 
that is enriched on the limiting membranes of both late endosomes and 
lysosomes.  LAMP2 is believed to be an important receptor for the 
selective uptake and degradation of cargo by lysosomes (Cuervo and 
Dice 1996).  This protein is also thought to have roles in lysosome 
biogenesis and autophagy (Eskelinen et al. 2002).  
 
Figure 4-3: LAMP2 immunofluorescence with different fixation methods.  MCF-7 
cells were either fixed with PFA and permeabilised with Triton x-100 or were fixed and 
permeabilised with -20ºC methanol. IF for LAMP2 was then performed. Nuclei were 
counterstained blue with Hoechst. Scale bars = 25 µm. 
Late endolysosomal labelling with the anti-LAMP2 antibody was 
sucessfully achieved through the implementation of a -20ºC methanol 
fixation protocol (Fig. 4-3).  The development of an effective LAMP2 IF 
protocol enabled the method to be used in a small collaboration between 
Cardiff University laboratories (Webber et al. 2015).  This is discussed in 
more detail in Section 4.3. 
 218 
 
For the endocytic profiling, methanol fixed MCF-10A, MCF-7 and 
MDA-MB-231 cells were fluorescently immunolabelled for LAMP2 and 
the nuclei were counterstained with Hoechst (Fig. 4-4).   
 
Figure 4-4: Subcellular localisation of late endosomes and lysosomes in breast and 
breast cancer cells. Cells were fluorescently immunolabelled for LAMP2 (green).  
Nuclei were counterstained blue with Hoechst. Scale bars = 25 µm. 
The late endosomes and lysosomes in both MDA-MB-231 and MCF-7 
cells were localised in polar perinuclear clusters.  In the MCF-7 cells 
these endocytic organelles were more densely clustered than in the 
MDA-MB-231 cells where individual endolysosomal structures were 
more clearly visible.  The late endosomes and lysosomes in the 
MCF-10A cells were enriched in the perinuclear region but there were 
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also more small structures scattered throughout the cytoplasm in these 
cells.  
The trans-golgi-network (TGN) has links to endocytosis via a process 
known as retrograde transport.  Retrograde transport is the trafficking of 
proteins from the early endosome to the TGN via recycling endosomes 
(Bonifacino and Rojas 2006).  The process is coordinated by Rab11 and 
is a key pathway in promoting recycling of endocytic cargo and 
inhibiting its lysosomal degradation (Wilcke et al. 2000).  The TGN also 
has an integral role in lysosome function as this compartment organises 
the transport of newly synthesised enzymes such as cathepsin D to the 
lysosomes (Press et al. 1998; Rojas et al. 2008).  The TGN was also of 
interest due to the in silico research which demonstrated co-expression of 
Golgi-associated genes with BCA2 (Table 3-2). 
PFA fixed MCF-7, MDA-MB-231 and MCF10A cells were subjected to 
immunofluorescence for TGN46 and the nuclei were counterstained with 
Hoechst (Fig. 4-5).   
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Figure 4-5: Trans-Golgi network structure and localisation in breast and breast 
cancer cells. Immunofluorescence was performed for TGN46 (red) in the three cell 
lines.  Nuclei were counterstained blue with Hoechst. Scale bars = 25 µm. 
The TGN in the MDA-MB-231 cells was highly condensed and polarised 
in the perinuclear area.  In the MCF-10A cells the TGN was also 
perinuclear however the morphology indicated a more layered, tubular 
configuration.  The TGN in the MCF-7 cells appeared to be more 
fragmented and dispersed than in the other cell lines. 
The transferrin receptor (TfR) is carrier protein responsible for the 
cellular uptake of iron via transferrin (Tf).  Tf protein, complexed with 
Ferric (FE
3+
) iron, binds to TfRs on the cell surface.  The receptor-
transferrin complex is imported into cells via endocytosis following 
clustering of TfRs and clathrin pit formation at the membrane (Liu et al. 
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2010).  Upon reaching the early endosomes TfR-Tf complexes are either 
recycled directly back to the cell surface or they enter the network of 
recycling endosomes that form the recycling compartment of the cell. 
The recycling compartment is usually found in the perinuclear region of 
the cell and from here TfR-Tf complexes may either be recycled to the 
cell surface or be transported to the TGN (van Dam et al. 2002; Maxfield 
and McGraw 2004).  Tf and the TfR are often used as proxy markers for 
the recycling endocytic pathway, early endosomes and CME. 
MCF-7, MDA-MB-231 and MCF-10A cells were fixed with PFA, 
labelled for TfR by immunofluorescence, and nuclei were counterstained 
with Hoechst (Fig. 4-6). Secondary antibody only controls were also 
performed and were confirmed to be negative.   
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Figure 4-6: Subcellular localisation of the transferrin receptor in breast cancer 
cells. Immunofluorescence was performed for TfR (green) in the three cell lines.  Nuclei 
were counterstained blue with Hoechst. Scale bars = 25 µm. 
Figure 4-6 demonstrates that in MCF-7 cells the TfR was primarily 
localised on the cell membrane.  In MCF-10A and MDA-MB-231 cells 
however the majority of the TfR was contained in intracellular vesicles. 
In MDA-MB-231 cells there was perinuclear enrichment of the receptor 
suggesting that a large portion of the receptor pool was contained within 
the recycling compartment.   
EGFR is an important oncoprotein in many cancers and alterations in the 
endocytosis of this receptor have been linked to resistance to EGFR 
inhibitors (see 1.2.7).  Following internalisation and trafficking to the 
early endosome EGFR may be recycled or degraded depending on a 
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number of conditions.  Factors influencing receptor fate once 
endocytosed include: the stimulating ligand (Roepstorff et al. 2009), the 
dimerisation partner receptor i.e. homodimerisation versus 
heterodimerisation, in particular with HER2 (Hendriks et al. 2009), 
receptor ubiquitination (Longva et al. 2002) and the internalisation 
pathway i.e. CME or NCME (Sigismund et al. 2008).   
PFA fixed MCF-7, MDA-MB-231 and MCF10A cells labelled for EGFR 
by immunofluorescence and nuclei were counterstained with Hoechst 
(Fig. 4-7).  Secondary antibody only controls were also performed and 
were confirmed to be negative.   
 
Figure 4-7: EGFR expression and localisation in breast and breast cancer cells. 
Cells were immunolabelled against EGFR (green) and nuclei were counterstained blue 
with Hoechst. White arrowheads indicate membranous EGFR, red arrowheads indicate 
vesicular EGFR. Scale bars = 25 µm. 
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MDA-MB-231 cells highly overexpress EGFR and this was reflected in 
the bright, abundant labelling in this cell line:  EGFR was enriched on the 
plasma membrane (white arrowheads, Fig. 4-7) and in large intracellular 
vesicle structures (red arrowheads, Fig. 4-7).  MCF-7 cells express very 
low EGFR levels and so only faint labelling was detected and this was 
largely limited to the cell membrane.  MCF-10A cells express moderate 
levels of EGFR and since their growth medium contains EGF (which 
stimulates endocytosis), this may explain why majority of the EGFR in 
these cells was confined to intracellular vesicles.  
4.2 Effect of Disulfiram treatment on BCA2 and EGFR 
expression and Trafficking in MCF-7 cells  
Dilsulfiram (DSF) has previously been shown to reduce BCA2 levels in 
breast cancer cells and to inhibit BCA2’s ubiquitination activity  
(Brahemi et al. 2010; Burger and Westwell 2011).  Experiments were 
conducted to determine whether DSF treatment affected the subcellular 
localisation of early and late endocytic organelles. MCF-7 cells were 
incubated with 1 µM DSF for three hours before fixation and IF for 
EEA1 and LAMP2 were carried out.   
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Figure 4-8: Effect of disulfiram on the subcellular localisation of early endosomes 
and late endosolysosomes in MCF-7 cells.  Cells were treated with 1 µM DSF for 3 hr 
before IF was performed for EEA1or LAMP2.  Nuclei were labelled blue with Hoechst. 
Scale bars = 25 µm. 
Figure 4-8 demonstrates that while no effect on early endosomes was 
detected after DSF treatment, the drug caused relocalisation of late 
endolysosomes from perinuclear clusters to a more scattered distribution 
throughout the cytoplasm (Fig. 4-8).  This work has been extended as 
part of a co-running breast cancer PhD project in the laboratory.  The 
focus of the second project is the effect of DSF on cell viability and on 
endolysosomal zinc sequestration.  A publication from the DSF project is 
being prepared for submission and incorporates the data, from Figure 
4-8. 
4.3 Application of methods utilised in endocytic profiling to a 
separate collaborative project 
Some of the IF methods developed and practiced in the endocytic 
profiling work were shared with researchers from Velindre Cancer 
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Hospital, Cardiff.  Dr. Aled Clayton works in the field of exosomes in 
cancer immunology.  The information and advice shared allowed 
researchers in the Clayton laboratory to perform IF to examine changes 
in endocytic organelles following ribozyme silencing of Rab27.  Methods 
developed for endocytic profiling here were then utilised in collaboration 
with Dr. Clayton to identify specific changes in late endosome/ lysosome 
distribution associated with Rab27 depletion in Du145 prostate cancer 
cells (Fig. 4-9).  The data showed Rab27 depletion  led to a dramatic cell 
phenotype with clustered late endolysosomes and has been published in 
Oncogene (Webber et al. 2015). 
 
Figure 4-9: Effect of Rab27 depletion on the subcellular localisation of early and 
late endocytic organelles in Du145 cells.  Rab27 depletion with ribozymes was 
performed by Dr. J. Webber who then performed IF according to protocols developed 
by J. Wymant.  Confocal microscopy was performed by J. Wymant. Scale bars = 25µm 
4.4 Investigating the subcellular localisation of endogenous BCA2 
with immunofluorescence 
The subcellular localisation of BCA2 is somewhat poorly illustrated in 
the literature and little detail beyond “cytoplasmic” and “nuclear” has 
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been described.  In order to determine and clearly image the endogenous 
distribution of BCA2, a variety of different IF techniques were tested.  
The methods developed were subjected to validation checks so that the 
optimum protocol for BCA2 IF could be identified.   
Alcohol and ketone fixative/permeabilisers were assessed for BCA2 IF 
compatibility alongside the more commonly used PFA and Triton X-100 
reagents.  PFA is a cross-linking fixative, so called because it generates 
covalent bonds between cellular proteins that fix them in place.  Alcohols 
and ketones are precipitating/dehydrating fixatives that work by 
disrupting the hydrophobic bonds of cellular proteins causing 
denaturation of their tertiary structure (Jamur and Oliver 2010a).   
Precipitating fixatives can be particularly useful for IF with antibodies 
directed against the internal regions of proteins.  Cross-linking fixatives 
can sometimes cause proteins to become rigidly fixed in a conformation 
that does not allow antibodies to reach their target epitopes.  In these 
instances precipitating fixatives can be utilised in order to expose the 
antibody binding sites (Schnell et al. 2012). 
A commercially available but un-validated goat anti-BCA2 antibody as a 
starting point, various fixative and permeabilisation agents were tested 
(Fig. 4-10).  MCF-7 cells were used as they have been described as high 
BCA2 expressing in the literature as a high BCA2 expressing cell line 
(Brahemi et al. 2010) and this is supported by mRNA data in Figure 3-4.  
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Figure 4-10: Comparison of fixative/permeabilisation agents for BCA2 IF with 
goat~BCA2 antibody (Sigma).  MCF-7 cells were fixed and permeabilised with a 
range of techniques as indicated above.  IF was performed for BCA2 using goat~BCA2. 
(1:200). Blue arrowheads indicate regions BCA2 enrichment. Scale bars = 25 µm. 
PFA and Triton X-100 gave predominantly diffuse cytoplasmic labelling 
though some very faint nuclear fluorescence was also detected (Fig. 4-
10). In some cells (~1%) there were regions of apparent BCA2 
enrichment (indicated by blue arrowheads in Fig. 4-10).  Vesicular-like 
structures of varying size and staining intensity were evident in these 
cells but they were not representative of the typical staining pattern.  The 
dehydrating and protein precipitating fixatives such as acetone and 
methanol appeared to indicate that BCA2 was enriched in the perinuclear 
region.  With these fixatives a reticular staining pattern was evident that 
was indicative of localisation on filamentous structures.  At the time of 
performing the experiments (2012) this localisation was in-keeping with 
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the BCA2 IF staining pattern depicted in A431 cells in the Human 
Protein Atlas (HPA; http://www.proteinatlas.org/).  However, the 
subcellular localisation images have since been removed from the HPA 
website. 
The primary antibody being used was against an internal region of the 
protein which indicated the potential suitability of a precipitating 
fixative.  In support of this, acetone and methanol fixation both produced 
similar patterns of fluorescence which suggested that the labelling 
produced by these methods was a reflection of true BCA2 localisation.  
In light of this, and the fact that acetone protocol produced the clearest 
labelling, the acetone fixation method was investigated further.   
Anti-BCA2 labelling in acetone-fixed MCF-7 and MDA-MB-231 cells 
was performed along with secondary controls (Fig. 4-11).  Since the two 
cell lines had been described in the literature as high and low BCA2 
expressers (Brahemi et al. 2010) their combined use was intended to 
determine whether differential BCA2 expression could be demonstrated 
with IF.   
The reticular labelling in the BCA2 overexpressing MCF-7 cells and 
filamentous staining in the MDA-MB-231 cells suggested BCA2 was 
possibly localising to the mitochondria.  However, although the data was 
initially promising, there did not appear to be a difference in staining 
intensity between the two cell lines which was a possible indication that 
the staining might not be specific for BCA2.  Also disquieting were the 
secondary only controls which showed similar (but fainter) staining 
patterns (right hand column, Fig 4-11).    
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Further investigation revealed that FBS and BSA may not be suitable for 
use in blocking solutions with anti-goat secondaries due to contamination 
from bovine IgG.  Cross-reactivity between goat secondary antibodies 
and bovine IgG can lead to the formation of immune complexes which 
can increase background staining and potentially produce false positive 
results (Buchwalow et al. 2011).  Rabbit serum was tested in place of 
FBS and this reduced but did not eradicate the background staining 
(bottom row of each cell line montage in Fig. 4-11). 
 
Figure 4-11: Comparing different serums in blocking solutions and antibody 
diluents for BCA2 immunolabelling.  MCF-7 and MDA-MB-231 cells were fixed 
with 80% acetone and IF was performed for BCA2 using the goat anti-BCA2 antibody 
(1:200).  Either 2% FBS + 2% BSA or 5% rabbit serum were used as blocking and 
diluents solutions as indicated.  Negative controls were performed by omitting the 
primary antibody (third column of images). Scale bars = 15 µm. 
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The lack of BCA2 staining specificity was ultimately confirmed by using 
a different fluorescent anti-goat secondary antibody. With a different 
secondary antibody, the BCA2 labelling was fairly diffuse throughout the 
cell and there was little/no sign of the structures that were visualised 
when using the original anti-goat antibody (Fig.4-12). 
 
Figure 4-12: Comparing fluorescent anti-goat secondary antibodies for BCA2 
labelling in acetone fixed MCF-7 cells. Nuclei are counterstained blue with Hoechst.  
Scale bars = 25 µm. 
A second anti-BCA2 antibody raised in rabbit was subsequently 
investigated in MCF-7 and MDA-MB-231 cells.  Experiments were 
initially performed solely with the PFA/Triton X-100 protocol.   
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Figure 4-13: Testing the suitability of a rabbit anti-BCA2 primary antibody for IF.  
PFA fixed breast cancer cells were subjected to IF for BCA2 using the rabbit anti-
BCA2 antibody diluted 1:200 A) Localisation in MCF-7 and MDA-MB-231 cells.  B) 
Secondary only controls. Scale bars = 15 µm. 
The staining produced using the rabbit anti-BCA2 antibody indicated 
cytoplasmic and nuclear BCA2 localisation with enrichment in the 
nucleoli (Fig. 4-13 A).  The nuclear and cytoplasmic labelling was in line 
with previous literature (Burger et al. 2005).   The prominent nucleolar 
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staining had also been demonstrated in a BCA2 publication (Kona et al. 
2012) and matched some localisation data shown on the HPA.   
However, nucleoli are a common site for off-target immunofluorescence 
labelling.  Non-specific nucleolar labelling has been reported for various 
primary antibodies including #2626 (Cell Signalling), ab78517 and 
ab27171 (Abcam).  A study by Sangale et al. (2011) described the 
limitations of a number of optimised anti-PTEN antibodies from Abcam, 
Millipore and Novus that all produced off-target, nucleolar fluorescence.  
Encouragingly the secondary-antibody-only controls in Figure 4-13 B 
were all negative, though further tests were necessary to validate the 
labelling.  For this a plasmid encoding an epitope tagged version of 
BCA2 was acquired and tested.  Overexpression of epitope tagged BCA2 
would enable dual detection by IF against the tag and the protein.  This 
would demonstrate whether an antibody could detect different cellular 
levels of the protein and would determine its suitability for IF. 
4.5 Subcellular localisation of HA-BCA2  
In view of the problems experienced in investigating the subcellular 
localisation of endogenous BCA2, transient overexpression was 
identified as an alternative means of characterising BCA2 localisation.   
4.5.1  pCMV-HA-BCA2 vector  
The pCMV-HA plasmid containing a BCA2 insert was a generous gift 
from Naoki Yamamoto at the National Institute of Infectious Diseases in 
Tokyo (Miyakawa et al. 2009).  For the plasmid map see Appendix D.  
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The plasmid was extracted from filter paper, amplified and purified as 
described in Chapter 2 (Section 2-10) for use in transient transfection 
experiments. 
4.5.2 Subcellular localisation of HA-BCA2 in breast cancer cells  
HA-BCA2 was transfected into MCF-7 cells which, after 24 hrs of 
transfection, were then PFA fixed and immunolabelled for the human 
influenza haemagglutinin (HA) protein tag. Using an anti-HA primary 
antibody from Cell Signalling there initially appeared to be evidence of 
intermittent cell membrane labelling, with particular enrichment at focal 
adhesions. There also seemed to be filamentous labelling within the cells. 
Such localisation of BCA2 had not been previously described in 
literature and upon examination of the untransfected controls the reason 
for this became clear. The untransfected controls displayed the same 
localisation pattern as the supposedly HA-BCA2 transfected cells (Fig. 
4-14). The labelling artefacts related to a problem with the primary rather 
than secondary antibody as two different secondary antibodies were tried 
without success.  The antibody (#2362) has been discontinued by Cell 
Signalling.  
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Figure 4-14: Labelling artefacts for IF with the Cell Signalling anti-HA primary 
antibody in untransfected controls.  Nuclei were counterstained with Hoechst.. Scale 
bars = 10 µm 
Having experienced problems with high background staining with the 
Cell Signalling antibody, a different anti-HA was tried from Sigma. Even 
at relatively high dilutions the background staining in untransfected cells, 
particularly in the MDA-MB-231 cells, was very high (Fig. 4-15 A). 
Under specific microscope settings it was possible to identify high HA-
BCA2 expressing cells from the transfected MCF-7 population (Fig. 4-15 
B). However, the high background staining made it very difficult 
distinguish the transfected but low/moderate BCA2 overexpressing cells. 
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Figure 4-15: Anti-HA labelling with the Sigma primary antibody. A) In 
untransfected MCF-7 and MDA-MB-231 cells, even at high dilutions, the anti –HA 
background staining was unworkably high, particularly in the MDA-MB-231 cells. B) 
In transfected MCF-7 cells, using an highly diluted primary antibody (1:5000) and 
altering the microscope settings, it was possible to distinguish transfected cells that were 
very highly expressing BCA2. Nuclei were counterstained blue with Hoechst. Scale 
bars = 10 µm 
A third anti-HA primary antibody was tested and the mouse anti-HA 
from Covance proved to be by far the most effective. Figure 4-16 shows 
that there was no background staining in untransfected cells and Figure 
 237 
 
4-17 demonstrates how clearly the transfected, HA-BCA2 expressing 
cells can be identified. 
 
Figure 4-16:  Negative (untransfected) controls for mouse anti-HA (Covance).  Cells 
were fixed in PFA and IF was performed with the mouse anti-HA antibody from 
Covance (1:1000). Nuclei were counterstained blue with Hoechst.  Scale bars = 10 µm 
Fugene 6 and Lipofectamine 2000 are widely used transfection reagents: 
~33,400 and ~62,500 literature references respectively.  The two reagents 
were tested and compared in order to determine the optimum method for 
HA-BCA2 transfection and expression. Figure 4-17 demonstrates that 
MCF-7 cells had much higher HA-BCA2 transfection efficiency than 
MDA-MB-231 cells, irrespective of the transfection reagent used.  
Fugene 6 provided higher transfection efficiency in MCF-7 cells (~60%) 
compared with Lipofectamine 2000 (~40%).   In MDA-MB-231 cells the 
transfection efficiency with Lipofectamine 2000 appeared to be slightly 
higher than with Fugene 6 but both efficiencies were very low (< 5%). 
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Figure 4-17: Optimising HA-BCA2 transfection and Covance anti-HA 
immunolabelling in MCF-7 and MDA-MB-231 cells. Cells were transfected with HA-
BCA2 using either Fugene 6 or Lipofectamine 2000. After 24 hours cells were PFA 
fixed and immunolabelled for HA (Mouse ~HA, Covance, 1:1000).  Nuclei were 
counterstained blue with Hoechst. Scale bars = 25 µm        
HA-BCA2 transfected MCF-7 cells display a number of different, 
seemingly expression-dependent phenotypes (Fig. 4-18, top row). High 
expressers tended to display ubiquitous small, uniform vesicles which 
were closely packed throughout the cytoplasm or they contained large, 
dense perinuclear vesicles and/or large cytoplasmic structures.   The 
moderate expressing cells tended to have diffuse cytoplasmic staining 
with some, more sparsely distributed vesicles. Low HA-BCA2 
expressing cells had faint, diffuse cytoplasmic labelling. There was some 
evidence of nuclear labelling in the transfected cells but it was more 
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rarely seen than the cytoplasmic structures (~5% of transfected cells).  
There was no evidence of nucleolar labelling.   
HA-BCA2 overexpressing MDA-MB-231 cells (Fig. 4-18, bottom row) 
showed signs of poor viability: most of the transfected cells appeared to 
be rounded or demonstrated cytoplasmic vacuolation.  Owing to the poor 
transfection efficiency and viability of the MDA-MB-231 cells it was 
decided that further experimentation would be performed using the 
MCF-7 cell line. 
 
Figure 4-18: Subcellular localisation of HA-BCA2 in MCF-7 and MDA-MB-231 
cells determined by immunofluorescence.  Cells were transfected with HA-BCA2, 
PFA fixed and immunolabelled for HA (Mouse~HA, Covance, 1:1000). Nuclei were 
counterstained blue with Hoechst. Blue arrowheads indicate vacuoles. Scale bars = 25 
µm 
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In order to verify that the subcellular localisation related to HA-tagged 
BCA2 (i.e. that the protein was expressed and the HA-tag was 
uncleaved): double-immunolabelling was performed for BCA2 and HA. 
The goat anti-BCA2 primary antibody was used at a relatively high 
dilution (1:5000) alongside the Covance anti-HA antibody.  
Colocalisation analysis confirmed that IF staining was specific to BCA2 
and that the HA tag remained attached in vitro (Fig. 4-19 A). Single 
labelling was also performed for both BCA2 and HA (Fig. 4-19 B). The 
staining patterns seen in single-labelled cells were very similar, further 
indicating the structures/localisation seen were not artefacts of the 
double-labelling process.  These findings also helped to validate the goat 
anti-BCA2 antibody for use in IF. 
 
Figure 4-19: Anti-HA and Anti-BCA2 IF in HA-BCA2 Transfected MCF-7 cells.  
A) Sequential double IF was performed in HA-BCA2 transfected cells using the goat 
anti-BCA2 antibody and mouse anti-HA. Nuclei were counterstained with Hoechst. B) 
Separate anti-HA and anti-BCA2 IF was performed. Scale bars = 25 µm 
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The localisation patterns produced by high levels of HA-BCA2 
overexpression were similar to those observed in a small subpopulation 
of MCF-7 cells when endogenous levels of BCA2 were examined (PFA 
fixation, Fig. 4-10).  Comparative IF images of HA-BCA2 transfected 
MCF-7 cells and the subpopulation of MCF-7 cells containing vesicle-
like cytoplasmic structures are presented in Figure 4-20.   
 
Figure 4-20: Comparison of HA-BCA2 localisation with endogenous BCA2 
localisation in a subpopulation of MCF-7 cells. Cells were either transfected with 
HA-BCA2 and IF was performed for HA (PFA fixation, Mouse~HA, Covance, 1:200, 
left column) or cells were untransfected  and IF was performed for BCA2 (PFA fixation, 
goat~BCA2, 1:200, right column). Scale bars = 25 µm 
Figure 4-20 demonstrates the similarity in localisation between 
overexpressed HA-BCA2 in MCF-7 cells and endogenous BCA2 found 
in a small subpopulation of the (untransfected) cell line.   The results 
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suggested that although expression levels were much higher in the 
transiently transfected cells, the cellular distribution of HA-BCA2 
approximated a localisation pattern found endogenously in a small cell 
subpopulation of the MCF-7 cells. 
A series of double-immunolabelling (colocalisation) experiments were 
performed in order to identify which cellular compartments could be said 
to house transfected BCA2.  The experiments had a dual purpose as they 
also enabled exploration of possible HA-BCA2 induced effects on 
endocytic and metabolic organelles. Secondary antibody only controls 
were also performed and were all confirmed to be negative.   
Figure 4-21 A shows that overexpressed HA-BCA2 neither altered nor 
co-localised with early endosomes in transfected MCF-7 cells that were 
fixed and immunolabelled for HA and EEA1. 
Fluorescent transferrin probes such as transferrin Alexa-488 (Tf-488) can 
be used to visualise the recycling endocytic pathway in addition to early 
endosomes (see 1.2.8.1).  HA-BCA2 overexpressing MCF-7 cells were 
serum-starved for one hour before being incubated with transferrin-488 
for 20 min, fixed with PFA and immunofluorescence for HA was 
performed against direct visualisation of Tf.  The results in Figure 4-21 B 
demonstrate that the localisation of Tf-488, and by proxy, the recycling 
pathway was minimally effected by BCA2 overexpression and BCA2 did 
not colocalise with Tf-488 suggesting that BCA2 does not localise to 
recycling compartments. 
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HA-BCA2 transfected MCF-7 cells immunolabelled for HA and stained 
with rhodmaine phalloidin indicated that BCA2 overexpression did not 
induce alterations in the actin cytoskeleton (Fig. 4-21 C). There was also 
no indication of colocalisation between the F-actin and HA-BCA2. 
HA-BCA2 did not co-localise with or appear to alter the TGN in 
transfected MCF-7 cells that were fixed and immunolabelled for TGN46 
and HA (Figure 4-21 D). 
Mitochondria have numerous cellular functions including generation of 
ATP and regulation of apoptosis.  Alterations in mitochondrial structure 
can therefore indicate changes in cell proliferation and viability.  
MitoTracker Red is a probe that accumulates and fluoresces in the 
mitochondria of viable cells and can be fixed with paraformaldehyde 
and/or acetone.  Because the accumulation of MitoTracker Red depends 
on the membrane potential of the mitochondria, changes in mitochondrial 
activity can be visualised in addition to changes in structure.  HA-BCA2 
overexpressing MCF-7 cells were incubated for 30 min with MitoTracker 
Red, fixed in 80% acetone and immunofluorescently labelled for HA.  
The results in Figure 4-21 E demonstrate that overexpressed BCA2 does 
not co-localise with or alter the structure and activity of the mitochondria 
in MCF-7 cells. 
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Figure 4-21: In MCF-7 cells HA-BCA2 does not co-localise with, or affect the 
distribution of A) EEA1, B) transferrin, C) actin D) the TGN or E) the 
mitochondria.  Nuclei were counterstained blue with Hoechst. Scale bar = 25 µm 
Both the primary antibody used for labelling late endosome/lysosomes 
(anti-LAMP2) and the anti-HA primary were produced in mice.  For the 
purposes of double-labelling a new antibody (from a non-mouse host 
species) was therefore purchased against LAMP1.  Like LAMP2, 
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LAMP1 is an integral lysosomal membrane protein that regulates 
lysosome biogenesis and maintenance of structural integrity (Eskelinen 
2006).   
An immunolabelling procedure for LAMP1 needed to be designed and 
optimised before colocalisation analysis with HA-BCA2 could be 
performed.  The fully optimised protocol involved PFA fixation with 
0.4% saponin permeabilisation.  Primary antibody incubation was 
performed overnight at 4
o
C in a humidified chamber.   These conditions 
produced clear immunolabelling with the rabbit anti-LAMP1 antibody 
(Fig. 4-22). The polar, perinuclear clustering of the LAMP1 positive 
vesicles is typical of terminal endocytic organelles (Korolchuk et al. 
2011). 
 
Figure 4-22:  Optimised LAMP1 IF in MCF-7 cells. Cells were PFA fixed and IF 
was performed for LAMP1 (1:100). Nuclei were counterstained with Hoechst. 
Arrowheads indicate perinuclear clusters. Scale bar = 25 µm.  
In spite of the of literature that suggests that BCA2 interacts with, and is 
recruited to the late endosomes by Rab7, double-IF with anti-LAMP1 
and anti-HA gave no indication of co-localisation (Fig. 4-23). Also not 
apparent were any clear and significant effects of HA-BCA2 
overexpression on late endosome/lysosome distribution. In some 
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transfected cells it seemed that there may have been slightly fewer and 
more sparsely arranged late endocytic organelles but this was by no 
means a universal trend (Fig. 4-23, bottom row). 
 
Figure 4-23: LAMP1 labelling in HA-BCA2 transfected MCF-7 Cells. Cells were 
PFA fixed and sequential IF was performed for LAMP1 (1:100) and HA (Mouse ~HA, 
Covance, 1:1000). Nuclei were counterstained blue with Hoechst. . Scale bar = 25 µm. 
The morphology and distribution of some of the larger HA-BCA2 
structures resembled that of autophagosomes (Jäger et al. 2004). 
Autophagosomes are large membrane bound organelles containing cell 
componenents that need to be broken down and recycled into new, 
essential proteins/structures. Autophagosomes fuse with lysosomes in 
order utilise their acid hydrolase enzymes to degrade cellular proteins. 
Autophagosomes often form when a cell is metabolically stressed as the 
recycling of cell components supports survival. Owing to the 
morphological similarity between autophagosomes and HA-BCA2 
structures, possible co-localisation was investigated by dual-IF with the 
autophagosome marker LC3B. An assay for autophagy needed to be 
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developed first in order to validate the anti-LC3B antibody. To achieve 
this, cells were treated for 6 hrs with 100mM of chloroquine as a positive 
control for autophagy (Fig. 4-24).   Chloroquine has been shown to 
inhibit lysosome acidification and prevent autophagosome-lysosome 
fusion, leading to accumulation of LC3B in autophagic vacuoles 
(Mizushima et al. 2010). 
 
Figure 4-24: LC3B labelling in MCF-7 cells with and without chloroquine 
treatment to induce autophagy.  Cells were treated for 6 hr ± 100 mM chloroquine 
then PFA fixed and IF for LC3B was performed (Rabbit~LC3B, 1:100). Nuclei were 
counterstained blue with Hoechst. Scale bars = 15 µm. 
The results in Figure 4-24 demonstrate that the anti-LC3B antibody could 
be successfully employed in the detection of autophagy.  Small 
cytoplasmic puncta were observed in the untreated control cells 
indicating that some autophagomes were present under normal cellular 
conditions.  Chloroquine induced formation of large LC3B positive 
structures in the cytoplasm that were indicative of autophagic vacuoles.   
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The successful establishment of this assay allowed HA-BCA2 to be 
evaluated for possible localisation to autophagosomes and for a role in 
induction/regulation of autophagy.  Double-labelling for LC3B then HA-
BCA2 was performed. 
 
Figure 4-25: LC3B labelling in MCF-7 cells transfected with HA-BCA2.  HA-
BCA2 transfected cells were fixed with PFA and sequential IF was performed for LC3B 
(Rabbit~LC3B, 1:100) and HA (Mouse~HA, Covance, 1:1000) Scale bars = 25 µm. 
The results in Figure 4-25 show that HA-BCA2 did not induce autophagy 
as no large accumulations of LC3B were detected in the transfected cells.  
HA-BCA2 also did not appear to suppress the normal autophagic process 
as transfected and untransfected cells contained similar numbers of the 
smaller L3CB positive puncta.  There was no evidence of HA-BCA2 and 
LC3B colocalisation. 
In order to further explore the documented interaction between HA-
BCA2 and Rab7 (Mizuno et al. 2003), HA-BCA2 was co-transfected into 
MCF-7 cells with fluorescently tagged (EGFP) Rab7. As a control the 
MCF-7 cells were also transfected with HA-BCA2 and EGFP-Rab21.  
Rab21 is a protein that localises to early endosomes and has been shown 
to affect endocytosis of EGFR and TfR (Simpson et al. 2004). The 
results of the co-transfections were somewhat inconclusive, although co-
localisation between HA-BCA2 and Rab7 was demonstrated; it was by 
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no means in all of the doubly-transfected cells (Fig. 4-26 A). 
Surprisingly, co-localisation between HA-BCA2 and Rab21 was also 
seen in a small number of cells (Fig. 4-26 B). It is unclear whether this is 
biologically significant, as interaction between BCA2 and Rab21 and 
early endosome localisation have not been previously reported. 
 
Figure 4-26: HA-BCA2 and EGFP-rab7 and 21 co-transfected MCF-7 cells. Cells 
were PFA fixed, and immunolabelled for HA (Mouse~HA, Covance, 1:1000). Nuclei 
were counterstained with Hoechst. Blue arrowheads indicate co-localisation. Scale bars 
= 25 µm 
4.5.3 EGFP-tagged BCA2 
In order to allow live-cell imaging of BCA2 and to rule out possible 
effects of the HA tag, BCA2 was subcloned into two EGFP vectors (C1 
and N1) that enable in vitro expression of N and C terminally tagged 
proteins respectively.  For the vector maps see Appendix E. 
Following subcloning and amplification and purification, the EGFP-
tagged BCA2 constructs (along with empty EGFP control vectors) were 
transfected into MCF-7 cells.  Transfection was performed using 
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Lipofectamine 2000 transfection method that was optimised for the 
EGFP control vectors.  Unfortunately the localisation of the EGFP-
tagged BCA2 was indistinguishable from that of EGFP alone.  EGFP, 
BCA2-EGFP and EGFP-BCA2 all saturated the cytoplasm and the 
nucleus of MCF-7 cells (Fig. 4-27). 
 
Figure 4-27: EGFP-BCA2 and BCA2-EGFP localisation in MCF-7 breast cancer 
cells compared with EGFP controls. Scale bars = 25 µm. 
The transfection efficiency of the EGFP-tagged BCA2 clones was also 
observed to be markedly lower than the efficiency of the EGFP vectors 
alone (Fig. 4-28).  The transfection efficiency was ~20% for the EGFP-
tagged BCA2 clones and ~50% for the EGFP vector alone. 
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Figure 4-28: Comparison of transfection efficiency between EGFP-BCA2 and 
EGFP-C1 in MCF-7 cells. Scale bars = 15 µm. 
 
Since EGFP fusion proteins can cause the protein of interest to misfold 
and also because BCA2 is an E3 ligase with known autoubiquitination 
activity, we thought it possible that the apparent low transfection 
efficiency was in fact a case of rapid protein degradation.  To investigate 
this possibility, 10 µM of the proteasome inhibitor MG132 was used to 
treat the transfected cells for 6 hrs.  The cells were then fixed, their nuclei 
stained with Hoechst and after mounting onto glass slides were analysed 
by fluorescence microscopy (Fig. 4-29)  The percentage of transfected 
cells in the treated and untreated conditions from two independent 
experiments was determined by cell counting in three fields of view, 
selected at random (but containing approximately the same number of 
cells).  Proteasome inhibition appeared to increase the average number of 
BCA2 expressing cells to levels in line with EGFP-vector alone.   
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Figure 4-29: Proteasome inhibition with 10 µM MG132 for 6 hr enhances 
fluorescent expression in EGFP-BCA2 transfected MCF-7 cells. Scale bars = 25 
µm. Error bars represent standard deviation from a single experiment. 
From these results it was initially thought that BCA2 was either 
ubiquitinating itself, or one of the EGFP lysine residues, thus marking the 
fusion protein for proteasomal degradation.  However, BCA2 could not 
be detected by Western blotting, indicating that the protein was not being 
produced.  Sequencing data later confirmed this (Fig. 4-30).  A 
frameshift between the BCA2 insert and the EGFP tag caused a 77 amino 
acid peptide to be attached to the fluorescent protein rather than BCA2.  
In light of this, the enhanced expression effect by MG132 can be 
explained in terms of a misfolded, frameshift protein product (fused with 
EGFP) being degraded by the proteasome.  The experimental findings in 
Figure 4-30 were therefore deemed unrelated to BCA2 function and no 
further work was performed with the EGFP constructs during the course 
of this project.   
Also revealed by the sequencing data was that within the BCA2 sequence 
there was a 209A>T point mutation that lead to an H70L amino acid 
substitution (Fig. 4-30 E).  The mutation was detected in forward and 
 253 
 
reverse sequencing and was also confirmed to be present in the parental 
HA-BCA2 plasmid that had been supplied by (Miyakawa et al. 2009). 
A   EGFP-BCA2 (C1) Insert Sequencing: Forward primer 
 
Key 
 
VECTOR 
INSERT 
BCA2 
CCGAGCTGATCGCTAGATCTCGAGCTCAGCTTCGAATTCGGTCGACCGAGATCCGGATGGCGGAGGCTTCGGCGG 
                                                        ATGGCGGAGGCTTCGGCGG 
 
 
CCGGGGCGGACTCGGGCGCCGCTGTAGCCGCCCACCGGTTTTTCTGCCACTTTTGCAAGGGCGAGGTCAGCCCCA 
CCGGGGCGGACTCGGGCGCCGCTGTAGCCGCCCACCGGTTTTTCTGCCACTTTTGCAAGGGCGAGGTCAGCCCCA 
 
 
AACTACCGGAATATATATGTCCCAGATGTGAATCAGGCTTTATTGAAGAAGTGACAGATGATTCCAGTTTTTTAG 
AACTACCGGAATATATATGTCCCAGATGTGAATCAGGCTTTATTGAAGAAGTGACAGATGATTCCAGTTTTTTAG 
 
 
GTGGTGGCGGCAGTCGGATAGACAATACCACAACAACACTTTTTGCAGAGCTTTGGGGCCATTTGGATCACACGA 
GTGGTGGCGGCAGTCGGATAGACAATACCACAACAACACATTTTGCAGAGCTTTGGGGCCATTTGGATCACACGA 
 
 
TGTTTTTTCAAGATTTTAGACCCTTTCTAAGTAGCAGTCCACTGGACCAAGATAATAGAGCCAATGAAAGGGGTC 
TGTTTTTTCAAGATTTTAGACCCTTTCTAAGTAGCAGTCCACTGGACCAAGATAATAGAGCCAATGAAAGGGGTC 
 
 
ACCAGACTCACACTGACTTCTGGGGAGCAAGACCTCCACGGTTGCCATTGGGTCGGAGATACAGATCTCGAGGAA 
ACCAGACTCACACTGACTTCTGGGGAGCAAGACCTCCACGGTTGCCATTGGGTCGGAGATACAGATCTCGAGGAA 
 
 
GTTCTCGTCCTGACAGATCTCCAGCTATTGAAGGAATACTACAACACATCTTTGCAGGATTCTTTGCAAATTCTG 
GTTCTCGTCCTGACAGATCTCCAGCTATTGAAGGAATACTACAACACATCTTTGCAGGATTCTTTGCAAATTCTG 
 
 
CCATTCCTGGATCTCCACACCCTTTTTCCTGGAGCGGGATGCTGCACTCCAACCCTGGGGACTATGCCTGGGGTC 
CCATTCCTGGATCTCCACACCCTTTTTCCTGGAGCGGGATGCTGCACTCCAACCCTGGGGACTATGCCTGGGGTC 
 
 
AGACAGGGCTTGATGCCATTGTAACCCAGCTTTTAGGACAACTGGAAAACACAGGCCCTCCCCCAGCTGACAAGG 
AGACAGGGCTTGATGCCATTGTAACCCAGCTTTTAGGACAACTGGAAAACACAGGCCCTCCCCCAGCTGACAAGG 
 
 
AAAAGATCACATCTCTTCCAACAGTGACAGTAACTCAGGAACAAGTTGATATGGGTTTAGAGTGTCCAGTATGCA 
AAAAGATCACATCTCTTCCAACAGTGACAGTAACTCAGGAACAAGTTGATATGGGTTTAGAGTGTCCAGTATGCA 
 
 
AAGAAGATTACACAGTTGAAGAGGAAGTCCGGCAGTTACCTTGCAATCACTTCTTTCACAGCAGTTGTATTGTGC 
AAGAAGATTACACAGTTGAAGAGGAAGTCCGGCAGTTACCTTGCAATCACTTCTTTCACAGCAGTTGTATTGTGC 
 
 
CGTGGCTAGAACTGCATGACACATGTCCTGTATGTAGGA_GAGCTTAA_TGGTGAG_ACTCTACTCGGCAAAGCC 
CGTGGCTAGAACTGCATGACACATGTCCTGTATGTAGGAAGAGCTTAAATGGTGAGGACTCTACTCGGCAAAGCC 
 
         
AGAGCACTGAG_CCTCTGCA_GCA_CAGATTAAGCATTGACAGTCAGCTACATGACGGAATGACTTTCTGAAT 
AGAGCACTGAGGCCTCTGCAAGCAACAGATTTAGCAATGACAGTCAGCTACATGACCGATGGACTTTCTGA 
 
CACTAGTGCGCAGGCAATTCCACCGGATCTAGAATAACCTTGGAATTCATAAAC 
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B  EGFP-BCA2 (C1) Insert Sequencing: Reverse primer  
Key 
 
VECTOR 
INSERT 
BCA2 
GTGGATCCCGGGCCGCACTAGTGATTCAGAAAGTCCATCGGTCATGTAGCTGACTGTCATTGCTAAATCTGTTGC 
          TCAGAAAGTCCATCGGTCATGTAGCTGACTGTCATTGCTAAATCTGTTGC 
 
 
TTGCAGAGGCCTCAGTGCTCTGGCTTTGCCGAGTAGAGTCCTCACCATTTAAGCTCTTCCTACATACAGGACATG 
TTGCAGAGGCCTCAGTGCTCTGGCTTTGCCGAGTAGAGTCCTCACCATTTAAGCTCTTCCTACATACAGGACATG 
 
 
TGTCATGCAGTTCTAGCCACGGCACAATACAACTGCTGTGAAAGAAGTGATTGCAAGGTAACTGCCGGACTTCCT 
TGTCATGCAGTTCTAGCCACGGCACAATACAACTGCTGTGAAAGAAGTGATTGCAAGGTAACTGCCGGACTTCCT 
 
 
CTTCAACTGTGTAATCTTCTTTGCATACTGGACACTCTAAACCCATATCAACTTGTTCCTGAGTTACTGTCACTG 
CTTCAACTGTGTAATCTTCTTTGCATACTGGACACTCTAAACCCATATCAACTTGTTCCTGAGTTACTGTCACTG 
 
 
TTGGAAGAGATGTGATCTTTTCCTTGTCAGCTGGGGGAGGGCCTGTGTTTTCCAGTTGTCCTAAAAGCTGGGTTA 
TTGGAAGAGATGTGATCTTTTCCTTGTCAGCTGGGGGAGGGCCTGTGTTTTCCAGTTGTCCTAAAAGCTGGGTTA 
 
 
CAATGGCATCAAGCCCTGTCTGACCCCAGGCATAGTCCCCAGGGTTGGAGTGCAGCATCCCGCTCCAGGAAAAAG 
CAATGGCATCAAGCCCTGTCTGACCCCAGGCATAGTCCCCAGGGTTGGAGTGCAGCATCCCGCTCCAGGAAAAAG 
 
 
GGTGTGGAGATCCAGGAATGGCAGAATTTGCAAAGAATCCTGCAAAGATGTGTTGTAGTATTCCTTCAATAGCTG 
GGTGTGGAGATCCAGGAATGGCAGAATTTGCAAAGAATCCTGCAAAGATGTGTTGTAGTATTCCTTCAATAGCTG 
 
 
GAGATCTGTCAGGACGAGAACTTCCTCGAGATCTGTATCTCCGACCCAATGGCAACCGTGGAGGTCTTGCTCCCC 
GAGATCTGTCAGGACGAGAACTTCCTCGAGATCTGTATCTCCGACCCAATGGCAACCGTGGAGGTCTTGCTCCCC 
 
 
AGAAGTCAGTGTGAGTCTGGTGACCCCTTTCATTGGCTCTATTATCTTGGTCCAGTGGACTGCTACTTAGAAAGG 
AGAAGTCAGTGTGAGTCTGGTGACCCCTTTCATTGGCTCTATTATCTTGGTCCAGTGGACTGCTACTTAGAAAGG 
 
 
GTCTAAAATCTTGAAAAAACATCGTGTGATCCAAATGGCCCCAAAGCTCTGCAAAAAGTGTTGTTGTGGTATTGT 
GTCTAAAATCTTGAAAAAACATCGTGTGATCCAAATGGCCCCAAAGCTCTGCAAAATGTGTTGTTGTGGTATTGT 
 
 
CTATCCGACTGCCGCCACCACCTAAAAAACTGGAATCATCTGTCACTTCTTCAATAAAGCCTGATTCACATCTGG 
CTATCCGACTGCCGCCACCACCTAAAAAACTGGAATCATCTGTCACTTCTTCAATAAAGCCTGATTCACATCTGG 
 
 
_ACATATATATTCCGGTAGTTTGGGGCTGACCTCGCCCT_GCAAA_GTGGCAGAAAAACCG_TGGACGCTTACGC 
GACATATATATTCCGGTAGTTTGGGGCTGACCTCGCCCTTGCAAAAGTGGCAGAAAAACCGGTGGGCGGCTACAG 
 
 
GA_CGCC_GAGTCCGCCCCGACCGCCGAAGCCTCCGCCAAAT 
CGGCGCCCGAGTCCGCCCCGGCCGCCGAAGCCTCCGCCAT 
 
C  EGFP-C1 and multiple cloning site (MCS) sequence 
 
 
 
D Frameshift mutation leading to aberrant/non-BCA2 translation
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E               Translated BCA2 amino acid sequence 
Insert 
BCA2 
M A E A S A A G A D S G A A V A A H R F F C H F C K G E V S P K L P  
M A E A S A A G A D S G A A V A A H R F F C H F C K G E V S P K L P  
 
E Y I C P R C E S G F I E E V T D D S S F L G G G G S R I D N T T T 
E Y I C P R C E S G F I E E V T D D S S F L G G G G S R I D N T T T 
 
T L F A E L W G H L D H T M F F Q D F R P F L S S S P L D Q D N R A  
T H F A E L W G H L D H T M F F Q D F R P F L S S S P L D Q D N R A  
 
N E R G H Q T H T D F W G A R P P R L P L G R R Y R S R G S S R P D 
N E R G H Q T H T D F W G A R P P R L P L G R R Y R S R G S S R P D 
 
R S P A I E G I L Q H I F A G F F A N S A I P G S P H P F S W S G M 
R S P A I E G I L Q H I F A G F F A N S A I P G S P H P F S W S G M 
 
L H S N P G D Y A W G Q T G L D A I V T Q L L G Q L E N T G P P P A  
L H S N P G D Y A W G Q T G L D A I V T Q L L G Q L E N T G P P P A  
 
D K E K I T S L P T V T V T Q E Q V D M G L E C P V C K E D Y T V E 
D K E K I T S L P T V T V T Q E Q V D M G L E C P V C K E D Y T V E 
 
E E V R Q L P C N H F F H S S C I V P W L E L H D T C P V C R K S L 
E E V R Q L P C N H F F H S S C I V P W L E L H D T C P V C R K S L 
 
N G E D S T R Q S Q S T E A S A S N R F S N D S Q L H D R W T F Stop 
N G E D S T R Q S Q S T E A S A S N R F S N D S Q L H D R W T F Stop 
 
    H70L Point mutation 
Figure 4-30:  Sequencing data demonstrating a reading frame shift between the 
EGFP tag and the BCA2 insert and point mutation in the BCA2 sequence. A) 
Forward sequencing and B) reverse sequencing data were combined with the vector 
sequence information in C) to produce the translational alignment in D) which shows 
that the BCA2 insert sequence (in red) is out of frame with the EGFP sequence (green). 
A fusion between EGFP an aberrant peptide is transcribed and translated.   E) 
Translated BCA2 insert amino acid sequence showing H70L substitution mutation. 
4.6 Discussion 
The MDA-MB-231 cell line represents a highly invasive “triple 
negative” breast cancer cell type.  MDA-MB-231 cells have a 
mesenchymal-like morphology in culture and the data from the endocytic 
profiling of these cells appear to reflect their aggressive, mesenchymal 
characteristics.   
The abundance of actin stress fibres in MDA-MB-231 cells may relate to 
the high migratory and invasive capacity of this cell line. Actin stress 
fibres are believed to have a role in the generation of the contractile force 
needed for cell migration (Kreis and Birchmeier 1980; Hotulainen and 
Lappalainen 2006) and stress fibres are thought to be characteristic 
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features of migrating mesenchymal cells (Vallenius 2013).  The greater 
abundance of stress fibres in the more motile and invasive MDA-MB-
231 cells compared with MCF-7 and MCF-10A cells would seem to 
support these theories (Fig. 4-1).   
Early endosomes are usually found throughout the cell cytoplasm, as 
seen in the MCF-10A and MCF-7 cells (Fig. 4-1).  The perinuclear 
enrichment of early endosomes seen in the MDA-MB-231 cells is more 
typical of recycling endosomes (e.g. Fig. 4-6) or late endolysosomes (e.g. 
Fig. 4-4).  The endocytic and broader cellular consequences of this 
clustered localisation of early endosomes is currently unknown.  
Clustering of early endosomes (and other endocytic organelles) has been 
reported as feature of multi-drug resistant myeloid leukaemia cells and in 
these studies was shown to occur concomitantly with extensive 
microtubule reorganisation (Jin et al. 2008).  Figure 4-2 indicates that the 
microtubule cytoskeleton of the MDA-MB-231 cells was less densely 
fibrous than nest-like filament networks seen in other cell lines.  This 
supports the idea that cytoskeletal reorganisation may be associated with 
the development/progression of some breast cancer types. 
MDA-MB-231 cells have been shown by some researchers to be unable 
to degrade EGFR in response to ligand stimulation (Decker 1988; Tsai et 
al. 2012), though it should be noted that this is not a universally reported 
phenomenon (Sun et al. 2013).  One explanation for a receptor 
degradation defect in these cells might be overexpression of EGFR 
leading to saturation of the lysosomal degradation machinery and 
redirection of internalised receptors to recycling pathway.  An 
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alternative/supplementary hypothesis is that the capacity and/or activity 
of recycling pathway of the MDA-MB-231 cells may be enhanced.   
To investigate the possible significance of the clustered early endosomes 
and (possible) receptor degradation defect in MDA-MB-231 cells, a 
small set of further experiments could be performed.  The investigations 
would comprise pulse-chase experiments with fluorescent EGF and Tf 
ligands in cells that would subsequently be immunolabelled for different 
endocytic organelles.  By performing these co-localisation experiments 
and following the progress of the ligands though the endocytic pathways 
it would be possible to gain a better understanding of the co-ordination of 
trafficking in the cell line. 
The fragmentation of the TGN apparent in the MCF-7 cells in Figure 4-5 
has been previously described (Schindler et al. 1996; Altan et al. 1998).  
The fragmentation reflects a defect in acidification of a number of 
intracellular compartments including the TGN and recycling 
compartments.  A functional consequence of this is that MCF-7 cells 
have enhanced sensitivity to cytotoxic drugs: the cells are less able to 
sequester cytotoxic compounds in vesicles and so cannot remove them 
from the cell via the secretory pathway.  Reduced recycling capacity may 
partly explain the low levels of EGFR and absence of TfR from a distinct 
recycling compartment in this cell line (Fig. 4-6 and 4-7). 
The clarity of vesicular LAMP2 labelling produced by the methanol 
fixation protocol compared with PFA (Fig. 4-3) may relate this fixative’s 
ability to preserve microtubule structure (Wheatley and Wang 1998).  
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Microtubule disruption has been shown to alter the subcellular 
localisation and morphology of late endosomes and lysosomes (Reaves et 
al. 1996).  However, the lack of vesicular labelling in PFA fixed cells is 
more likely to be the result of impaired antibody access to the LAMP2 
epitope caused by protein cross-linking (Schnell et al. 2012).  
Alternatively, the lack of distinct LAMP2 labelling in PFA fixed cells 
may be a consequence of Triton X-100 permeabilisation. Triton X-100 
induces solubilisation of lipid bilayers, including endosomal membranes, 
and has been reported to cause extraction of proteins from cells (Jamur 
and Oliver 2010b).  The absence of vesicular LAMP2 labelling in the 
PFA-fixed/Triton X-100 permeabilised cells may therefore be due to the 
detergent inducing leaching of LAMP2 protein. 
A study by (Nishimura et al. 1998)  indicated that malignant 
transformation of MCF-10A cells with a mutant ras potein led to 
redistribution of lysosomes from the perinuclear region to throughout the 
cytoplasm of cells.  The lysosomal scattering was shown to be a result of 
reorganisation of the microtubule network.  Using LAMP2 
immunofluorescence, the late endosomes and lysosomes were slightly 
more dispersed in the MDA-MB-231 cells than in MCF-7s but contrary 
to Nishimura et al.’s findings the late-endosomes and lysosomes were 
more scattered in the normal MCF-10A cells (Fig. 4-4). 
The endocytic profiling data was herein only discussed in the context of 
cell type rather than BCA2 status as too many other differences between 
the cells exist for any variance to be attributed to BCA2 effects.  Recent 
publications (Buac et al. 2013; Wang et al. 2013) and our own data (Fig. 
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3-4 and 6-4) indicate that in actual fact the difference in BCA2 protein 
expression between these cell lines is fairly minimal.  Differences in 
disulfiram sensitivity between MDA-MB-231 and MCF-7 cells have 
been attributed to differences in BCA2 levels (Brahemi et al. 2013).  
However, given the uncertainty of BCA2 expression differences, it may 
be that DSF activity against breast cancer is dependent on the cellular 
context of BCA2 expression rather than the level of expression.  There 
are many differences between MCF-7 and MDA-MB-231 cells, as 
indicated by the endocytic profiles (Figs. 4-1 to 4-7), and there are many 
reported effects/targets of DSF so it may also be that differences in drug 
sensitivity are unrelated to or only partly involve BCA2.  Other data from 
this lab suggests that the DSF induced scattering of the lysosomes 
observed in Figure 4-8 may relate to endolysosomal sequestration of 
extracellular zinc (Wiggins et al. 2015).  Sequestration of zinc into 
endocytic structures was the mechanism proposed for DSF cytotoxicity, 
though the possible involvement of BCA2 in this was not explored. 
During this initial methodological development phase difficulty was 
experienced in obtaining a validated siRNA and then further difficulties 
were encountered in achieving adequate (and detectable) BCA2 
depletion.  These siRNA problems were later resolved for Western 
blotting (see Chapter 6). Without an efficient siRNA knockdown 
procedure to fully validate the IF data it was difficult to draw reliable 
conclusions about the endogenous localisation of BCA2. The most 
promising localisation would appear to be that produced by the goat anti-
BCA2 antibody.  This antibody was able to detect and distinguish 
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elevated BCA2 levels in cells transiently transfected with the HA-tagged 
protein (Fig. 4-19).   When used with a PFA fixation protocol to detect 
the endogenous protein, the goat anti-BCA2 antibody demonstrated 
strong cytoplasmic labelling (Fig. 4-10).  Some heterogeneity of BCA2 
expression levels between cells was evident and a small subpopulation 
was identified that contained vesicle-like regions of BCA2 enrichment 
that varied in size.  Because these cells did not represent typical examples 
of BCA2 localisation they were not investigated in detail but may be of 
interest for future studies.   
The results of experiments exploring the subcellular localisation of 
HA-BCA2 are extremely difficult to interpret. The data itself is clear: 
HA-BCA2 does not co-localise with actin, with the mitochondria, the 
TGN, the recycling pathway, early or late endosomes or lysosomes in 
MCF-7 cells. This poses the question, what are the BCA2 positive 
structures? Are they membrane bound? Are they aggregates? 
Transmission electron microscopy could be implemented to answer some 
of these questions but was beyond the scope of this project.  The 
structures resembled those seen in the subpopulation of MCF-7 cells 
(Fig. 4-20).  The similarity in labelling confers a degree of confidence 
that the HA-BCA2 structures may not simply be artefacts of transient 
transfection.  The similarity also presents a possible explanation for the 
subpopulation of MCF-7 cells: that they represent a fraction of high 
BCA2 expressing cells.   It may be that once BCA2 levels exceed a 
certain threshold, the protein accumulates in the currently unidentified 
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cytoplasmic structures.  This hypothesis was not tested during the course 
of this project but could be examined as part of future investigations. 
Another confounding aspect of the HA-BCA2 overexpression system is 
why such heterogeneity exists in the localisation of transfected cells. It 
may be that the different localisation patterns correlate with biological 
processes e.g. stage of the cell cycle.  Culture synchronisation 
experiments may have been an experimental approach worth exploring to 
see if a more homogenous localisation pattern could be produced.  
However, the efficacy and validity of cell synchronisation methods is 
somewhat controversial (Pirkmajer and Chibalin  2011; Cooper 2004) so 
in the interests of minimising further confounding factors such 
approaches were avoided.  Stable transfection is an experimental 
approach that can overcome the problems of heterogeneity produced by 
transient transfection.  Chapter 5 details the process of generating a stable 
HA-BCA2 expressing cell line as a future tool to try and address the 
issue of intercellular heterogeneity.   
The effect of the HA-tag and the H70L mutation (Fig. 4-30) on BCA2 
localisation and function is still uncertain.  The HA sequence is very 
short (9 amino acids) and such a small tag is unlikely to alter BCA2 
localisation.  However, it is worth noting that the HA tag is translated 
upstream of the BCA2 insert, such that extra amino acids are also fused 
to the N-terminus of BCA2; 24 in total.  The BCA2 N-terminus is the 
Rab7 interacting domain so while the fused peptide may be small, it 
could potentially have functional consequences for BCA2.   
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The H70L mutation is located in a region with no known structural or 
functional features but since BCA2s crystal structure has not been solved 
the impact of the substitution is difficult to predict.  The 209A>T point 
mutation was not listed in a database of single nucleotide polymorphisms 
(SNPs; http://www.ncbi.nlm.nih.gov/snp). In addition to this a protein 
sequence alignment performed using the Basic Local Alignment Search 
Tool (BLAST) revealed that the histidine is conserved 
(http://blast.ncbi.nlm.nih.gov/Blast).  Taken together these facts suggest 
that the mutation could potentially be significant.   
Though not conducted as part of this project, future experiments will be 
carried out using a sequence-corrected HA-BCA2 construct in order to 
evaluate possible effects of the point mutation.  Further investigations 
will also explore the possible impact of epitope tagging on BCA2 
biology.  To this end, the EGFP-BCA2 construct will be subjected to site 
directed mutagenesis (SDM) to bring BCA2 into frame with the 
fluorescent tag.  A (sequence corrected) HA-BCA2 plasmid will also be 
modified to encode BCA2 without an epitope tag (see Appendix H). 
The apparently cytotoxic effect of overexpressing HA-BCA2 in 
MDA-MB-231 cells is interesting when compared with the minimal 
evidence of cytotoxicity seen in the MCF-7 cells (Fig. 4-17 and 4-18).  
The difference in tolerance of transient HA-BCA2 transfection between 
the cell lines may reflect context dependency of BCA2 expression.  
Evidence of context-dependence had been previously suggested by 
survival analyses (Figs. 3-1 and 3-2) and by conflict in the literature 
surrounding BCA2’s function (Mizuno et al. 2003, Sakane et al. 2007).   
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Despite any limitations, the HA-BCA2 co-localisation data with the 
EGFP-tagged Rab7 and Rab21 proteins was of particular interest due to 
BCA2’s documented effects on EGFR trafficking and interaction with 
Rab7.   BCA2 colocalisation with another Rab protein has not been 
previously reported and may be a significant finding in terms of the 
function of the protein or in terms of appropriate experimental 
approaches for studying BCA2.  The relationship between BCA2, EGFR 
and Rab7 is explored in more detail in Chapter 6. 
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Chapter 5: Generating a stable HA-BCA2 expressing cell 
line 
Transient transfection experiments can be used to generate meaningful 
data regarding protein function and localisation; however the approach is 
not without its limitations.  One of the potential disadvantages of 
transient transfection is intercellular heterogeneity of protein expression, 
as exemplified by HA-BCA2 in Figure 4-18.  Heterogeneity in protein 
expression levels and/or localisation makes biological effect patterns 
more difficult to identify and can impinge on experimental 
reproducibility.  Another limitation of the approach is that the high levels 
of overexpression that can be achieved in transiently transfected cells can 
be many orders of magnitude greater than levels that would occur 
physiologically (Menke et al. 1998).  This could lead to misinterpretation 
of transient overexpression data and potentially undermine the biological 
relevance of results.   
Other drawbacks of transient protein overexpression are limited and/or 
variable transfection efficiencies which can, respectively, reduce the 
effect-sizes of results and increase inter-assay variability (Mosser et al. 
1997).  The reagents used in transient transfection have documented side-
effects on cell viability and gene expression which in turn could have 
confounding effects on results and their interpretation (Calvin et al. 
2006).  Technical disadvantages of transient transfection include 
increased experimental complexity and time/labour intensiveness and the 
inability to study longer term effects of overexpression.    
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An experimental approach that can avoid some of the discussed problems 
with transient transfection is the use of stable cell lines.  Stable cells are 
produced by co-expressing a gene of interest (GOI) with a selectable 
marker gene for antibiotic resistance.  Cells are then cultured under the 
selection pressure of antibiotic-containing medium.  Non-transfected 
cells succumb to antibiotic toxicity allowing resistant cells to be isolated 
and propagated.  The drug-resistant clones produced by this approach 
will have all integrated the GOI at random, possibly multiple, genomic 
loci.  Expression levels between clones may therefore vary but should be 
equal within a clonal population.  One potential limitation of the stable 
cell line approach however arises due the gradual loss of cell 
differentiation that occurs with increasing passage number (O’Driscoll et 
al. 2006).  Parental cells and stable clones overexpressing wild-type or 
mutant genes may all be affected differently by the passaging process 
(Arden et al. 2007). 
In order to overcome some of the main problems observed here with 
transient HA-BCA2 overexpression, in particular the issue of 
intercellular heterogeneity, it was decided that a stable cell line would be 
produced.  Cell lines stably overexpressing mutant BCA2 proteins were 
to be generated alongside the wild-type-overexpressing cells to allow 
functional comparison of protein domains.  If successfully produced the 
stable cell lines would be a future resource for functional studies 
complementary to siRNA and transient transfection.  Complementary 
transient and stable transfection experiments in HeLa cells would help to 
identify possible artefacts intrinsically generated by the separate 
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approaches.  Flp-In™ HeLa S3 parental cells were generously donated 
by Prof. Michael Clague and Prof. Sylvie Urbé and this enabled the 
stable cell line development to proceed.  The theory and process of stable 
cell line generation using a Flp-In system is discussed in more detail in 
section 5.1 which follows. 
5.1 Overview of the theory and process of Flp-In stable cell line 
generation 
Flp-FRT recombination strategies offer a further refinement to stable cell 
line development.  The approach allows a GOI to be incorporated into a 
single genomic integration site which, theoretically, produces clonal, 
isogenic cell lines (O'Gorman et al. 1991).  Overexpression with a Flp-In 
approach is therefore usually more moderate than in transient transfection 
so results may be more biologically relevant.  
Flp-FRT recombination systems require two key components for site-
specific recombination to occur (Turan and Bode 2011): 
- Flp recombinase - an enzyme with nuclease and ligase activity 
that mediates homologous recombination of genes between two 
flippase recognition target (FRT) sites. 
- FRT sites: Flp recombinase recognises and binds to two inverted 
repeat sequences of 13 bp that flank an 8 bp core region of the 
FRT site.  Cleavage occurs upstream of the core (highlighted in 
red below).  The FRT sequence is as follows: 
5'GAAGTTCCTATTCcGAAGTTCCTATTCtctagaaaGtATAGGAACTTC3' 
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Flp-FRT mediated recombination allows genes to be introduced at 
specific sites and its use in stable cell line generation is illustrated later, 
in Figure 5-1. 
The background summary in the paragraph that follows was synthesised 
from the Life Technologies product information for Flp-In systems along 
with indicated reference sources.  To avoid repetition, the manufacturer’s 
information will not be referenced every time but it should be noted that 
specific methodological details (vector names, promoters, cell lines etc.) 
were all based on the Flp-In system product information. 
An overview of stable cell generation is shown in Figure 5-1.  Flp-In 
HeLa cells have an Flp Recognition Target (FRT) site inserted 
downstream of an SV40 promoter and an ATG start codon for a Zeocin 
resistance gene.  The pEF5/FRT/V5-D-TOPO vector contains a 
hygromycin resistance gene lacking an ATG start codon and promoter 
sequence.  The plasmid also contains a TOPO site into which a GOI can 
be inserted.  The GOI is then under the control of an hEF-1α promoter 
and an FRT site.  The pOG44 plasmid codes for Flp recombinase (Flp).  
Once the pOG44 and pEF5/FRT/V5-D-TOPO plasmids have been 
co-transfected into the host Flp-in HeLa cells, Flp recombinase is 
expressed and mediates homologous recombination between the FRT 
sites in the genomic DNA and pEF5/FRT/V5-D-TOPO plasmid 
(O'Gorman et al. 1991).  The result of this recombination event is that the 
Hygromycin B resistance gene is inserted into the genomic DNA in 
frame with the ATG start codon and SV40 promoter.  The GOI is also 
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inserted into the genomic DNA along with its hEF-1α promoter and the 
Zeocin resistance gene is inactivated.  The result of a successful stable 
transfection is an Hygromycin B resistant, Zeocin-sensitive HeLa cell 
that expresses the GOI.  The process is summarised in Figure 5-1. 
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Figure 5-1: Schematic diagrams outlining the principle and process of stable cell 
generation. A) Demonstrates the FRT site and key adjacent sequence domains in HeLa 
S3 parental cells.  B) Depicts homologous recombination in parental cells following co-
transfection with Flp recombinase and GOI construct vectors. C) Summarizes key steps 
of the selection process following GOI integration. 
Prior to stable cell line generation, truncation mutants were designed for 
BCA2 based on the location domains predicted by HHPred online 
(http://toolkit.tuebingen.mpg.de/hhpred).  pEF5/FRT constructs were 
produced by designing PCR primers that would to allow wild-type HA-
BCA2 (“WT-BCA2”), the zinc finger truncation mutant (“-Zn-BCA2”) 
and RING-H2 mutant (“-RING-BCA2”) to be amplified from the parent 
plasmid.  These primers were then used to amplify the wild-type HA-
BCA2 and the truncation mutants by PCR.  The PCR products were 
TOPO cloned into the destination pEF5/FRT/V5-D-TOPO vector.  The 
plasmid constructs were then used to transform TOP10 competent cells 
for amplification and purification.    PCR analysis and restriction analysis 
were performed in order to verify that cloning was successful and that the 
inserts were correctly orientated in the vector.  
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5.2 Generating stable cell lines with wild-type HA-BCA2 
Due to time constraints only the wild-type HA-BCA2 construct was 
utilised in the stable cell line development in this project. 
Flp-In S3 HeLa cells were transfected with pOG44 (the plasmid coding 
for Flp recombinase) and wild-type HA-BCA2 plasmid construct (WT-
BCA2).   After a media change and a total of 24 hours post-transfection 
incubation, the cells in each well were split 1/6 and replated onto 10 cm 
dishes.  1/6 splits were also made from a well of untransfected cells to act 
as negative (i.e. hygromycin sensitive) controls.   
5.2.1 Growth and maintenance of cells 
Cells were maintained in the hygromycin selection media, which was 
changed every 3 days till day 18 of the experiment.  During media 
changes the cells were monitored and their progress was documented 
with low resolution microscopy images, examples of which are shown in 
Figure 5-2.    
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Figure 5-2: Light microscopy images of WT-BCA2 and untransfected/negative 
control cells taken 9 days after commencing hygromycin selection. Small colonies 
of hygromycin-resistant clones were only seen in the WT-BCA2 transfected cells and 
are indicated by circles. 
The untransfected control cells showed increasing cytotoxicity and 
ultimately total cell death between 9 and 12 days of hygromycin 
treatment.  Following a period of extensive cell death in the WT-BCA2 
transfected cells, small colonies began forming after ~9-days. 
Nineteen days after plating, large colonies had grown in all the 
transfected dishes and these colonies were then transferred into 
individual wells for amplification of the cell clones. 
5.2.2 Colony picking 
Candidate colonies for propagation were identified; those with the largest 
colony-size and with the greatest separation from neighbouring colonies 
were selected. Example images of marked colonies and their microscopic 
appearance are shown in Figure 5-3  
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Figure 5-3:  Colony picking of stable WT-BCA2 clones.  10 cm dishes with marked colonies 
are shown on the left and the microscopic appearance of example colonies are shown on the right. 
5.2.3 Growth and maintenance of clones 
The cells were left to grow in 24 well plates for a week and the media 
was changed every 2-3 days.  After 7 days all the cells that had reached 
>60% confluency were replated into two wells of 12-well plates.  When 
these cells then became ~70% confluent lysates were collected from one 
of the wells for expression testing by Western blotting.  To maintain the 
cell population the second of each of the two clone wells was divided 
into two wells of separate 6-well plates.  One of the 6-well plates was 
then used for creating frozen stocks and one was used for Zeocin 
sensitivity testing.   
5.2.4 Zeocin sensitivity testing 
Zeocin sensitivity testing was performed by seeding at low density into 
6-well plates. Untransfected HeLa Flp-In S3 cells and normal HeLa cells 
were also seeded and used as negative control and positive controls for 
Zeocin sensitivity respectively.   
  
279 
 
The cells were grown in Zeocin media for one week and the media was 
changed twice.  Zeocin’s mechanism of killing is different from 
hygromycin, the cells do not round-up, rather they exhibit morphological 
and growth rate changes induced by the drug cleaving DNA.  Highly 
sensitive cells will die after long term exposure.  
Clones were classified according to changes in growth rate and 
morphology.  Example images of cells exhibiting hallmarks of each 
sensitivity classification are shown in Figure 5-4.   
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Figure 5-4:  Classification criteria and examples of Zeocin sensitivity testing. 
Example images of WT-BCA2 clones from each classification are shown (except for 
the “highly sensitive” category which is positive control HeLa cells). 
Varying degrees of Zeocin sensitivity were exhibited by the different 
WT-BCA2 clones.  Each of the 78 clones was classified into one of the 
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Zeocin sensitivity categories and a tally for each of the sensitivity classes 
was taken.  The results are summarized in Figure 5-5. 
 
Figure 5-5: Number of clones falling into the different Zeocin sesntivity classes. 
The finding that many of the clones were resistant to Zeocin was 
surprising.  The Flp-In system documentation provided by Life 
Technologies however suggests that this is not uncommon.  One possible 
explanation is a phenomenon called “transcriptional read-through”. 
Transcriptional read through leading to doubly-resistant clones, has been 
reported previously in FLP-In CHO cells supplied by Life Technologies.  
In the CHO cells the FRT site is highly transcriptionally active and even 
after successful integration of an FRT construct the cells can retain 
Zeocin resistance.  In CHO cells Life Technologies confirm that Zeocin 
sensitivity testing is not sufficiently indicative of successful Flp-In.  
Since some of the clones did demonstrate Zeocin sensitivity and not all 
the clones could be maintained, the Zeocin resistant cells were discarded 
at this stage.       
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5.3 WT-BCA2 expression analysis by Western blotting 
All the Zeocin sensitive clones and a selection of those exhibiting some 
Zeocin sensitivity were then subjected to Western blotting analysis for 
WT-BCA2 expression. Lysates of untransfected parental cells and 
transient HA-BCA2 overexpressing HeLa cells served as negative and 
positive controls.  Immunoblotting for HA was performed according to 
the protocol described in Section 1.15.3.2.  In order to detect the lower 
protein overexpression levels in stable cells compared with transient 
transfects, Femto High sensitivity ECL reagent was applied to the 
immunoblotting membrane.  Very low level but positive HA-BCA2 
signals were detected in 10 of the clones after 10 min exposure on the 
Chemidoc imaging system (Fig. 5-6).  This was significantly longer than 
the ~20 s that is usually required for detection in transiently transfected 
cells, despite ~2.5 x the amount of protein being loaded (50 µg). 
 
Figure 5-6: Immnuoblotting of WT-BCA2 clones for detection of stably expressed 
HA-BCA2. Clone nomenclature e.g. 1WTA1 relates to well and plate reference 
numbers and was simply means of distinguishing between individual clones. Red font 
indicates clones that were subject to further testing.  
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Following resurrection from frozen storage the ten clones that indicated 
positive (though still very low) HA-BCA2 expression were tested to 
determine whether expression was maintained over time.  Lysates were 
collected after three passages post-resurrection.  As previously Western 
blotting was used to determine HA expression. 
 
Figure 5-7: Immunoblotting of ten HA-BCA2 positive clones to determine whether 
HA-BCA2 expression was maintained over time. 
Expression appeared to have been lost from five of the clones but was 
maintained in five others.  Further lysates of the clones still expressing 
HA-BCA2 were taken after another two passages to test for HA-BCA2 
expression.  EGFR levels were also examined to see if any major 
differences in expression were apparent in the stable cells (as has been 
demonstrated with transient transfection in Chapter 5).  However, due to 
the large amount of protein being loaded on the gel the EGFR 
immunoblotting signal was oversaturated, even with 1 s exposures and so 
could not be used for reliable quantitative comparison.   
The immunoblotting results are shown in Figure 5-8. 
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Figure 5-8:  Immunoblotting of five HA-BCA2 positive clones at later passages to 
determine whether HA-BCA2 expression was lost or maintained with time. 
HA-BCA2 expression appeared to be maintained in the remaining clones 
but was still at very low level.  Experiments were conducted to try and 
elucidate and reverse the mechanism responsible for the minimal 
expression.  Prior to this optimisation experiments needed to be carried 
out such that endogenous BCA2 protein levels could be examined. 
5.4 Anti-BCA2 testing for Western blotting 
A series of experiments were performed to find the best primary antibody 
and Western blotting protocol such that BCA2 protein expression could 
be examined in the clones.   BCA2 is a poorly-studied protein so widely-
used and/or validated commercial antibodies were not available for use in 
this project.  Three antibodies were tried in the first instance: two 
polyclonal antibodies, raised in rabbit and in goat (also tested for IF in 
Chapter 4) and one monoclonal antibody raised in mouse.  To test the 
antibodies, lysates were collected from a selection of cell lines.  Included 
in the small panel of cells tested were cell lines that had been shown to 
express different levels of BCA2 at the protein level (Brahemi et al. 
2010; Buac et al. 2013; Wang et al. 2013) and at the mRNA level (Fig 3-
4). 
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A standard Western blotting protocol was adopted: lysates were 
separated by SDS-PAGE and transferred to PVDF membranes.  The 
membranes were blocked in 5% milk in PBST for an hour at room 
temperature then incubated overnight at 4
o
C with primary antibody 
diluted 1:250 in 2% milk in PBST. The following day the membranes 
were washed 3x 5 min in PBST then incubated with HRP-conjugated, 
species specific secondary antibodies diluted 1:2,000 in 2% milk in 
PBST for an hour.  The membranes were washed thrice in PBST and the 
protein expression signal was detected by ECL.  Figure 1 shows that the 
three antibodies produced highly varied results in detection of BCA2, a 
protein with a predicted molecular weight of 34 kDa.  The mouse anti-
BCA2 antibody failed to detect a signal (Fig. 5-9 A).  The rabbit anti-
BCA2 antibody (Fig. 5-9 B) did detect a faint band at approximately the 
right molecular weight (~36 kDa) but the immunoblot was dominated by 
a strong signal at ~48 kDa.  This prominent signal is likely to be non-
specific as it showed no variation between cell lines and was not the 
correct molecular weight.  The immunoblot with the goat anti-BCA2 
antibody was the most promising (Fig. 5-9 C).  Despite high background 
it was possible to see bands/a large band at around 37 kDa that varied 
between the cell lines and was strongest in MCF-7s; reported to be high 
BCA2 expressers (Brahemi et al. 2010; Wang et al. 2013).  
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Figure 5-9: Anti-BCA2 primary antibody selection for Western blotting.  Lysates 
of cells thought to express differing levels of BCA2 were separated by SDS-PAGE, 
transferred to PVDF and immunoblotted for BCA2 using different primary antibodies:  
A) Mouse anti-BCA2,  B) Rabbit anti-BCA2 and C) Goat anti-BCA2. 
The goat anti-BCA2 antibody was subjected to further optimisation 
experiments.  Different blocking and antibody diluent solutions were 
tested: 5% milk and 2% milk were tested as antibody diluents and in one 
experiment BSA was substituted for milk. In all experiments a lower 
concentration of primary and secondary antibody was used (1:500 and 
1:5,000 respectively).  Given the uncertainty surrounding endogenous 
BCA2 levels, for these experiments some lysates were taken from MCF-
7 and HeLa cells that were transiently transfected with HA-BCA2 to 
ensure different expression levels of the protein between lanes.  
 
Figure 5-10: Optimisation of the goat anti-BCA2 primary antibody for Western 
blotting.  HeLa and MCF-7 cells were transiently transfected with HA-BCA2 or an 
empty control vector (Mock).  Western blotting for BCA2 was performed using 
different protocols. A) BSA was used in place of milk in blocking and antibody diluent 
buffers B) 5% milk blocking solution was used with 2% milk antibody diluent. C) 5% 
milk was used for both blocking solution and diluent.  D) Optimised protocol for MCF-
7 endogenous levels (n=4): 5% milk blocking buffer and 3% milk antibody diluent. 
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The protocol using 5% milk gave the best immunoblotting result for 
overexpressed BCA2 (Fig. 5-10 C) but a stronger signal was desirable for 
studying endogenous expression. A protocol was therefore tested wherein 
the percentage of milk in the antibody diluent was decreased to 3% in 
order to reduce antigen masking (Fig. 5-10 D).  This method gave two 
strong, defined bands for BCA2 in MCF-7 cells and was therefore 
adopted for further experiments studying endogenous protein levels. 
5.5 Investigating multiple BCA2 immunoblotting bands 
Immunoblots of BCA2 demonstrate that both endogenous and 
overexpressed BCA2 form multiple bands following separation by SDS-
PAGE, most frequently the protein appears as a doublet.  This has been 
seen multiple times in the literature (Miyakawa et al. 2009; Bacopulos et 
al. 2012; Smith et al. 2013) but the phenomenon has not been fully 
explained.   
Splice variants were ruled out as a source of the multiple BCA2 bands 
since they are present in both endogenous cells and those transiently 
overexpressing BCA2 (Fig. 5-10).  It is also worth noting that in HA-
BCA2 overexpressing cells multiple bands can also be detected with an 
anti-HA antibody (Fig. 5-6).   
Reviewer’s comments and the authors’ responses to the 2012 paper by 
Bacopulos et al. are available to view online and in them the multiple 
BCA2 bands are discussed (http://www.biomedcentral.com/1471-
2407/12/63/prepub).   The authors attributed the two BCA2 bands seen 
by Western blotting to incomplete denaturation of the strong secondary 
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and tertiary structures of the protein’s RING-H2 domain.  Supporting this 
hypothesis was evidence that in immunoblots of cell lysates transfected 
with RING-H2 mutant (that could not form secondary structures) BCA2 
only appeared as a single band (Bacopulos et al. 2012).   
Experiments were conducted in order to determine whether the multiple 
BCA2 bands were the result of a failure of the RING-H2 domain to fully 
denature.  Lysates of MCF-7 cells were collected, prepared and 
electrophoretically separated on a 12% acrylamide gel.  A variety of gel 
and sample conditions were tested: reducing and non-reducing, 
denaturing and native.  Table 5-1 summarises the experimental 
adjustments necessary to create the different Western blotting conditions: 
Table 5-1: SDS and DTT requirements for buffers and gels to produce different 
Western blotting conditions 
 
Conditions SDS DTT 
Reducing, denaturing   
Reducing, native   
Non-reducing, denaturing   
Non-reducing, native   
 
Following separation, the proteins were transferred to PDVF membranes 
and immunoblotted for BCA2 (Fig. 5-11). 
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Figure 5-11:  Immunoblots of endogenous BCA2 expression in MCF-7 cells under 
different Western blotting conditions.  Cell lysates were prepared in reducing and 
non-reducing sample buffer and separated by electrophoresis on A) a native acrylamide 
gel and B) a denaturing acrylamide gel. After transfer to PVDF membrane separated 
proteins were subject to BCA2 immunoblotting. Red arrows indicate faint bands. 
The immunoblots for BCA2 on lysates separated under native PAGE 
conditions (Fig. 5-11 A) feature a strong band at the top of the gel ~180 
kDa.  This suggests that in native conditions, BCA2 may be unable to 
move into the acrylamide gel.  In the reducing conditions a faint band 
was visible at ~34 kDa and another at ~42 kDa.  Under denaturing, 
reducing conditions (Fig. 5-11 B) the BCA2 immunoblotting signal 
appeared as multiple bands.  On a 12% gel the doublet at 37 and 34 kDa 
was resolved into a triplet at 37, 39 and 34 kDa.  Other heavier and rather 
smeared bands were also apparent at ~75, ~180 and ~200 kDa in these 
Western blotting conditions.  The heavier bands were indicative of 
ubiquitinated BCA2 and have been previously reported in the literature 
(Burger et al. 2005).  Under denaturing, non-reducing conditions, 
multiple BCA2 bands were again apparent in the immunoblot; the 
strongest signals in these conditions appearing at 34 and ~200 kDa.   
For the purposes of further studies, both bands of the BCA2 doublet at 
~37 and ~34 kDa were used to evaluate protein expression.  This was in 
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light of data showing that both bands appeared in the immunoblots of 
cells transiently transfected with HA-BCA2 (Fig. 5-10 C).  In some 
experiments the bands did not separate into doublet and in these instances 
the large unresolved band was shown for BCA2.   
Once the BCA2 immunoblotting protocol had been developed, the 
endogenous BCA2 in the stable cell lines could be examined to provide 
more information about the low protein expression in the stable HA-
BCA2 clones. Experiments were therefore conducted to attempt to 
enhance/restore BCA2 levels with pharmacological manipulation. 
5.6 Investigating low BCA2 expression in the stable HA-BCA2 
expressing clones 
Transcriptional repression is known to be a potential pitfall in stable cell 
line generation (communication: S. Urbé, Liverpool University) and is 
referred to in the Life Technologies guide to mammalian expression 
systems.  Epigenetic modifications that impair access of the transcription 
machinery to target DNA sequences are natural biological mechanisms 
for modulating gene transcription.  Promoter methylation and histone 
acetylation are two such epigenetic modifications that are important in 
transcriptional control (Grassi et al. 2003).  Methylation of cytosine 
nucleotides in promoter CpG islands (adjacent cyotsine and guanine 
bases) represses transcription of downstream genes (Robertson 2001).  
Acetylation of lysine residues in histone proteins reduces their affinity 
for DNA.  This chromatin remodelling exposes more DNA to the 
transcription machinery and consequently enhances transcription.  
Histone deacetylases catalyse the removal of acetyl groups from histone 
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proteins and the resulting changes to chromatin structure reduce gene 
transcription (Marks et al. 2001).  Silencing of the CMV promoter 
following exogenous introduction to mammalian cells, including HeLa, 
has been widely reported (Guo et al. 1996; Löser et al. 1998; Grassi et al. 
2003).  The Flp-In system utilises an EF-1A promoter for GOI 
expression and an SV40 promoter for expression of the hygromycin 
resistance gene (Fig. 5-1B).  It is therefore possible that through specific 
epigenetic modification of the EF-1A promoter, stable clones could 
retain drug-resistance while reducing expression of the GOI.  The EF-1A 
promoter has more CpG islands than the CMV promoter (Alméciga-Díaz 
et al. 2009) and therefore has more potential methylation sites.  The EF-
1A promoter has also been shown to be susceptible to silencing in 
cultured cells (Norrman et al. 2010).  Promoter silencing can be 
prevented/minimised by compounds that inhibit DNA methylation, such 
as 5-azacytidine, and by inhibitors of histone decetylation such as butyric 
acid (Boffa et al. 1978; Escher et al. 2005).   
BCA2 has been shown to regulate its own protein levels through 
autoubiquination (Amemiya et al. 2008).  Another possible reason for 
low expression levels was therefore proteasomal degradation.  To 
elucidate whether promoter silencing or proteasomal degradation were 
responsible for the low BCA2 expression levels, a number of inhibitor 
investigations were performed.  One of the stable WT-BCA2 clones was 
selected for experimentation which was performed in 5-well plates.  Cells 
were treated with 5-azacytidine or butyric acid for 48 hr or with the 
proteasome inhibitor MG132 for 8 hr.  Prior to lysate collection the cells 
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were imaged by phase contrast microscopy on a Leica wide-field system.  
Western blotting for HA and for BCA2 was then performed and the 
results of the experiments are shown in Figure 5-12.   
 
Figure 5-12: Immunoblotting and DIC microscopy images of stable WT-BCA2 
cells treated with DNA-methylation, histone deacetylase and proteasome 
inhibitors. Cells were treated for 48 hours with either 5-azacytidine or butyric acid or 
for 8 hours with MG132.  A) HA-BCA2 expression was measured by Western blotting 
after cells were imaged by DIC microscopy (B). 
The HA-immunoblot confirmed low BCA2 expression in the stable clone 
1WTA2 (Fig. 5-12 A).  BCA2 was strongly detected but this is due to the 
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necessarily heavy sample loading (to detect HA) rather than due to high 
levels of BCA2 expression.  Figure 5-12 A also shows that treatment of 
the WT-BCA2 clone with 5-azacytidine or butyric acid did not appear to 
significantly increase HA-BCA2 expression.  This suggested that 
promoter repression was either not responsible for the low HA-BCA2 
levels or that promoter silencing could not be adequately reversed by 
these treatments.  The unusual, spiculated morphology of the cells 
following butyric acid treatment (Fig. 5-12 B) has been previously 
reported for other cell lines (Prasad and Sinha 1976).  The morphological 
changes are thought to be due to the incorporation of the butyric acid into 
the lipid component of the plasma membrane altering its configuration 
and thereby changing cell morphology.   These morphological changes 
seen with butyric acid were not therefore attributable to a BCA2-
mediated effect.  MG132 treatment increased the level of HA-BCA2 but 
had no effect on total BCA2 levels.   
5.7 Discussion 
The attempt to generate a stable BCA2 overexpressing cell line was both 
a failure and a success.  Stable clones expressing BCA2 were indeed 
generated but were of limited value for further work due to the extremely 
low level at which BCA2 was expressed (Fig. 5-6).  Large amounts of 
protein (50 µg) were required for positive detection by Western blotting 
and needed to be coupled with high-sensitivity ECL reagent with and 
long exposure times for signal detection.  Because of these procedural 
requirements, the immunoblots that were produced had low signal to 
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noise ratios which made experiments difficult to perform and results 
difficult to analyse. 
Exploring the reasons for the low expression levels in light of other data 
presented in previous chapters and in the context of BCA2 literature does 
provide some insights into BCA2 regulation.  The significance of 
different experimental approaches in BCA2 also becomes more apparent.       
Difficulties in stable cell line generation have been reported for proteins, 
such as transcription factors, where overexpression has cytotoxic effects. 
In the case of some transcription factors, overexpression leads to aberrant 
and ultimately fatal expression of their regulated genes (Wu and Chiang 
1996).  If BCA2 overexpression impinges on cell viability, which is 
suggested by IF in the cell context of MDA-MB-231 cells (Fig. 4-18), 
this may help to explain the failure of the clones to express high BCA2 
levels.  Perhaps HA-BCA2 stable cells represent a self-limiting system 
with higher expressing clones dying due to growth inhibition and thus 
only the lowest expressing cells surviving long enough to be tested.  For 
potentially cytotoxic proteins, inducible expression approaches, such as 
the tetracycline controlled transcriptional activation (Tet-On/Tet-Off) 
systems, can be used.  Such an approach may be useful for future BCA2 
studies. 
Typically for an E3 ligase, BCA2 is thought to regulate its own stability 
via autoubiquitination.  One study has shown that an intact RING-H2 
domain and ubiquitin binding sites are required for overexpressed BCA2 
to accumulate upon proteasome inhibition (Amemiya et al. 2008).  A 
cyclohexamide time course experiment in which endogenous BCA2 
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levels were monitored in MCF-7 cells suggested a protein half-life of 
between 6 and 12 hours (Kona et al. 2012).  In an experiment where 
overexpressed, GST-BCA2 was examined in HEK293 cells however the 
half life appears to be much shorter (Bacopulos et al. 2012).  Data 
presented in this paper show the relative level of GST-BCA2 falls from 1 
to 0.39 in 6 hours.  These numbers can be used to estimate BCA2 half-
life using the following equation:  T1/2 = t * ln(2)/ln(P1/P2).  Where P1 
is the starting amount of protein (1), P2 is the final amount of protein 
(0.39) and t is the time interval (6).  This gives an estimate half life of 
1.62 hours ~ 96 minutes.   
The apparent disparity in half life between endogenous and 
overexpressed BCA2 (Bacopulos et al. 2012; Kona et al. 2012) may 
relate to differences in proteasome function between the cell lines in 
which the experiments were conducted.  However the variation in 
turnover rate may reflect differences in the way that epitope tagged 
and/or overexpressed BCA2 behaves within the cell, compared with the 
endogenous protein.      
The average half-life of a protein is 46 hours (Schwanhäusser et al. 2011) 
so whether endogenous or overexpressed half-lives are considered, 
BCA2 has a high protein turnover rate.  Rapid protein turnover may 
explain why such low levels of HA-BCA2 expression were achieved in 
the stable cell line (Fig. 5-6) and why proteasome inhibition was able to 
increase the expression (Fig. 5-12 A).  The fact that total BCA2 protein 
levels (endogenous plus HA-BCA2) were not increased by proteasome 
inhibition suggests that BCA2 levels are tightly regulated.   
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It has been shown that proteins that have an increased tendency to 
aggregate have faster degradation rates (De Baets et al. 2011).  It may be 
that BCA2 has a high propensity to aggregate and this is what 
necessitates strict control of protein levels.  This is supported by confocal 
microscopy images showing large accumulations HA-BCA2 in 
transiently transfected cells (Fig. 4-17 and 4-18) and by various 
publications that demonstrate similar patterns of intracellular localisation 
upon overexpression (Mizuno et al. 2003; Miyakawa et al. 2009; 
Nityanandam and Serra-Moreno 2014).   
So called “sticky” proteins tend to form aggregates when expressed in 
recombinant form and can give rise to false identification of interaction 
partners (Feller and Lewitzky 2012).  BCA2 has been linked to a large 
number of proteins with very disparate functions and localisations: from 
Rab7 sorting at the late endosomes to c-myc in the nucleus to tetherin in 
plasma membrane microdomains (Miyakawa et al. 2009; Bacopulos et 
al. 2012; Narita et al. 2012). The majority of these interactions have been 
identified through fusion protein overexpression methods, predominantly 
yeast-two-hybrid and co-immunoprecipitation.  Many proteins do have 
diverse functions and localisations but the large number and diversity of 
purported BCA2 binding partners may be indicative of artefacts 
generated by “stickiness”.   
In light of the findings presented in this chapter, it appears that stable 
overexpression systems may not be the most appropriate method for 
gathering meaningful data about BCA2 function.  However, BCA2 
stability has been shown to be regulated by other proteins.  HR23a, for 
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example, has been shown to inhibit UbcH5 mediated poly-ubiquitination 
of BCA2 which prevents its proteasomal degradation (Bacopulos et al. 
2012).  It may be that to generate a stable overexpressing cell line one or 
more BCA2 regulator proteins/binding partners may need to be co-
expressed to ensure the protein’s stability.  
Transient depletion with siRNA has been used in published BCA2 
experiments and represents a useful tool for interrogating BCA2 function 
(Burger et al. 2005; Smith et al. 2013).  However, as long-term effects of 
depletion have not been explored, stable loss-of-function approaches 
(such as shRNA) would provide valuable data.  An alternative novel 
approach to understanding BCA2 function could be the use of 
transcription activator-like effector nucleases (TALENs) for targeted 
gene disruption.  TALEN technology uses synthetically engineered 
restriction enzymes to cleave DNA at a specific sequence in the promoter 
of a GOI.  The resulting frame-shift mutation prevents downstream 
transcription leading to complete and permanent silencing of the gene 
(Boch 2011).  A TALEN-based approach would have the advantages of 
allowing loss of function phenotypes to be studied over long term culture 
and would facilitate experimentation in live cells. 
Although stable HA-BCA2 expressing clones were generated, the protein 
levels were insufficient and so the cell models were ultimately not 
meaningful alternatives to transient transfection.  In light of this, transient 
BCA2 overexpression was used in further investigations alongside 
transient siRNA studies.   
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Chapter 6: The Effects of BCA2 on EGFR Expression and 
Trafficking 
 
A role for BCA2 in EGFR trafficking has been reported but is 
incompletely described in the literature (Mizuno et al. 2003; Sakane et al. 
2007; Smith et al. 2013).  To address some of the gaps and apparent 
discord in published BCA2 data, experiments were conducted to better 
characterise the effects and function of BCA2 in EGFR trafficking.  
    
6.1 siRNA depletion of BCA2 
In order to carry out loss-of-function studies and to help validate 
immunoblotting techniques, siRNA depletion of BCA2 needed to be 
optimised and used.  Initial attempts to deplete BCA2 were carried out 
using an siRNA sequence as previously described (Burger et al. 2005).  
This sequence was dubbed BCA2-K. MCF-7 cells were incubated at 
37ºC, 5% CO2 in SFM with transfection reagent:siRNA complex.  The 
complex was comprised of Oligofectamine and either BCA2-K siRNA or 
non-targeting GFP control siRNA at final concentrations of 50 nM.  For 
the siRNA sequences see section 2.13.2.1. After four hours incubation 
30% serum media was added to the cells to complete the media and the 
cells were returned to the incubator for 44 hours.  Lysates were collected 
after 48 hrs total siRNA depletion time and Western blotting for BCA2 
was performed.  The immunoblots in Figure 6-1 A demonstrate that the 
initial attempt at BCA2 depletion was unsuccessful.  In parallel with this 
experiment a positive control for the siRNA depletion protocol was 
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performed.  An siRNA sequence for Flotillin-1A (Flot1A) was used as 
the siRNA had been previously validated in the laboratory (Al Soraj et al. 
2012).  Figure 6-1 B shows immunoblots for flotillin-1 and indicates 
significant depletion of the target protein.  This suggested that the failure 
to deplete BCA2 shown in Fig. 6-1 A was less likely to be due to 
methodological error or problems with transfection efficiency.  
Having failed to successfully deplete BCA2, a second siRNA sequence 
was obtained from a pre-designed but unvalidated selection at Eurofins 
MWG Operon.  The MWG siRNA (herein called BCA2-1) was then 
tested alongside the BCA2-K sequence using the same protocol described 
above.  Figure 6-1 C indicates that neither siRNA sequence was able to 
significantly reduce the BCA2 levels in MCF-7 cells, though saturation 
of the BCA2 signal band meant that a subtle reduction in BCA2 levels 
may have been masked.  For the subsequent experiments a slightly 
reduced exposure time and longer SDS-PAGE separation time were used.   
A SMARTpool cocktail of four BCA2 siRNA sequences were then 
purchased from Dharmacon (via Fisher Scientific).  For depletion of 
BCA2 using the SMARTpool siRNAs: MCF-7 cells were incubated in 
complete media for 48 hr with a Dharmafect 1 transfection reagent-
siRNA complex.  The final concentration of the BCA2 siRNA cocktail 
(BCA2-SP) was 25 nM.  Alongside the SMARTpool BCA2 depletion, 
and using the same method, cells were also incubated with non-targeting 
GFP control siRNA and the BCA2-1 siRNA.  The data in Figure 6-1 D 
indicates that the BCA2-SP siRNA was able to deplete BCA2 in MCF-7 
cells as indicated by the reduction in both bands of the BCA2 doublet.  
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This further confirms that both bands observed with this antibody 
represent BCA2.  Quantification of the extent of BCA2 depletion in 
multiple experiments is provided in Figure 6-2.  
 
Figure 6-1: Optimisation of BCA2 siRNA depletion in MCF-7 cells.  Cells were 
treated with siRNAs against BCA2 (A, C and D) and against Flotillin 1 (B). Lysates of 
siRNA treated cells subject to Western blotting for BCA2. A and C) unsuccessful 
attempts to deplete BCA2 siRNA with the BCA2-K and BCA2-1 siRNA sequences. B) 
Positive control for the protocol used in A and C showing successful siRNA depletion 
of Flotillin 1 D) Successful depletion of BCA2 by a SMARTpool siRNA cocktail and 
associated protocol. 
The successful siRNA and Western blotting method demonstrated with 
Flot1A formed the basis of a small collaboration with a visiting scientist 
that has lead to a manuscript currently under review (Pereira et al. 2015, 
accepted).  
6.2 BCA2 depletion and EGFR expression in MCF-7 cells 
BCA2 depletion with the SMARTpool protocol and siRNAs was tested 
further in three-independent experiments, performed in MCF-7 cells as 
previously described.  Lysates of the siRNA treated cells were subjected 
to Western blotting for BCA2.  Immunoblotting for EGFR and transferrin 
receptor (TfR) were also performed to investigate whether changes in 
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BCA2 levels might also affect receptor protein expression levels.  BCA2 
has been shown to alter EGFR trafficking (Mizuno et al. 2003; Smith et 
al. 2013) but effects on levels of EGFR have not been explored.  TfR has 
no known association with BCA2 and served as an indicator of the 
specificity of BCA2’s possible effects on receptor levels. 
As expected EGFR and TfR immunoblotting produced bands at ~180 and 
~95 kDa respectively (Fig. 6-2A). Relative changes in BCA2, EGFR and 
TfR levels were quantified using ImageJ software.  The results were 
statistically analysed with two-tailed, students independent T-tests.  The 
results in Figure 6-2 show that BCA2 expression was reduced by ~80% 
in the BCA2 siRNA treated cells and this reduction was statistically 
significant (p=0.012; Fig. 6-2 B).  In line with MCF-7 literature 
(Davidson et al. 1987) EGFR levels in the non-targeting control lysates 
were very low: Femto™ Maximum Sensitivity ECL substrate was 
required to detect a signal.  EGFR protein levels were significantly 
elevated by 2.5 fold (p=0.040) in the BCA2 depleted cells (Fig. 6-2 C) 
while levels of TfR were unaffected (p=0.451; Fig. 6-2 D).  
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Figure 6-2: Relative levels of BCA2, EGFR and TfR in MCF-7 cells treated with 
BCA2 or non-targeting siRNA.  A) Immunoblots for BCA2 and selected recptors in 
cells treated with BCA2 SMARTpool siRNA or GFP non-targeting control siRNA. B, C 
and D) Relative protein expression was quantified with ImageJ software and normalised 
to tubulin loading control. Results from three independent, single experiments are 
shown. Error bars represent 95% confidence intervals. * statistical significance p ≤ 
0.05. 
6.3 BCA2 overexpression and EGFR expression in MCF-7 cells 
To further investigate the effect of BCA2 on EGFR levels, MCF-7 cells 
were transiently transfected with HA-BCA2 (or mock transfected with an 
empty control vector).  Cell lysates were collected in duplicate from three 
independent experiments and subject to immunoblotting for HA and for 
EGFR (Fig 6-3 A).  EGFR expression was quantified using ImageJ 
software and a student’s independent T-test was performed to determine 
the statistical significance of differences in receptor levels (Fig. 6-3 B). 
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Figure 6-3: Relative EGFR levels in mock transfected and HA-BCA2 
overexpressing MCF-7 cells. A) Immunoblots for HA and EGFR in cells transiently 
transfected with HA-BCA2 or mock transfected with an empty control vector. B) 
Relative protein expression was quantified with ImageJ software and normalised to 
tubulin loading control.  Results from three independent, duplicate experiments are 
shown. Red arrow indicates underloaded lane. Error bars represent 95% confidence 
intervals. * statistical significance p ≤ 0.05 
There was a problem with incorrect loading in the first lane of the gel 
(the first mock transfected replicate of the first experiment).  However, 
since EGFR band densities were quantified relative to the tubulin loading 
control this difference in loading was accounted for in the data analysis.  
There was some intra-experimental variation but overall the data show 
that HA-BCA2 overexpression significantly decreases EGFR levels in 
MCF-7 cells (p=0.028). 
6.4 BCA2 expression in a panel of cell lines 
The relative expression levels of BCA2 and EGFR in selected cell lines 
were measured by Western Blotting. Band intensities were quantified 
using ImageJ software, normalised to tubulin and calculated relative to 
MCF-10A levels (Fig. 6-4).  Endogenous BCA2 expression varied across 
the panel of cell lines that included: immortalised breast epithelial cells 
(MCF-10A), luminal A, ER
+
 breast cancer cells (MCF-7 and T47D), 
triple negative breast cancer (MDA-MB-231) and luminal B, HER2
+ 
breast cancer (BT474).  This panel of cell lines also included the HeLa 
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cervical carcinoma line as EGFR trafficking in these cells is well 
characterised.   
 
Figure 6-4: Immunoblots of endogenous BCA2 and EGFR levels in a panel of cell 
lines.  BCA2 protein levels quantified with ImageJ software, normalised to the tubulin 
loading control and their expression levels were calculated relative to MCF-10A cells. 
Figure 6-4 suggests a possible inverse relationship between BCA2 and 
EGFR expression, though the panel of cell lines tested was not 
sufficiently large to perform meaningful correlation analyses.  T47D and 
MCF-7 cells expressed the highest levels of BCA2 while HeLa expressed 
the lowest.  MDA-MB-231 cells were also found to express relatively 
high levels of BCA2, contrary to some published work on the protein 
(Brahemi et al. 2010) but in line with others (Buac et al. 2013).   
6.5 BCA2 overexpression and EGFR levels in HeLa cells. 
HeLa cells naturally express low quantities of BCA2 (Fig. 6-4) and 
EGFR trafficking in these cells has been extensively studied.  This made 
the HeLa cell line a useful model for studying the effects of BCA2 
overexpression on EGFR in cancer cells.  Research involving further 
BCA2 depletion in HeLa has been previously published and was shown 
to impair ligand induced degradation of both EGFR and c-Met (Smith et 
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al. 2013).  Having already demonstrated that altering BCA2 levels 
influenced total EGFR levels in MCF-7 cells (Fig. 6-2 and 6-3) it was 
hypothesised that HA-BCA2 overexpression in HeLa may produce 
similar effects.  BCA2 induced changes in total EGFR and c-Met levels 
were investigated by Western blotting of HeLa cell lysates that had been 
transfected with HA-tagged BCA2 or mock transfected with an empty 
control vector.  Three independent, duplicate experiments were 
performed and showed a significant decrease in total EGFR (p=0.001) 
and c-Met (p=0.003) levels in the HA-BCA2 overexpressing cells (Fig. 
6-5 A-C). Levels of (non-tyrosine kinase) TfR were also analysed to 
determine whether other cell surface receptors internalised by CME were 
affected by BCA2 overexpression. TrfR expression was not found to be 
significantly altered by BCA2 overexpression (p=0.365.  Figures 6-5 A 
and D). 
  
 310 
 
 
Figure 6-5: Relative levels of EGFR, c-Met and TfR in mock transfected control 
and HA-BCA2 overexpressing HeLa cells.  A) Immunoblots for selected receptors in 
cells transfected with HA-BCA2 or mock transfected with an empty control vector. B) 
Protein expression was quantified with ImageJ software. Results from three 
independent, duplicate experiments are shown. Error bars represent 95% confidence 
intervals. ** statistical significance  p ≤ 0.01. *** statistical significance p ≤ 0.001 
In order to see if the changes in EGFR levels could be visualised in 
individual cells, two different immunofluorescence microscopy (IF) 
experiments were performed: one in which cells were treated with 
20 ng/ml unlabelled EGF to induce EGFR accumulation in early 
endosomes and one in which cells were incubated with fluorescently 
labelled EGF on ice.  Incubating cells with ligand at 4ºC for a sufficient 
time period allows the ligand to bind to surface receptors without 
inducing internalisation.  In the case of EGF, 30 min has been shown to 
be sufficient to allow maximal surface binding (Roepstorff et al. 2009).  
Performing a 4ºC incubation with fluorescently labelled EGF has been 
used in the literature to demonstrate reduced EGFR levels (Wang et al. 
2011). 
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Figure 6-6 A shows the results of double-labelling IF for HA and for 
EGFR.  HA-BCA2 transfected HeLa cells were first stimulated with EGF 
for 15 min in order to uniformly localise the receptor into easily 
detectable vesicles throughout the cells. When immunofluorescence for 
HA and EGFR was then carried out, BCA2 overexpressing cells showed 
a marked reduction in EGFR labelling.  Figure 6-6 B is a confocal 
microscopy image of HA-BCA2 over-expressing HeLa that were serum 
starved for 60 min prior to incubation with EGF Alexa 488 on ice.  After 
30 min incubation with EGF-488 the cells were fixed and IF for HA was 
performed.  Confocal microscopy revealed some heterogeneity in 
labelling of the non-transfected cells, implying that the number of 
receptors on the membrane varies within the normal HeLa cell 
population.  Despite this heterogeneity it was possible to observe a trend 
of reduced EGF-488 binding to the HA-BCA2 overexpressing cells, 
indicative of reduced receptor numbers on the cell surface.  
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Figure 6-6: Confocal microscopy images of EGFR in HA-BCA2 overexpressing 
HeLa cells. HA-BCA2 transfected cells were serum starved for 60 min then either A) 
stimulated with 20 ng/mL EGF for 15 min or B) incubated with EGF Alexa 488 for 
30 min on ice. Cells were then fixed and immunolabelled for HA-BCA2 (red) and for 
EGFR (green) in the cells stimulated with unlabelled EGF. Nuclei were stained blue 
with Hoechst.  Representative images from two independent, duplicate experiments are 
shown. Scale bars = 50 µm. Arrowheads indicate examples of HA-BCA2 transfected 
cells. 
Both Western blotting and IF experiments showed that there was a 
significant decrease (p ≤ 0.05) in EGFR expression in the HA-BCA2 
transfected cells after 24 hrs.  From these initial findings it was not 
possible to determine whether increased degradation or reduced synthesis 
was responsible for the lower levels of EGFR in the HA-BCA2 
overexpressing cells.   
6.6 BCA2 overexpression delays EGFR degradation in HeLa cells 
The binding of EGF to EGFR stimulates internalisation and trafficking of 
the receptor-ligand complex, primarily to the lysosomes for degradation 
(Roepstorff et al. 2009).  BCA2 has been reported to alter ligand induced 
degradation of EGFR though there is some debate as to whether the 
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protein promotes or inhibits degradation of the receptor (Mizuno et al. 
2003; Sakane et al. 2007; Smith et al. 2013).  Having shown that total 
EGFR levels are influenced by changes in BCA2 expression we 
investigated the effect of BCA2 overexpression on EGF stimulated 
trafficking of EGFR (Fig. 6-7 to 6-10).  
HA-BCA2 and mock transfected HeLa cells were serum starved for 60 
min then either serum starved for a further 60 min or stimulated with 20 
ng/mL EGF for the same time period.  Cell lysates were collected in 
three independent, triplicate experiments.  Western blotting was 
performed for EGFR, HA and tubulin (Fig. 6-7 A) and intensities were 
quantified using ImageJ software (Fig. 6-7 B). 
 
Figure 6-7: Immunoblots showing ligand induced EGFR degradation in mock 
transfected control and HA-BCA2 overexpressing HeLa cells. A) HA-BCA2 and 
mock transfected HeLa cells were serum starved for 60 min then stimulated with 
20 ng/ml EGF for 0 or 60 min.  Cell lysates were collected in three independent, 
triplicate experiments.  Western blotting was performed for EGFR and HA.  B) Band 
intensities were quantified using ImageJ software. Error bars represent 95% confidence 
intervals. * statistical significance  p ≤ 0.05. ** statistical significance  p ≤ 0.01.  
Representative blot of a single experiment is shown 
Student’s independent two-tailed t-test of immunoblotting data showed 
that in unstimulated cells (0 EGF) there was a significant reduction in 
EGFR expression in HA-BCA2 overexpressing cells relative to mock 
A B 
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transfected controls (p=0.002).  Conversely, after 60 min significantly 
more EGFR remained in the HA-BCA2 overexpressing cells (p=0.030) 
indicating that EGFR degradation was delayed by BCA2 overexpression. 
Visualising the changes in EGFR degradation was achieved by IF of HA-
BCA2 overexpressing HeLa cells stimulated with EGF.  HA-BCA2 
transfected HeLa were serum starved for 60 min then incubated with 
20 ng/ml EGF for 15, 60 or 120 min as indicated.  The cells were then 
fixed and sequentially immunolabelled for HA and for EGFR before 
imaging with confocal microscopy.  The fluorescence microscopy images 
in Figure 6-8 show that EGF uptake is initially reduced in HA-BCA2 
transfected cells at 15 min versus non-transfected cells.  However, after 
60 and 120 min incubation the EGF persists in the BCA2 overexpressers, 
indicating reduced degradation. At 15 min all non-transfected cells 
displayed fairly uniform EGFR internalisation and prominent fluorescent 
vesicles were observed throughout the cytoplasm. EGFR labelling in the 
HA-BCA2 overexpressing cells was markedly reduced by comparison, in 
line with the reduction in EGFR levels previously seen by Western 
blotting (Figs. 6-5 and 6-7). At the 60 min time point the EGFR in non-
transfected cells was localised to perinuclear vesicles and the 
fluorescence signal had reduced in intensity, suggesting lysosomal 
degradation.  In the BCA2 overexpressing cells however the EGFR 
signal remained visible and the receptor was localised to smaller, diffuse 
cytoplasmic vesicles.  The data supported the Western blotting findings 
shown in Figure 6-7.  By 120 min the EGFR signal had mostly 
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disappeared from the non-transfected cells however in the HA-BCA2 
overexpressers the EGFR persisted. 
 
Figure 6-8: Confocal microscopy images of EGFR trafficking in HA-BCA2 
overexpressing HeLa cells stimulated with 20 ng/ml EGF.  20 ng/mL EGF was 
applied to serum starved, HA-BCA2 transfected cells.  After 15, 60 & 120 min the cells 
were fixed and immunolabelled for HA-BCA2 and EGFR.  Scale bar = 25 µm. 
Arrowheads indicate examples of HA-BCA2 transfected cells. 
The time-course experiment was also repeated with lower concentrations 
of EGF (1 ng/mL) as it has been suggested that EGFR is internalised via 
different mechanisms depending on ligand concentration. Sigismund et 
al. in (2005; 2008; 2013) published data showing that low concentrations 
of EGF (< 3 ng/mL) lead to EGFR internalisation solely by CME.  
However, higher EGF concentrations (> 20 ng/mL) stimulated EGFR 
internalisation by another endocytic pathway (caveolin mediated 
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endocytosis).  In order to see whether ligand concentration altered the 
pattern of EGFR degradation in BCA2 overexpressing cells, the EGFR 
trafficking experiment was repeated as previously described but with a 
lower stimulating EGF concentration (1 ng/ml).  Figure 6-9 shows the 
results of this experiment.  After 15 min incubation with EGF, all non-
transfected HeLa cells had begun to internalise EGFR and the EGFR had 
begun to accumulate in relatively large vesicles throughout the 
cytoplasm.  EGFR labelling in the HA-BCA2 overexpressing cells was 
markedly less intense than in non-transfected cells.  At the 1 hr time 
point the EGFR in non-transfected cells had moved to perinuclear 
vesicles and the fluorescence had diminished in intensity (compared with 
starting levels in these cells).  However, in the BCA2 overexpressing 
cells the EGFR signal persisted.  By 2 hrs the EGFR signal had almost 
entirely disappeared from the non-transfected cells through lysosomal 
degradation.  In the HA-BCA2 overexpressing cells however the EGFR 
signal remained.  
The results trend produced by stimulation with 20 ng/mL EGF (Fig. 6-8) 
and 1 ng/mL EGF (Fig. 6-9) were similar: HA-BCA2 overexpressing 
cells had less EGFR but the EGFR was degraded more slowly in 
response to EGF stimulation.   
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Figure 6-9: Confocal microscopy images of EGFR trafficking in HA-BCA2 
overexpressing HeLa cells stimulated with 1 ng/ml EGF. 1 ng/mL EGF was applied 
to serum starved HA-BCA2 transfected cells.  After 15, 60 & 120 min the cells were 
fixed and immunolabelled for HA-BCA2 and EGFR.  Scale bars = 50 µm. Arrowheads 
indicate examples of HA-BCA2 transfected cells 
6.7 BCA2 overexpression specifically alters EGF trafficking 
Experiments were conducted to determine whether all receptor-ligand 
trafficking by CME was altered by BCA2 overexpression or if the effect 
was specific to EGFR.  Trafficking of fluorescently labelled EGF was 
compared with that of transferrin (Tf) in HA-BCA2 overexpressing 
HeLa.  Transfected cells were incubated for 15, 60 or 120 min with either 
0.5 µg/mL Alexa-488 EGF or 100 nM Alexa-488 Tf.  After incubation 
with the fluorescent ligands the cells were fixed and immunolabelled for 
HA-BCA2 (Fig. 6-10).  
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Tf internalisation was somewhat varied in terms of the quantity and 
intracellular distribution of ligand: even in the non-tranfected population 
there was heterogeneity between cells in the intensity of fluorescence and 
the degree of Tf enrichment in a perinuclear recycling compartment.  
There was little discernible difference between HA-BCA2 
overexpressing cells and non-transfected controls.  EGF internalisation 
on the other hand was delayed in the BCA2 overexpressing HeLa cells as 
indicated by the low EGF signal at the earlier time point.  At the later 
time points (60 and 120 min) the EGF appeared to accumulate in the 
BCA2 overexpressing HeLa cells but appeared to be degraded in the non-
transfected cells.  This mirrors results seen for EGFR by Western blotting 
(Fig. 6-7) and immunofluorescence (Fig. 6-8).   
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Figure 6-10: Confocal microscopy images of Fluorescent EGF and Tf trafficking in 
HA-BCA2 overexpressing HeLa cells. HA-BCA2 transfected cells were incubated 
with 0.5 µg/mL Alexa-488 EGF (A) or 100 nM Alexa-488 Tf (B) for 15, 60 or 120 min 
before being fixed and immunolabelled for HA (red). Nuclei were stained blue with 
Hoechst.  Scale bar = 50 µm. Arrowheads indicate examples of HA-BCA2 transfected 
cells. The red channel for the 120 min time point in the EGF time course was 
overexposed to show all transfected cells.  
The EGF trafficking experiment was also performed in HA-BCA2 
overexpressing MDA-MB-231 cells.  MDA-MB-231 cells express very 
high levels of EGFR so in this cell line trafficking of the EGF-rhodamine 
(EGF-rhd), a less-sensitive fluorescent EGF probe, was examined (Fig. 
6-11).   
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Figure 6-11: Epifluorescence microscopy images of EGF-Rhd trafficking in HA-
BCA2 overexpressing MDA-MB-231 cells.  Cells were transfected with HA-BCA2 
and after 24 hrs were serum starved and incubatated with 0.5  µg/mL of EGF-Rhd. 
Scale bar = 15 µm. 
 
Figure 6-11 demonstrates that in untransfected MDA-MB-231 cells, 
EGF-Rhd was not degraded after 60 min.  The failure of MDA-MB-231 
cells to degrade EGF/EGFR has been previously reported but not 
thoroughly explored or explained (Decker 1988).   
As had been previously observed (Fig. 4-17 and 4-18) the transfection 
efficiency with HA-BCA2 in the MDA-MB-231 cells was very low 
(< 5%) and many of the overexpressing cells had morphological 
indications of poor viability.  The HA-BCA2 overexpressing cells 
appeared to be unable to internalise EGF-Rhd after 15 or 60 min.  
However, there were very few transfected cells to examine and most 
HA-BCA2 overexpressing cells appeared to be in very poor health.  It 
was therefore very difficult to make reliable inferences regarding a direct 
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effect on EGF trafficking and it was decided that no further experiments 
would be conducted with the MDA-MB-231 cell line.   
EGF trafficking experiments were also tested in MCF-7 cells.  However, 
even with very high EGF levels (2 µg/mL) and attempts at pre-binding 
EGF to the membrane on ice, no EGF-488 was detected in the cells or  
on the plasma membrane (data not shown) so this experimental approach 
was not pursued.   
6.8 Subcellular localisation of EGF during delayed internalisation 
in HA-BCA2 overexpressing HeLa cells 
Having established that EGF degradation was delayed/impaired by 
HA-BCA2 overexpression we then wanted to determine which endocytic 
compartment/s the EGF accumulated in.   Following 60 min of serum 
starvation, HA-BCA2 overexpressing HeLa cells were incubated with 
EGF-488 for 15 and 60 min.  After fixation, double-immunofluorescence 
labelling for HA and either EEA1 or LAMP1 was performed.  Figure 6-
12 A shows that at the 15 min time point there was some colocalisation 
between EGF and EEA1.  This indicates that 15 min after internalisation 
a moderate proportion of the EGF-488 was localised to early endosomes 
in untransfected cells.  At this time point the EGF was excluded from the 
late endosomes and lysosomes as no colocalisation was seen between the 
EGF containing vesicles and the LAMP1 positive compartments 
(LAMP1 merge channel insert).  As previously seen (Fig. 6-10) very 
little EGF was internalised by HA-BCA2 overexpressing cells at 15 min, 
making colocalisation experiments difficult to perform.  After 60 min 
EGF incubation (Fig. 6-12 B) EGF-488 accumulated in the early 
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endosomes of HA-BCA2 overexpressing cells but did not appear to have 
reached the late endolysosomal compartments (merge channel inserts). In 
the untransfected cells the EGF-488 signal had largely been lost, 
indicative of degradation. 
 323 
 
 
 324 
 
 
Figure 6-12: Confocal microscopy images showing the endocytic localisation of 
EGF Alexa-488 during trafficking in HA-BCA2 overexpressing HeLa cells.  HA-
BCA2 transfected cells were incubated with 0.5 ug/mL Alexa-488 EGF (green) for 15 
min (A), or 60 min (B) before being fixed and immunolabelled for HA (far red) and 
either EEA1 or LAMP1 (red).  Scale bar = 50 µm. White arrowheads indicate examples 
of HA-BCA2 transfected cells. Blue arrowheads indicate colocalisation. 
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6.9 The effect of BCA2 overexpression on downstream EGFR 
signalling in HeLa cells 
Upon EGF binding and receptor dimerisation, the intracellular domain of 
EGFR becomes phosphorylated.  Activation of EGFR initiates 
downstream activation of oncogenic signalling, predominantly via the 
MAPK and PI3K/Akt pathways.  EGFR is internalised following 
activation and there is a strong body of evidence to indicate that EGFR 
continues actively signalling during endocytosis.  It has been shown that 
disrupting EGFR endocytosis, via mutation of the endocytic protein 
dynamin, inhibits ligand-induced activation of PI3K and ERK1/2 (Vieira 
et al. 1996).  This finding suggested that internalisation of EGFR was 
required for some components of downstream signalling.  In another 
study, signalling proteins were shown to be recruited to endosomes and 
to induce activation of Akt and ERK1/2 in response to EGFR signals 
generated from early endosomes, post-receptor internalisation.  Cells 
were stimulated with EGF in the presence of inhibitors that prevented 
EGFR activation and recycling but allowed internalisation. When the 
inhibitors were then withdrawn after ligand stimulation, endosome 
signalling of EGFR was initiated and lead to downstream stimulation of 
pro-survival signalling pathways (Wang et al. 2002).  
Since EGFR is capable of signalling following internalisation, it was 
hypothesised that BCA2 induced changes in receptor trafficking and 
degradation rate might give rise to differences in downstream signalling 
pathways.  Three independent experiments were performed to test this 
hypothesis.  HA-BCA2 or mock transfected HeLa cells were serum 
starved then stimulated with 20 ng/mL of EGF for 5 or 60 min before 
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lysates were collected on ice.  No baseline phosphorylation of EGFR was 
observed in unstimulated cells (data not shown) so a 5 min pulse of EGF 
was selected as the starting point.  5 min EGF stimulation was sufficient 
to provide a measure of the initial EGFR activation and signalling 
response with no/minimal endocytic downregulation effects on receptor 
levels. The cell lysates were subjected to Western blotting for HA and a 
panel of signalling proteins: phosphorylated EGFR (pEGFR) and total 
EGFR, phosphorylated and total Akt and phosphorylated and total 
ERK1/2.  The complete panel of immunoblots shown in Figure 6-13 A 
was achieved by stripping and re-probing of PVDF membranes cut into 
low and high molecular weight strips. Band intensities were quantified 
using ImageJ software and protein activation was determined by the ratio 
of phosphoprotein to total protein (Fig. 6-13 B, D and E).  Activation of 
EGFR was also examined in terms of the ratio of pEGFR to total Akt.  In 
this instance total Akt acted as a loading control and enabled further 
information to be obtained about the relative proportion of active EGFR 
while taking into account changes in total protein levels (Fig. 6-13 C).   
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Figure 6-13: Immunoblots of EGFR activation and signalling in HA-BCA2 
overexpressing HeLa cells following EGF stimulation. HA-BCA2 and mock 
transfected cells were serum starved for 60 min then stimulated with 20 ng/mL EGF for 
5 or 60 min.  Cell lysates were collected in three independent experiments.  A) Western 
blotting was performed for EGFR, pEGFR, AKT, pAKT, ERK, pERK and HA.  B) 
Band intensities  were quantified using ImageJ software. Error bars represent 95% 
confidence intervals. ** statistical significance  p ≤ 0.01. *** statistical significance 
p ≤ 0.001. 
Quantification and student’s independent two-tailed t-test of the 
immunoblotting data in Figure 6-13 A revealed that after 5 min EGF 
stimulation there was a significant reduction in total EGFR, pEGFR, p 
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Akt and pERK in BCA2 overexpressing HeLa cells compared with mock 
transfected controls (6-13 C, D and E).  Conversely, although there was a 
fall in both transfected and untransfected cells, after 60 min EGF 
stimulation, significantly more EGFR, Akt and ERK remained active in 
those overexpressing BCA2 (Fig. 6-13 B, D and E).  The changes in 
EGFR activation at the early time point were proportional to the 
reduction in total receptor level.  However, after an hour of EGF 
stimulation, the increase in pEGFR activation in HA-BCA2 
overexpressing cells relative to controls was greater than the increase in 
total EGFR i.e. in HA-BCA2 overexpressing cells at 60 min post-EGF 
stimulation, a greater proportion of the remaining EGFR was active.  
6.10 The effect of BCA2 overexpression on HeLa cell viability 
The results from the signalling experiment indicated that BCA2 
overexpression permits a downstream EGFR signalling response of 
reduced magnitude (at 5 min) but prolonged duration (at 60 min) in EGF 
stimulated HeLa cells.  Cell viability studies were conducted to see 
whether these changes in signalling translated to changes in cell 
behaviour.  To this end: 24 hr post-transfection HA-BCA2 or Mock 
transfected HeLa cells were serum starved in SFM for 1 hr.  Cells were 
then either grown in reduced serum media (0.5% FBS) or in media 
supplemented with 10% FBS or 20 ng/ml EGF for 48 hr.  Cell Viabilities 
were analysed by CellTitre-Blue assay.  Three-independent, triplicate 
experiments were conducted and data was processed by converting mean 
fluorescence intensity values to “cell viability” as a percentage of mock-
transfected controls grown in complete media (10% serum).  The data in 
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Fig. 6-14 demonstrate that the viability of HA-BCA2 overexpressing 
cells was significantly less than controls in all tested conditions.  For 
cells grown in complete media (10% serum): viability of the HA-BCA2 
transfected population was ~20% lower than the mock transfected 
controls (viability = 82% and 100% respectively).  Both BCA2 and mock 
transfected cells grown in reduced serum media showed diminished 
viability compared with those grown in 10% serum: viabilities were 46% 
and 53% respectively. The HA-BCA2 overexpressing cells therefore 
demonstrated a ~15% reduction in viability compared with mock 
transfected cells under the same conditions. Mock transfected cells 
grown in media supplemented with 20 ng/mL EGF showed 
approximately equal cell viability with those grown in complete media 
(viability = 96%).  The viability of BCA2 overexpressing cells was 70% 
of the complete media control which equated to a 27% reduction in 
viability compared to the mock transfected cells grown with EGF.   
 
Figure 6-14: The effect of BCA2 overexpression on the viability of transiently 
transfected HeLa cells. HA-BCA2 or Mock transfected cells were either serum-starved 
or grown in the presence of 10% FBS or 20 ng/ml EGF for 48 hr.  Cell Viabilities were 
analysed by CellTitre- Blue
TM
 assay.  Results from three independent, triplicate 
experiments were normalised relative to mock transfected control cells grown in FBS. 
Error bars represent 95% confidence intervals. ** statistical significance p ≤ 0.001.  
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Mitochondria are key regulators of cell viability: they are the source of 
cellular energy and have a critical role in apoptosis via cytochrome c 
release and activation of caspases. Caspases are cysteine proteases that 
are responsible for the degradation of intracellular proteins in apoptosis 
(Gottlieb 2000).  Mitochondria make use of oxidisable substrates 
generated by glycolysis to maintain a proton gradient across their inner 
membrane.  It has been shown that the concentration of external growth 
factors can influence the delivery of oxidisable substrates to the 
mitochondria.  Reduction in interleukin-3 (IL-3) availability leads to a 
loss of mitochrondrial membrane potential and sustained withdrawal 
induces apoptosis.  (Vander Heiden et al. 2001).  Changes in 
mitochondrial morphology associated with a loss in cell viability have 
been associated with growth factor withdrawal.  Reduced IL-3 
concentration causes mitochondria to condense due to reconfiguration of 
the mitochondrial matrix in response to lost membrane potential (Gottlieb 
et al. 2003).   
To see whether the mitochondria of HeLa cells were affected by BCA2 
overexpression, confocal microscopy was performed on HA-BCA2 
transfected cells incubated with the fluorescent mitochondrial probe 
Mitotracker Red and immunolabelled for HA.  Figure 6-15 indicates that 
HA-BCA2 overexpressing cells were associated with a slightly more 
condensed mitochondrial phenotype with some loss of the filamentous 
morphology typically seen in the control cells.  There was no apparent 
decrease in Mitotracker fluorescence intensity that would correspond to a 
loss of membrane potential.  There was however a suggestion that in 
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some transfected cells HA-BCA2 co-localised with the condensed 
mitochondria; this is demonstrated by areas of yellow fluorescence in the 
merge image indicated by arrowheads.  HA-BCA2 colocalisation with 
mitochondria and alteration in mitochondrial structure were not 
previously observed in equivalent experiments performed in MCF-7 cells 
(Fig.  4-21 E). 
 
Figure 6-15: Confocal microscopy image showing mitochondrial morphology and 
colocalisation with HA-BCA2 in transfected HeLa cells.  HA-BCA2 overexpressing 
cells were incubated with Mitotracker red for 30 min prior to fixation.  
Immunofluoresnce labelling for HA (green) was then performed and nuclei were stained 
blue with Hoechst. White arrowheads indicate transfected cells, blue arrowheads 
indicate colocalisation.   Scale bars = 50 µm. 
6.11 The relationship between BCA2 and Rab7 in HeLa cells. 
BCA2 and Rab7 (also called Rab7a) have been shown to interact and in 
agreement with this colocalisation was found between EGFP-Rab7 and 
HA-BCA2 in dual-transfected MCF-7 cells (Fig. 4-26 A).  HeLa were 
simultaneously transfected with HA-BCA2 and either EGFP-tagged 
Rab7a, Rab7b, Rab5 or Rab21.  Rab7b was chosen since this protein has 
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been shown to 50% identity and 65% similarity with Rab7 (Yang et al. 
2004). 
IF for HA was performed and cells were imaged by confocal microscopy. 
The images in Figure 6-16 provide evidence of HA-BCA2 colocalisation 
with all the tested EGFP-Rab proteins.   
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Figure 6-16: Confocal microscopy images of HeLa cells cotransfected with HA-
BCA2 and selected EGFP-tagged Rab proteins. Cells were transiently transfected 
with HA-BCA2 and A) EGFP-Rab7, B) EGFP-Rab7b, C) EGFP-Rab5 and D) EGFP-
Rab21. IF was performed for HA (red) and nuclei were stained blue with Hoechst.  Blue 
arrowheads indicate colocalisation.   Scale bars = 50 µm. 
BCA2 had only previously been shown to co-localise with Rab7 and this 
was deemed specific since BCA2 did not colocalise with Rab4 or Rab8 
(Mizuno et al. 2003).  Since we had not been able to demonstrate 
specificity of HA-BCA2 colocalisation with EGFP-Rab7 we decided to 
 334 
 
examine the effects of HA-BCA2 overexpression on endogenous Rab7.  
In order to achieve this an IF protocol needed to be developed and 
optimised to detect endogenous Rab7.  The optimised IF protocol 
deviated from the standard IF method and mirrored the protocol for anti-
LC3B labelling (Fig. 4-24).  For Rab7 IF: 0.3% Triton-X was in the 
blocking buffer and antibody diluent (which were made with 5% and 3% 
BSA respectively).  The primary antibody incubation step was performed 
overnight in a 12-well plate enclosed in a humidified chamber.  An 
example of the Rab7 immunofluorescence produced in HeLa is shown in 
Figure 6-17. Clusters of Rab7 positive vesicles were apparent in the 
perinuclear region of cells, typical of the morphology and subcellular 
localisation of late endolysosomal structures (Korolchuk et al. 2011).               
 
Figure 6-17: Confocal microscopy images of optimised Rab7 immunofluorescence 
in HeLa cells. Cells were PFA fixed then permeabilised and blocked before being 
immunolabelled overnight at 4ºC with anti-Rab7 antibody (1:100) in diluent buffer. 
Secondary antibody incubation was performed the following day and was preceded and 
followed by PBS washes. Nuclei were stained blue with Hoechst. Scale bars = 25 µm. 
Using the optimised Rab7 IF method, HeLa cells that had been 
transiently transfected with HA-BCA2 were sequentially labelled first for 
Rab7 then for HA.  The Rab7 protocol was followed up to the final wash 
steps then the standard immunofluorescence protocol was followed for 
HA, starting with the blocking step in 2% BSA, 2% FBS.  The doubly-
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labelled cells were eventually imaged by confocal microscopy.  As seen 
previously in Fig. 6-17, the untransfected cells featured perinuclear 
clusters of Rab7 positive vesicles.  In the HA-BCA2 overexpressing cells 
there was a marked reduction Rab7 fluorescence and in the number of the 
Rab7 positive vesicles (Fig. 6-18).  Contrary to expected findings, based 
on the literature (Mizuno et al. 2003) and our EGFP-Rab7 data in HeLa 
(Fig. 6-16A) and in MCF-7 cells (Fig 4-26), there was no evidence of 
colocalisation between HA-BCA2 and Rab7. 
 
Figure 6-18: Confocal microscopy images of Rab7 in HA-BCA2 overexpressing 
HeLa cells. HA-BCA2 overexpressing cells were subject to sequential IF for Rab7 
(green) then HA (Red). Nuclei were stained blue with Hoechst. Arrowheads indicate 
examples of HA-BCA2 transfected cells.  Scale bars = 50 µm. 
Rab proteins are able to associate with intracellular membranes through 
geranylgeranyl lipid groups which are attached to the Rab carboxy 
terminus by Rab geranylgeranyl transferase (RGGT).  This 
post-translational modification is known as prenylation and is critical for 
Rab membrane targeting and association.  Unprenylated Rabs remain 
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cytosolic and are unable to carry out their roles in vesicle docking and 
fusion (Pfeffer and Aivazian 2004).   
The reduction in vesicular Rab7 labelling seen in Figure 6-18 could have 
been the result of the protein remaining cytosolic or be due to a decrease 
in Rab7 protein levels in the transfected cells. Therefore, to help interpret 
the IF data, Western blotting for Rab7 was performed.  Rab7 protein 
levels were examined in HA-BCA2 overexpressing and mock transfected 
HeLa after 5 and 60 min EGF incubation.  Residual lysates from the 
signalling experiment in Figure 6-13 were repurposed for this 
experiment.  The data in Figure 6-19 demonstrates that Rab7 levels were 
unchanged by HA-BCA2 overexpression at either time point with EGF.  
This suggests that the loss of vesicular Rab7 seen by IF was the result of 
altered localisation rather than a reduction in protein level. 
 
Figure 6-19: Immunoblot showing Rab7 levels in mock transfected and HA-BCA2 
overexpressing HeLa following EGF stimulation.  HA-BCA2 and mock transfected 
cells were serum starved for 60 min then stimulated with 20 ng/mL EGF for 5 or 60 
min.  Cell lysates were collected in three independent experiments.  Western blotting 
was performed for HA and Rab7. 
6.12 The effect  of HA-BCA2 overexpression on early and late 
endosomal organelles 
No significant HA-BCA2 induced effects on endolysosomal structure or 
localisation were observed in the EGF trafficking and EEA1/LAMP1 
colocalisation experiment presented in Figure 6-12.  However, given the 
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effect of BCA2 overexpression on Rab7 localisation (Fig. 6-18), early 
and late endosomes/lysosomes were re-examined in unstimulated cells.  
To investigate the effect of BCA2 on these endocytic organelles double-
labelling of HA with EEA1 and with LAMP1 was performed in HA-
BCA2 transfected HeLa.  Results are presented in Figure 6-20. 
 
Figure 6-20: Confocal microscopy images showing the effects of HA-BCA2 
overexpression on early and late endocytic organelles in HeLa cells.  Cells were 
fixed and IF for HA-BCA2 and EEA1 or LAMP1 was performed.  Nuclei were 
counterstained blue with Hoechst. Scale bars = 50 µM. 
Mirroring observations made in EGF stimulated cells (Fig 6-12) no 
significant changes in early endosomes or late endolysosomes were 
detected in the HA-BCA2 overexpressing HeLa cells.   
6.13 Discussion 
The accumulated data for this thesis suggest that BCA2 has an important 
role in breast cancer with both positive and negative contributions and 
can have a regulatory function in the trafficking and expression of EGFR 
impacting on signalling and viability of cancer cells.   
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Correlation between BCA2 and ER expression has been described in the 
literature (Burger et al. 2005), and Chapter 3 here, and transcriptional 
regulation of BCA2 by the ER has been demonstrated (Kona et al. 2012).  
To some extent the correlation between expression of the two proteins is 
reflected in the findings presented in Figure 6-4.  The highest, luminal A 
ER
+
 cell lines MCF-7 and T47D showed the highest BCA2 expression, 
however the ER
-
 cell line MDA-MB-231 also had relatively high levels.  
The results suggest that while the ER may have a role in BCA2 
regulation it is not obligate for expression.  After HeLa, the MCF-10A 
breast epithelial cell line had the next lowest levels of BCA2.  This is in 
keeping with the in silico findings that BCA2 expression increases with 
increasing malignant transformation of breast epithelial cells (Fig. 3-6) 
and also the lack of ER in this cell line.  The HER2
+
 BT474 cell line also 
showed relatively low BCA2 expression which is in line with in silico 
findings that BCA2 expression is reduced by HER2 expression (Fig. 3-
11).   BCA2 expression at the protein level in the breast cell lines 
correlated with mRNA levels examined in Figure 3-4.  The exception 
was the T47D cell line which appeared to express higher BCA2 levels 
than MCF-7s at the protein level but not the mRNA level.  This might 
reflect a difference in BCA2 regulation between the two cell lines that 
may be specific for BCA2 or relate to global differences in proteasomal 
degradation of ubiquitinated proteins.           
The data demonstrating that BCA2 overexpression reduces total levels of 
EGFR (Fig. 6-3 and 6-5) while inhibiting the receptors degradation (Fig. 
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6-7 to 6-13) initially appears to be contradictory.  However, there are a 
number of possible theories that could reconcile this apparent paradox.   
Others have shown that BCA2 interacts with Rab7 and supporting this 
we find co-localisation between EGFP-Rab7 and HA-BCA2 when they 
are co-expressed in MCF-7 (Fig. 4-26 A) and in HeLa (Fig. 6-16 A).  
Contrary to this however we do not see colocalisation between 
HA-BCA2 and endogenous Rab7; rather HA-BCA2 overexpression 
appears to induce a failure of Rab7 membrane association (Fig. 6-18 and 
6-19).  BCA2’s interaction with Rab7 may help to explain these 
seemingly disparate findings with regards to EGFR levels and 
trafficking.  The interaction between the GTP-bound (active) form of 
Rab7 and BCA2 has previously been shown to inhibit EGFR degradation 
(Mizuno et al. 2003).  In other studies, siRNA depletion of Rab7 has 
been shown to inhibit lysosomal degradation of EGFR (Vanlandingham 
and Ceresa 2009).  The strongest hypothesis to explain the data presented 
in this thesis is that overexpressed BCA2 sequesters Rab7 and prevents 
the GTPase from carrying out its endosomal function.  In this manner 
BCA2 overexpression produces an effect analogous to Rab7 depletion 
i.e. it induces a functional Rab7 depletion.  Such an effect is not 
uncommon with transient overexpression approaches: in a systematic 
study of overexpression systems ~23% of the phenotypes produced by 
overexpression were attributed to disruption of a stoichometric balance 
between interacting proteins (Sopko et al. 2006; Prelich 2012).  
Disruption of a stoichometric balance between BCA2 and its interactors 
may include effects on BCA2 regulation by deubiqutinating enzymes 
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(DUBs).  As their name suggests, DUBs are responsible for the cleavage 
of ubiquitin moieties from Ub-tagged proteins.  A BCA2 specific DUB 
has not been identified but it is likely that BCA2 has a partner DUB since 
they are known to associate with E3 ligases (Wilkinson 2009).   
Other literature supporting the “functional Rab7 depletion” hypothesis 
are the findings from a study which showed that cellular transfection with 
Rab7 siRNA led to a concomitant decrease in total EGFR levels and an 
inhibition of EGFR degradation.  In this study it was shown that Rab7 
depletion rendered EGFR (and HER2) more susceptible to proteasome 
mediated degradation (Wang et al. 2011).  Applying this to the 
“functional Rab7 depletion” hypothesis: overexpressed BCA2 may 
competitively inhibit Rab7’s function at the late endosome thereby 
inhibiting lysosomal degradation of EGFR while potentially enhancing 
its proteasomal degradation.   Counter to the Rab7 hypothesis is the data 
in Figure 6-20 showing that late endolysosomes are not significantly 
altered by HA-BCA2 overexpression.  Rab7 depletion with siRNA has 
been associated with the enlargement of late endosomes  
(Vanlandingham and Ceresa 2009).  However, no late endosomal 
enlargement was demonstrated in Figure 6-20 so further studies are 
required to confirm or refute the Rab7 hypothesis.  One possibly 
informative experiment would be to conduct an autophagy induction 
experiment with serum starvation in HA-BCA2 overexpressing cells.  If 
Rab7 function is impaired then autophagosome maturation will be 
inhibited and this would manifest as a reduction in the number of LC3B 
positive structures (Jäger et al. 2004).  Also informative would be to 
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examine the effects of BCA2 on EGFR biosynthesis by carrying out RT-
PCR experiments with/without BCA2 depletion and HA-BCA2 
overexpression to determine whether EGFR mRNA levels were altered in 
addition to the protein level changes (Fig. 6-2, 6-3 and 6-5).  
Investigations of EGFR protein levels following HA-BCA2 expression in 
the presence of the proteasome inhibitor MG132 would also provide 
information regarding BCA2’s influence on regulation of the receptor. 
An alternative theory is that the inhibition of EGFR degradation arises 
because of the reduced EGFR levels (which may be reduced as result of 
enhanced proteasomal degradation or an alternative mechanism).  Having 
fewer receptors on the cell surface reduces the chance of ligand binding 
and receptor dimerisation.  This would in turn delay the internalisation 
and degradation of EGFR.  It has been shown that reducing EGFR levels 
by RNAi leads to reduced dimerisation, ligand binding and activation 
(Chung et al. 2010).  The effects of reduced EGFR levels on receptor 
endocytosis and endosomal signalling however have not been directly 
examined.  One study demonstrated that decreased EGFR 
phosphorylation, prevents c-Cbl from associating with the receptor which 
in turn leads to reduced EGFR polyubiquitination and internalisation 
(Schmidt et al. 2003).   The data in Figure 6-13 however show that the 
reduction in EGFR activity in HA-BCA2 overexpressing cells is 
proportional to the reduction in total receptor levels.  The findings 
reported by Schmitt et al. were based on scenarios where EGFR 
phosphorylation was reduced by chemical inhibition or due to mutations 
in the intracellular domain i.e. total receptor levels were conserved but 
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the proportion of active receptors was reduced.  It cannot therefore be 
inferred from these findings that the reduction in EGFR activity 
demonstrated in Fig. 6-13 could account for changes in EGFR 
degradation rate. 
Another possible theory to explain the data presented in this chapter is 
that BCA2 overexpression leads to reduced degradation of EGFR and 
that intracellular accumulation of the receptor triggers apoptosis.  In 2012 
(Rush et al.) demonstrated that accumulation of EGFR in the early 
endosome, after blockade of late endocytic transport, gave rise to EGF 
induced apoptosis in HeLa cells.  Apoptotic activation of caspase-3 has 
been shown to lead to direct enzymatic cleavage of EGFR which could 
then account for the reduced receptor levels (He et al. 2006).  Potentially 
supporting this theory are the observations that: a) transfection of BCA2 
into the EGFR overexpressing cell line MDA-MB-231 appears to be 
cytotoxic (Figs. 4-17 and 4-18).  B) Overexpression of BCA2 in HeLa 
leads to decreased cell viability and disruption of the mitochondria (Figs. 
6-14 and 6-15).  C) Overexpression of BCA2 in (caspase-3-deficient) 
MCF-7 cells does not appear to affect the mitochondria of the cells (Fig. 
4-21 E) and unlike in MDA-MB-231 cells, HA-BCA2 transfected MCF-
7 cells appear to retain morphological integrity (Fig. 4-17 and 4-18).    
BCA2 may also be triggering apoptosis by an unknown mechanism as 
caspase 3-mediated cleavage of EGFR during apoptosis has also been 
shown to be associated with a reduced rate of receptor degradation (He et 
al. 2005). 
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BCA2 has many putative interaction partners and it is not uncommon for 
proteins that have a variety of partners to have multiple, antagonistic 
functions.  An example of such a protein is the E3 ligase Mdm2.  Mdm2 
downregulates the so called “guardian of the genome” p53 and its role as 
an oncogene is well documented.  There is however increasing evidence 
that through its other binding partners Mdm2 may have a separate role as 
a tumour suppressor (Manfredi 2010).  There may be a threshold 
expression level for BCA2 and either positive or negative deviations 
from this cause disruptions in functional pathways that produce similar 
global cellular effects.  For example, Figure 6-14 demonstrates that 
BCA2 overexpression decreases cell viability while others have shown 
that viability is reduced by BCA2 depletion  (Wang et al. 2013). Such 
findings are not paradoxical when viewed in the context of BCA2 having 
multiple cellular functions and/or interaction partners and in light of the 
collective evidence of context dependent BCA2 effects.    
The findings that BCA2 overexpression inhibits EGFR trafficking (Figs. 
6-7 to 6-13) are directly supported by some literature (Mizuno et al. 
2003) but appear to be contrary to others (Smith et al. 2013). 
In research published by (Sakane et al.)  in 2007, BCA2 overexpression 
was suggested to accelerate ligand induced EGFR degradation.  
Interestingly, analysis of the Western blotting data from this study 
reveals that in the unstimulated cells the total amount of EGFR was 
lower in the BCA2 overexpressing cells.  Quantification and statistical 
analysis were not performed/presented in the paper but using ImageJ 
software it was possible to roughly quantify the changes in EGFR.  
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Quantification suggested that BCA2 overexpression was associated with 
a reduction in total EGFR levels of ~25%, an observation not described 
in the publication but in keeping with the findings presented in Figures 6-
3 and 6-5.  Overexpression of BCA2 in the Sakane study appeared to 
enhance the degradation of EGFR by ~30%.   
The HEK293 cell line used in the Sakane study did not appear to readily 
degrade EGFR in response to EGF stimulation: after three hours the 
receptor levels had still only been reduced to 80% in the mock 
transfected control cells.  When compared with the large and rapid 
decrease in EGFR levels in HeLa cells shown in Figure 6-7 it is apparent 
that the two cell lines have very different receptor trafficking kinetics.  
HEK293 cells do not naturally express detectable levels of EGFR so in 
order to conduct the degradation experiment, EGFR and ubiquitin had to 
be transfected into the cells along with BCA2.  This is a potentially 
important methodological difference between the investigations 
conducted in this thesis and those performed by Sakane et al.   
Cells that do not express or have very low levels of a receptor may also 
lack other proteins that are needed for its regulation and function.  In 
another experiment from the Sakane study, HEK293 cells were 
transfected with c-Cbl in addition to EGFR, ubiquitin and BCA2 or a 
vector control.   A RING domain mutant of BCA2 was also examined as 
part of these experiments.  c-Cbl expression greatly accelerated EGFR 
degradation in the control cells compared with the earlier experiment 
performed in its absence.  After 1 hr EGF stimulation, receptor levels in 
the c-Cbl co-transfected cells were reduced to 18% of their starting 
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amount, significantly different from the drop to 80% that occurred 
without c-Cbl.   Overexpression of BCA2 or the RING mutant in the 
presence of c-Cbl delayed receptor degradation compared with the 
control but the effect was more pronounced with the RING mutant.  
In the experimental conditions that more closely mimic those of normal 
EGFR endocytosis i.e. in the presence of c-Cbl, EGFR degradation was 
shown to be inhibited by BCA2 overexpression, as here.  The fact that 
the RING mutant produced a greater inhibitory effect than wild-type 
BCA2 is interesting and can potentially be explained by its interaction 
with Rab7.  GTP-bound Rab7 interacts with the N-terminus of BCA2, a 
region of the protein that would potentially remain functionally intact in a 
RING mutant.  Truncation mutants of BCA2 have been shown to retain 
their affinity for Rab7 in vitro (Mizuno et al. 2003).  What the RING 
mutant lacks is the ability to autoubiquinate (Amemiya et al. 2008) so 
intracellular levels of this protein could be much higher than the wild-
type protein would reach.  If the Rab7 interacting domain was still 
present and functional this could explain Sakane et al.’s findings that 
RING mutant BCA2 has a more potent inhibitory effect on EGFR 
degradation than the wild-type protein. 
As with many EGFR degradation experiments, the cells in the Sakane 
study were serum starved for a long duration (24 hr) prior to EGF 
stimulation.  Extended serum starvation times are often used in research 
as a method for cell synchronisation.  However despite its wide usage 
there is relatively little supporting evidence for serum starvation being an 
effective means of synchronising cells (Cooper 2003).  Serum starvation 
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has also been shown to induce irregular and inconsistent signalling 
responses in different cell lines and experimental conditions (Pirkmajer 
and Chibalin 2011).  For our experiments, serum starvation time was 
restricted to one hour in order to limit possible confounding experimental 
effects.  For similar reasons we also refrained from using cyclohexamide 
(CHX) in our experiments.  Although it is common to use CHX to inhibit 
protein synthesis when performing receptor degradation assays, the drug 
has been shown to induce EGFR internalisation in a ligand independent 
manner (Oksvold et al. 2012). To minimise the potential for added 
complexity and error CHX was omitted from our experiments. 
The data in Fig. 6-16 raise some potentially important methodological 
questions about the validity of performing BCA2 and EGFP-Rab protein 
co-transfection.  There was no apparent specificity of BCA2 for Rab7 
compared with the other three EGFP-Rab proteins that were tested.  
Although Rab7a and Rab7b share a high level of sequence identity (Yang 
et al. 2004) the interaction properties of the two proteins have been 
shown to be very different (Stein et al. 2012).  This study also 
demonstrated that Rab5 and Rab21 are dissimilar from each other and 
from Rab7a and -b in terms of their electrostatic charge.  These findings 
would appear to reduce the likelihood that the Rab proteins share a 
common interaction partner in BCA2.  Direct protein binding however is 
not obligate for co-localisation.  For example, a study has demonstrated 
endosomal colocalisation of Rab5 and Rab7 in compartments thought to 
denote intermediary stages of early to late endosomal transport 
(Vonderheit and Helenius 2005) 
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Based on the findings in Figure 6-16, dual overexpression of BCA2 and 
EGFP-Rab proteins may not be an appropriate experimental approach for 
interrogating BCA2 function.  However, Mizuno et al. showed 
colocalisation between BCA2 and EGFP-Rab7 but not with EGFP-Rabs 
4 and 8 so some specificity has been previously demonstrated.  Further 
experimental work to investigate the suitability of the co-transfection 
approach should therefore include EGFP-Rab4 and –Rab8 as putative 
negative controls.   
The BCA2 research that invites the closest comparison and is potentially 
the most directly applicable to the work presented in this chapter is that 
conducted by (Smith et al.) in 2013.  These studies also examined the 
relationship between BCA2 and EGFR trafficking using a HeLa cell 
model. Using a BCA2 depletion approach the group were able to 
demonstrate that reduction in BCA2 levels delays the degradation of 
EGFR.  This was the first study to then examine EGFR activation and 
signalling and it was shown that BCA2 depletion lead to increased EGFR 
phosphorylation between 30 and 45 min following EGF stimulation. This 
was mirrored by an increased association between EGFR and the 
signalling protein SHC1 at these time points.  We extend this work by 
showing novel downstream signalling effects, induced in a BCA2 
overexpression system (Fig. 6-13). Our findings indicate that BCA2 
overexpression leads to an initially smaller but ultimately more 
prolonged signalling response in MAPK (ERK1/2) and Akt pathways.  
The consequences of such a signalling pattern are not fully resolved, 
though it may well be the cause of the reduced cell viability seen in 
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Figure 6-14.   There is very little in the literature about how signal 
magnitude and duration interact to control cell behaviour.  Proliferation 
of fibroblasts is associated with sustained ERK1/2 activation or with 
weak activation, and fibroblast differentiation is associated with transient 
or strong ERK1/2 activity (Ebisuya et al. 2005).  It might be a reasonable 
hypothesis to suggest that since weaker or more prolonged ERK1/2 
activity are both associated with proliferation that enhanced growth 
would be the ultimate consequence of the combined signalling properties 
but this does not have a strong evidence base and would need to be 
tested.  Fundamentally this is the basis of a computational question.  Is a 
signal of half the size but twice the duration the same in the cellular 
context?  We can consider this question in the context of two very 
simplified signalling scenarios.  Figure 6-21 A shows a scenario with a 
signal of large size but short duration and Figure 6-21 B shows the result 
of a signal of half the strength and twice the duration.  It can be seen that 
in terms of overall signalling output that there no difference between 
these two cases: the net result is that 4 signals are generated in each 
instance.  This model quickly becomes much more complicated when 
you consider the multitude of signalling proteins and cell context.  
Further complexity is added if the spatial component of signalling is 
taken into consideration.  As EGFR moves through the cell via 
endocytosis its active cytoplasmic tail remains exposed to the cytoplasm 
and so is exposed to a different pallet of substrates which coordinate 
different downstream effects (Burke et al. 2001).  The subcellular 
localisation of EGFR has been shown to differentially regulate the 
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growth and survival of MDA-MB-468 breast cancer cells which 
overexpress the receptor (Hyatt and Ceresa 2008).   
 
Figure 6-21:  Simplified computational signalling illustration. A) Scenario with a 
signal of twice the size but half the duration. B) Scenario with a signal of half the size 
and twice the duration 
Trying to interpret the possible cellular consequence of a signal of 
smaller size and altered duration is clearly not a simple matter but it 
presents an opportunity for future collaborations with systems biologists.  
Results of experiments run with some computational models of EGFR 
trafficking have been published and potentially have implications for this 
project, for example (Pérez-Jiménez and Romero-Campero 2006).  
Changes in EGF concentration in this model were shown to alter EGFR 
phosphorylation but had relatively little impact on downstream MEK 
activation.  This is actually not surprising given that the lowest 
concentration of EGF tested in the model was 100 nM which is still 
equates to a large excess of ligand compared to receptor number.  Unlike 
EGF concentration, alterations in receptor numbers profoundly impacted 
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on MEK phosphorylation.  This supports our findings that in the EGFR 
reduced HA-BCA2 overexpressing cells downstream signalling is 
reduced (Fig. 6-13).  It also highlights a limitation of the model that does 
not take into account changes in duration or receptor localisation.       
Given the interaction between BCA2 and Rab7 we hypothesise an inter-
related role for these two proteins in EGFR regulation and trafficking. 
The findings present an interesting insight into BCA2-mediated EGFR 
regulation through altered endocytosis. 
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Chapter 7: General Discussion 
Since BCA2 was first discovered in 2003, interest in the protein 
(originally named Rabring7) has been steadily increasing.  As the pool of 
BCA2 research has expanded so too has the apparent conflict in the 
literature surrounding the protein’s role in receptor trafficking and breast 
cancer.  In addition to gaining more functional information on BCA2 and 
thus extending the research field, this project aimed to address and 
explain some of the disparities in the existing BCA2 literature.  In these 
respects the project has been fairly successful.   
Meeting the aim of describing BCA2’s subcellular localisation was 
impinged by the limited availability of reliable commercial antibody 
resources.  Extensive preliminary optimisation and validation work for 
BCA2 and endosome markers (including Rab7) needed to be carried out 
before basic experiments could be performed.  However, the 
development of reliable methods of determining the subcellular 
distribution of endocytic proteins such as EEA1 and LAMP2 in addition 
to robust siRNA and Western blotting methods led to two small 
collaborations.  The collaborations resulted in one publication (Webber et 
al. 2015) and a manuscript that is currently under review (Pereira et al. 
2015, accepted).  
Ultimately it was through the use of a transient overexpression system 
and confocal microscopy techniques that the most detailed images of 
BCA2 localisation were produced.  In line with published findings 
(Mizuno et al. 2003) evidence of colocalisation between overexpressed 
BCA2 and Rab7 was obtained via co-transfection of epitope tagged 
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proteins.  However, diverging/extending from previous reports, 
BCA2:Rab colocalisation was not found to be unique to Rab7.  Co-
transfection results also demonstrated BCA2 colocalisation with EGFP 
tagged Rab5, Rab21 and Rab7b.  Further experiments would need to be 
conducted to ascertain whether the colocalisation was a universal 
phenomenon for all EGFP-Rab proteins and therefore, potentially, an 
artefact of the method.  Ideally further experiments would include Rab4 
and Rab8 which were originally shown not to colocalise with BCA2 
(Mizuno et al. 2003).  A Rab protein that has not been shown to associate 
with endocytic pathways such as Rab1 could also be incorporated into 
co-transfection studies to serve as a negative control for BCA2 
colocalisation.  
It had been previously reported that BCA2 was recruited to late 
endosomes and lysosomes by Rab7 (Mizuno et al. 2003).  However, in 
dual IF experiments conducted as part of this project, no colocalisation 
was observed between BCA2 and the late endolysosomal markers 
LAMP1 or (endogenous) Rab7.   Furthermore, it was observed that 
endogenous Rab7 failed to localise to late endosomes and lysosomes in 
HA-BCA2 overexpressing cells.  This novel demonstration of a BCA2-
mediated effect on the endolysosomal recruitment of Rab7 provides a 
possible mechanistic explanation for the protein’s effects on receptor 
trafficking.  This data therefore helped to meet the second aim of the 
project: to further characterise the role of BCA2 in receptor endocytosis.   
The role of BCA2 in receptor endocytosis was predominately examined 
in Chapter 6 wherein the data extended the existing body of knowledge 
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(and fulfilled the second project aim) with a few key findings.  BCA2 
overexpression was shown to reduce total EGFR levels and to delay 
internalisation and degradation of the receptor and EGF ligand.  These 
effects were shown to have a degree of specificity as TfR levels and Tf 
trafficking were not significantly altered by BCA2 overexpression.  The 
reduction in total EGFR levels and delay in ligand induced degradation 
was shown to be associated with a downstream signalling response that 
was tempered in size but prolonged in duration.  It was demonstrated that 
protein levels of Rab7 were unaltered by HA-BCA2 overexpression and 
as previously described in this thesis the overexpression led to a failure 
of Rab7 membrane association.   
The effects of BCA2 overexpression on cell viability were novel findings 
and as discussed in Chapter 6, have potential impact as either a cause or 
consequence of BCA2’s role in EGFR trafficking.  A network of the 
possible mechanisms linking BCA2 overexpression with cell viability 
and receptor trafficking is presented in Figure 7-1 which summaries 
different hypotheses discussed in Chapter 6. 
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Figure 7-1: Summary of the possible mechanisms to explain BCA2 mediated 
effects on cell survival and on total receptor levels and trafficking.  Novel or 
confirmatory BCA2 findings from this thesis are underlined and in bold. 
The investigations into the endocytic function of BCA2 formed the basis 
of an abstract that was presented as a poster at the 23
rd
 European Cancer 
Research Association Congress (Wymant et al. 2014).  During the 
conference there was particular interest in the downstream signalling data 
and the concept of magnitude versus duration of signalling.  There is 
potential for further work to explore this principle more generically i.e. to 
investigate how receptor number affects trafficking and downstream 
responses.  Novel and potentially impactful investigations could be made 
into the cellular responses induced by different ratios of signalling 
magnitude and duration.  Collaboration with systems biologists would 
greatly enrich such studies. 
Novel findings from the in silico MEM and DAVID analyses 
demonstrated that BCA2 expression was significantly correlated with a 
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number of membrane trafficking proteins. Notable coexpressed genes 
included VPS37A (a component of the ESCRT-1 complex), VAMP7 a 
regulator of late endolysosomal fusion and AP2B1 a critical adaptor 
subunit for CME.  The list of ontologically related and co-expressed 
genes warrants further investigation in terms of possible BCA2 binding 
partners and effectors.  The possibility of a BCA2-mediated impact on 
Golgi trafficking should also be explored in light of the protein’s 
association with Rab7 and the number of co-expressed proteins with 
known or putative functions at the Golgi apparatus (Rojas et al. 2008). 
The first aim of the project was to investigate the role of BCA2 in breast 
cancer development, progression and prognosis; in these respects the 
project was moderately successful.  A limitation to meeting this aim 
more fully was that in vitro work primarily focused on receptor 
trafficking using the (well-characterised) HeLa cell line as a model for 
EGFR endocytosis.  Once a clearer mechanism for BCA2’s effects on 
EGFR trafficking has been elucidated by further work, breast cancer cell 
line models should then be examined.  In doing so it may then be 
determined if/how the BCA2-mediated effects on receptor trafficking 
apply in breast cancer.  Overexpression of BCA2 in a cellular model of 
normal breast epithelium, such as the MCF-10A cell line, would enable 
exploration of a potential role for BCA2 in breast cancer development.  
The possible involvement of BCA2 in mammary carcinogenesis was 
suggested by in silco data showing BCA2 upregulation in a putative stem 
cell population of breast epithelial cells and progressive BCA2 
upregulation in an increasingly transformed breast epithelial cell line.   
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Other promising findings to emerge from the in silico work that present 
opportunities for in vitro study were results showing that overexpression 
of HER2 and EGFR/oncogenic signalling reduced BCA2 levels.  In light 
of the effects of BCA2 on EGFR trafficking, it may be the case that 
BCA2 and HER2 and EGFR/Ras are involved in a mutually regulatory 
interaction/network.  Further studies would ideally extend to examining 
the BCA2’s effects on the total levels of HER2 in addition to receptor 
internalisation, trafficking and downstream signalling.  Methods to 
determine expression of this oncoprotein have now been developed in the 
laboratory. 
The most successful component of the in silico work in terms of meeting 
the first project aim, was the survival analysis.  Increased BCA2 was 
shown to be associated with better relapse free survival across all breast 
cancers and in ER+, high grade and lymph node positive disease.  This 
data may reflect a tumour suppressive function of BCA2 and is in 
keeping with the observed effects on cell viability and on EGFR and 
c-Met levels presented in Chapter 6.  How these findings fit in with some 
of the pro-proliferation and invasion effects that BCA2 has previously 
exhibited remains to be discovered (Burger et al. 2005; Amemiya et al. 
2008).  How these results link with in silico findings that BCA2 levels 
appear to be enriched in stem cells and to increase with increasing 
transformation is also unknown.  Understanding this apparent conflict 
will be essential for determining whether BCA2 is a potential therapeutic 
target in breast cancer and is something that should be prioritised in 
future BCA2 studies.   
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Context-dependency of BCA2 on survival was highlighted by the 
evidence that high BCA2 levels were associated with poorer prognosis in 
HER2+ breast cancers.  Interpretation of survival analyses in luminal B 
breast cancer was complicated as KMPlotter and GOBO data presented 
slightly differing relationships between BCA2 expression and relapse 
free survival.  In KMPlotter the data showed clearly that high BCA2 
expression adversely impinged on luminal B patient survival.  However, 
GOBO data suggested a more complex picture whereby moderate BCA2 
expression was associated with better chance of survival but low and 
high expressing breast cancers had poorer prognosis.  This may relate to 
the complexity of the luminal B disease as a single classification for 
potentially quite different types of breast cancer, particularly in terms of 
HER2 expression.  Evidence of context dependency of BCA2 extended 
to in vitro studies where overexpression of the protein induced differing 
cellular effects, particularly striking were effects (or lack thereof) in 
mitochondria between MCF-7 and HeLa and differences in viability 
between MCF-7 and MDA-MB-231 cells. 
An important aspect of this project has been in highlighting some 
potentially significant issues involving and affecting BCA2 research 
methods.  The first problem is that of the intracellular heterogeneity that 
arises from BCA2 overexpression.  Transient transfection with 
HA-BCA2 did not produce uniform patterns of protein expression and 
localisation in all transfected cells.  It may be that BCA2s localisation is 
naturally heterogeneous and depends on factors such as cell confluency 
and stage of cell cycle.  However, the issue of heterogeneity does raise 
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some questions about the validity of this approach for interrogating 
BCA2 localisation and/or function.   
One possible limitation of the work in this thesis is that the effects of 
nuclear versus cytoplasmic BCA2 were not examined.  Localisation in 
the nucleus was not observed for endogenous or overexpressed BCA2 
but how and why this is the case is not clear.  How the data therefore 
relate to publications in which nuclear BCA2 has been examined is also 
not certain.  Further studies are required to determine whether nuclear 
BCA2 localisation (or lack thereof) has a real physiological/pathological 
basis, or if the presence (or absence) of nuclear detection is an artefact of 
the method by which BCA2 localisation is interrogated. 
Another possible factor that needs further consideration and investigation 
is that of BCA2 aggregate formation.  Despite heterogeneity, the most 
commonly seen patterns of BCA2 localisation were: large perinuclear 
accumulations and cytoplasmic inclusions that resembled large vesicles.  
Whether the structures were true vesicles, i.e. membrane-bound, was not 
determined so they are intentionally not defined as such.  The localisation 
patterns seen with BCA2 may indicate a natural tendency for the protein 
to cluster and/or aggregate but they may also be an artefact of 
overexpression.  Protein aggregation is known to cause cytotoxicity 
(Bucciantini et al. 2002) and is a known limitation of transient 
transfection as research technique (Feller and Lewitzky 2012).  
Misfolding and aggregation of ubiqutinated proteins is a hallmark of a 
number of neurodegenerative diseases and is thought to potentially be of 
importance in cancer (Bence et al. 2001; Rodriguez-Gonzalez et al. 
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2008).  Aggresomes are cytoplasmic inclusions into which aggregates of 
ubiquinated, often misfolded, proteins are deposited.  Aggresomes are 
believed to be form when the production rate of aggregation-prone 
proteins exceeds proteasome capacity (Johnston et al. 1998).  
Overexpression of BCA2 may lead to aggresome formation for a number 
of reasons: a natural propensity of the native protein to aggregate or 
insufficient chaperone availability for the high levels of protein 
expression, leading to BCA2 misfolding and aggregation.  Aggregation 
may be a side-effect of the HA epitope tag and/or possibly the result of 
the H70L mutation in the HA-BCA2 sequence.  It is of critical 
importance to determine whether a) protein aggregation definitely occurs 
and b) whether it the aggregation is a physiological phenomenon, an 
artefact of BCA2 overexpression generally or a specific issue for the HA-
BCA2 sequence used in this project and by (Miyakawa et al. 2009).  
Further work will be carried out using three different plasmids: one 
containing a sequence corrected HA-BCA2 insert (L70H) and one 
(sequence corrected) plasmid in which the HA-tag sequence has been 
removed.  Experiments will also be conducted using the EGFP-BCA2 
plasmid that was synthesised as part of this project.  The EGFP-BCA2 
plasmid has also been sequence corrected and the protein has now been 
brought into frame with the tag.  Initial research will focus on protein 
half-life and localisation and will then extend to cover effects on receptor 
trafficking, signalling and cell survival.       
The demonstration of endogenously occurring, BCA2 positive 
accumulations in a small subpopulation of MCF-7 cells was a novel 
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finding of this project.  The similarity in labelling compared with HA-
BCA2 provides confidence that the localisation produced by BCA2 
overexpression has a biological basis but does not however rule out 
aggresome formation.  Further experiments to try and characterise the 
subpopulation of MCF-7 cells and their intracellular BCA2 positive 
structures would potentially yield novel and informative data for BCA2 
function.  Initial work would involve MG132 treatment to try and 
enhance BCA2 levels and increase the number of visible structures.  
Colocalisation experiments with endocytic marker proteins would also be 
performed and finally other breast cancer cell lines would be examined to 
determine whether or not the subpopulation was unique to MCF-7 cells. 
Although many questions remain to be answered, this project has 
achieved a critical exploration of BCA2 research methodology. This 
thesis provides an interesting insight into the role of BCA2 in receptor 
endocytosis and breast cancer, including the likely importance of cellular 
context in understanding the impact of this interesting protein. 
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Appendix A: Products and suppliers 
 
Biorad (Hemel Hempstead, UK): 
- Precision plus protein dual colour standards (#161-0374) 
- Clarity, Western ECL substrate (#170-5060) 
- Agarose (#161-3100) 
- SDS (#161-0301) 
 
Cambridge Biosciences (Cambridge, UK): 
- PrecisionShuttle vector pCMV6-AC-HA (#PS100008) 
 
DAKO (Ely, UK): 
- Fluorescence mounting medium “Dako oil” / (#S3023) 
 
Fisher Scientific (Loughborough, UK): 
- Coverslips No. 1 circle 16mm diameter (#12313138) 
- 40% acrylamide/Bis (#10376643) 
- PVDF membrane (#10344661) 
- SuperSignal West Femto Chemiluminescent Substrate (#34094) 
- SMARTpool: ON-TARGETplus RNF115 siRNA  
(#L-006974-00-0005) 
- Dharmafect 1 transfection reagent (#11866654) 
 
Life Technologies (Paisley, UK): 
- DMEM (#21885) 
- RPMI 1640 (#21875) 
- DMEM/F12 (#11330) 
- FBS (#16000-044) 
- Horse serum (#16050) 
- 0.05% Trypsin EDTA (#25300062) 
- Hoechst 33342 (#H3570) 
- Rhodamine Phalloidin (#R415) 
- Alexa 488-EGF (#E-13345) 
- EGF-Rhd (#E-3481) 
- Transferrin Alexa 488 (#T-13342) 
- Transferrin Alexa 647 (#T-23366)  
- DH5α competent E.coli and SOC medium (#18263-012)  
- BigDye Direct cycle sequencing kit (#4458687)  
- Dynabeads Sequencing Clean-Up Kit (#66101)  
- Lipofectamine 2000 transfection reagent (#11668027) 
- Oligofectamine transfection reagent (#12252-011) 
-  pEF5/FRT/V5 Directional TOPO® Expression Kit (#K6035-01) 
- Zeocin (#R25001) 
 
Mast Group Ltd, ( Merseyside, UK):  
- Cryobank ceramic bead bacterial storage system (#CRYO/M)  
 
Merck Millipore (Feltham, UK):  
- GeneJuice transfection reagent (#70967-3) 
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New England Biolabs (Hitchin, UK): 
- EcoRI (#R0101) 
- PspOMI (#R0653) 
- NotI (#R0189) 
- BstEII (#R0162) 
- Antarctic Phosphatase (#M0289S) 
- 1 kb DNA Ladder (#N3232) 
- T4 ligase (#M0102S) 
 
Promega (Loughborough, UK) 
- Fugene 6 transfection reagent (#E2691) 
- CellTitre Blue viability assay (#G8080) 
 
Qiagen (Manchester, UK) 
- Miniprep kit (#27014) 
- Maxiprep kit (#12262) 
- HotStar HiFidelity Polymerase Kit (#202602) 
- QIAquick gel extraction kit (#28704) 
 
Roche Diagnostics (Burgess Hill, UK): 
- cOmplete Protease Inhibitor Cocktail Tablets (#11836153001) 
- PhosStop Phosphatase inhibitor cocktail (#4906837001) 
- Hygromycin (#10843555001) 
 
Sigma Aldrich (Poole, UK): 
- EGF (#E9644) 
- Hydrocortisone (#H0888) 
- Cholera toxin (#S8052) 
- Insulin (#I9278) 
- Triton X-100 (#X100) 
- BSA (#A7906) 
- Saponin (#47036) 
- Bicinchoninic Acid solution (#B9643) 
- Copper (II) Sulphate solution (#C2284) 
- TEMED (#T9281) 
- Ponceau S solution (#P7170) 
- Tween 20 (#P1379) 
- LB AGAR (#A5306) 
- LB Broth (#L3022) 
- Ampicillin (#A1593) 
- Kanamycin (#K1377) 
- Ethidium bromide (#E1510) 
- MG132 (#C2211) 
- Butyric acid (#B103500) 
- 5-azacytidine (#A2385) 
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Appendix B: Coexpressed gene list from MEM analysis 
 
#Gene name Gene locus #Score #probeset id 
RNF115 1q21.1 #QUERY 212742_AT 
POLR3C 1q21.1 4.52E-44 209382_at 
RNF14 5q31.3 1.37E-36 201823_s_at 
SBDS 7q11.21 7.21E-36 1554089_s_at 
ANXA7 10q22.2 3.69E-35 209860_s_at 
CALM1 14q32.11 6.24E-35 211985_s_at 
VDAC2 10q22  6.88E-35 211662_s_at 
C3ORF38 3p11.1 7.95E-35 226524_at 
VAMP7 Xq28 / yq12 8.88E-35 202829_s_at 
TIMM17A 1q32.1  1.97E-34 201821_s_at 
PTPLAD1 15q22.2   2.06E-34 222404_x_at 
YME1L1 10p14 2.21E-34 201351_s_at 
BCAP29 7q22.3  4.91E-34 205084_at 
RAB18 10p12.1 7.64E-34 224787_s_at 
YWHAQ 2p25.1 1.55E-33 200693_at 
AZIN1 8q22.3 1.83E-33 201772_at 
TM9SF3 10q24.1  3.51E-33 222399_s_at 
PTPLAD1 15q22.2  4.57E-33 234000_s_at 
TNPO1 5q13.2  5.63E-33 209226_s_at 
AP2B1 17q11.2-q12  6.26E-33 200615_s_at 
TMCO1 1q22-q25  7.59E-33 208716_s_at 
ATF7 12q13  8.87E-33 228829_at 
ANKIB1 7q21.2 1.09E-32 224687_at 
ABI1 10p11.2  1.09E-32 209027_s_at 
DLD 7q31-q32  1.19E-32 209095_at 
NAA35 9q21.33 1.45E-32 220925_at 
METTL2B 7q32.1 1.88E-32 225253_s_at 
SLC25A32 8q22.3 1.89E-32 221020_s_at 
SERINC3 20q13.12  2.23E-32 211769_x_at 
CSRNP2 12q13.11-.12  2.60E-32 221260_s_at 
TRAM1 8q13.3  3.32E-32 201399_s_at 
PSMA3 14q23 4.19E-32 201532_at 
RNASEH1 2p25 5.45E-32 218497_s_at 
TMEM189 20q13.2  1.03E-31 201001_s_at 
ARL1 12q23.2  1.21E-31 201659_s_at 
PSMD12 17q24.2 2.06E-31 202352_s_at 
VIMP 15q26.3 2.08E-31 223209_s_at 
COPB1 11p15.2 2.32E-31 201359_at 
UBE2Q1 1q21.3   2.34E-31 217978_s_at 
TROVE2 1q31  2.43E-31 210438_x_at 
BUB3 10q26  2.52E-31 201457_x_at 
SPPL2A 15q21.2 2.60E-31 226353_at 
VPS37A 8p22  2.71E-31 225378_at 
RHEBP2 10q11.22  3.39E-31 1555780_a_at 
INTS12 4q24  3.82E-31 218616_at 
PPP2CB 8p12 3.97E-31 201375_s_at 
HAX1 1q21.3  4.11E-31 201145_at 
RC3H2 9q34 4.27E-31 220202_s_at 
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Appendix C: Functional annotation clustering analysis for the genes co-expressed with RNF115 (BCA2) 
Category Term Count % Genes P -value Benjamini 
 
corrected                
P-value 
SP_PIR_KEYWORDS protein transport 9 19 BCAP29, RAB18, AP2B1, COPB1, TIMM17A, TRAM1, TNPO1, VPS37A, VAMP7 1.50E-05 9.40E-04 
GOTERM_BP_FAT protein transport 11 23 BCAP29, RAB18, AP2B1, COPB1, VIMP, TIMM17A, TRAM1, TNPO1, YWHAQ, VPS37A, VAMP7 3.40E-05 1.70E-02 
GOTERM_BP_FAT establishment of protein localization 11 23 
BCAP29, RAB18, AP2B1, COPB1, VIMP, TIMM17A, TRAM1, TNPO1, YWHAQ, 
VPS37A, VAMP7 3.70E-05 9.00E-03 
GOTERM_BP_FAT intracellular transport 10 21 ARL1, BCAP29, AP2B1, COPB1, VIMP, TIMM17A, TRAM1, TNPO1, YWHAQ, VAMP7 6.50E-05 1.10E-02 
GOTERM_BP_FAT intracellular protein transport 8 17 BCAP29, AP2B1, COPB1, VIMP, TIMM17A, TRAM1, TNPO1, YWHAQ 7.00E-05 8.70E-03 
GOTERM_BP_FAT protein localization 11 23 BCAP29, RAB18, AP2B1, COPB1, VIMP, TIMM17A, TRAM1, TNPO1, YWHAQ, VPS37A, VAMP7 1.20E-04 1.10E-02 
GOTERM_BP_FAT cellular protein localization 8 17 BCAP29, AP2B1, COPB1, VIMP, TIMM17A, TRAM1, TNPO1, YWHAQ 1.30E-04 1.00E-02 
GOTERM_BP_FAT cellular macromolecule localization 8 17 BCAP29, AP2B1, COPB1, VIMP, TIMM17A, TRAM1, TNPO1, YWHAQ 1.30E-04 9.40E-03 
GOTERM_CC_FAT endomembrane system 9 19 HAX1, AP2B1, ANXA7, COPB1, RC3H2, VIMP, TRAM1, TNPO1, VAMP7 1.20E-03 1.70E-01 
SP_PIR_KEYWORDS Transport 11 23 BCAP29, RAB18, AP2B1, COPB1, SLC25A32, TIMM17A, TRAM1, TNPO1, VPS37A, VAMP7, VDAC2* 4.50E-03 1.80E-01 
GOTERM_CC_FAT organelle membrane 9 19 HAX1, AP2B1, COPB1, VIMP, SLC25A32, TIMM17A, TRAM1, TNPO1, VAMP7, VDAC2* 9.90E-03 5.20E-01 
GOTERM_MF_FAT protein transporter activity 3 6 AP2B1, TIMM17A, TNPO1 2.00E-02 7.40E-01 
GOTERM_BP_FAT vesicle-mediated transport 6 13 ARL1, BCAP29, RAB18, AP2B1, COPB1, VAMP7 2.20E-02 3.80E-01 
GOTERM_BP_FAT protein targeting 4 8 TIMM17A, TRAM1, TNPO1, YWHAQ 2.20E-02 3.60E-01 
INTERPRO Armadillo-like helical 3 6 AP2B1, COPB1, TNPO1 4.30E-02 9.30E-01 
*pseudogene
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Appendix D: Vector map for pCMV-HA-N produced by 
vector into which BCA2 insert was cloned by 
Miyakawa et al. (2009) 
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Appendix E: Vector maps for pEGFP-C1 and pEGFP-N1  
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Appendix F: Electropherograms for forward and reverse 
HA-BCA2 sequencing 
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Appendix G: Vector map for pEF5-FRT/D-TOPO for 
stable cell generation 
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Appendix H: Site directed mutagenesis strategies for 
sequence correction and tag removal using HA-BCA2 
construct and combined sequence correction and frame 
shift in EGFP-BCA2 construct 
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Appendix I: Homology detection and structure prediction 
by HMM-HMM comparison 
 
Key BCA2 structural domains predicted by the HHPred online 
bioinformatics software:  http://toolkit.tuebingen.mpg.de/hhpred 
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Appendix J: KM Plotter and GOBO patient numbers 
 
KM Plotter 
 
Stratification Number of patients 
None (all tumours) 3458 
ER Positive 2000 
ER Negative 806 
Grade 1 306 
Grade 2 716 
Grade 3 792 
LN Positive 1178 
LN Negative 1973 
Luminal A 2069 
Luminal B 1165 
Basal-like 669 
HER2 239 
 
 
GOBO 
 
Stratification Number of patients 
None (all tumours) 914 
ER Positive 738 
ER Negative 166 
Grade 1 190 
Grade 2 411 
Grade 3 257 
LN Positive 229 
LN Negative 662 
Luminal A 268 
Luminal B 204 
Basal-like 114 
HER2 122 
Normal-like 160 
 
